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SUMMARY 
Treatment of human African trypanosomiasis (sleeping sickness) with the currently available 
drugs is unsatisfactory and new drugs and approaches are urgently needed. Despite being 
associated with severe adverse reactions and a long, complicated treatment schedule, 
melarsoprol (Arsobal®) is expected to remain the most used drug for the treatment of late-
stage sleeping sickness for the next decade because alternative treatments are too 
expensive and only at very preliminary stages of development.  
In the presented study, the overall effectiveness of an abridged application scheme of 
melarsoprol for the treatment of late-stage gambiense sleeping sickness was evaluated. In a 
first part, the long-term efficacy of the 10-day schedule was concluded based on the follow-
up of the patients treated in a large-scale controlled clinical trial in Angola in 1998 (IMPAMEL 
I). In a second part, the overall effectiveness of this abridged treatment schedule was 
assessed in a multinational drug utilisation study (IMPAMEL II) that was executed under field 
conditions. Clinical effectiveness was shown by addressing specifically the usefulness in 
different settings, e.g. in different countries / centres and in children below 15 years of age. 
An economic appraisal was also done to assess the monetary benefit if switching from the 
standard treatment schedule to the short course of melarsoprol. 
2800 patients from 16 different treatment centres of 7 African countries endemic for T.b 
gambiense trypanosomiasis were treated with 10 daily doses of 2.2 mg melarsoprol/kg 
bodyweight on consecutive days. The short- and long-term efficacies of the 10-day schedule 
were good and comparable to the standard schedules found in the randomised, controlled 
clinical trial in Angola and in previous trials published in literature. However, poor follow-up is 
an inherent problem of sleeping sickness control and therefore highly variable attendance 
rates of the follow-up examinations could be anticipated. In our studies, they varied from 
acceptable in the controlled trial in Angola to rather low rates in many treatment centres of 
the multinational study.  
Highly variable outcomes were also found for the safety of the 10-day treatment schedule 
reported from the different treatment centres in the multinational evaluation. But 
nevertheless, the safety under field conditions proved to be well comparable to the findings 
of the clinical trial previously executed in Angola, the literature and the retrospective data 
from the participating treatment centres. No unexpected findings were reported.  
In addition, the tolerability and effectiveness of the abridged treatment schedule in children 
were assessed by reviewing all patients treated in the multinational study who were below 
the age of 15 years. There is evidence that the safety and efficacy profile of the 10-day 
schedule is similar in children and adults. The abridged treatment schedule was well 
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tolerated by the children and we found only non-significant differences in the occurrence of 
adverse events compared to adults. Some of these differences could be explained by higher 
rates of concomitant parasitic diseases in children and the fact that some adverse events 
cannot be separated from common signs and symptoms of the disease, especially in 
younger children (e.g. headache). The cure rates were identical in the subpopulations.  
We found the 10-day treatment schedule to be more cost-effective than the standard 
treatment and a highly cost-effective treatment option for late-stage gambiense sleeping 
sickness in areas with scarce resources. The costs of treatment (diagnosis, hospitalisation 
and sleeping sickness specific treatment) were assessed in two rural treatment centres and 
compared to the benefits of the 10-day treatment and of the standard treatments, measured 
by the cost of treatment per DALY (disability-adjusted life-year) averted. The net benefit from 
switching from the standard (26 to 30 days hospitalisation) to the 10-day treatment schedule 
did reduce the costs per DALY averted by almost half of the costs calculated for the standard 
schedules and represented a “good value for money” option in the control of sleeping 
sickness. 
In addition, the 10-day schedule bears several advantages over the standard national 
treatment schedules: It reduces treatment duration, hospitalisation time, and total drug 
amount per patient, it is easier to implement in basic, rural treatment centres, and it 
increases the treatment centres’ capacity.  
Based on our findings and the experience of the sleeping sickness control programs in the 
respective countries, the abridged protocol was recommended by the 27th ISCTRC in late 
2003 as the standard schedule for melarsoprol treatment of late-stage sleeping sickness due 
to T.b. gambiense. However, because of the different clinical nature and the high 
parasitaemia, the use of the 10-day schedule against T.b. rhodesiense is strongly 
discouraged until the necessary clinical evaluation will be conducted. Based on its simplified 
implementation, the 10-day schedule offers straightforward adaptation for combination 
therapy with other existing drugs, especially for melarsoprol refractory patients. 
Résumé  vii 
RÉSUMÉ 
Le traitement de la trypanosomiase humaine africaine (maladie du sommeil) à l’aide des 
médicaments actuellement disponibles est insatisfaisant. Il y a donc un besoin urgent de 
trouver de nouveaux médicaments et de nouvelles approches thérapeutiques. Malgré de ses 
effets secondaires sévères et son schéma thérapeutique long et compliqué, le mélarsoprol 
devrait rester au cours de la prochaine décennie le médicament le plus utilisé pour le 
traitement de la maladie du sommeil au stade neurologique. Les traitements alternatifs étant 
trop chers ou à des stades préliminaires de développement.  
Dans l’étude présentée, l’efficacité globale d’un schéma d’administration raccourci de 
mélarsoprol pour le traitement de la maladie du sommeil à T.b. gambiense au stade 
neurologique a été évaluée. Dans la première partie, l’évaluation de l’efficacité à long terme 
du schéma de dix jours a été effectuée sur la base d’un suivi des malades traités au cours 
d’un essai clinique en Angola en 1998 (IMPAMEL II). Dans la deuxième partie, l’efficacité 
globale de ce schéma abrégé a été évaluée dans une étude multinationale d’utilisation du 
médicament, effectuée dans les conditions naturelles de terrain. L’efficacité clinique a été 
étudiée dans le cadre des différents contextes existant dans les pays/centres participant à 
l’étude, ainsi que chez des enfants âgés de moins de 15 ans. Une évaluation économique de 
l’impact monétaire de la substitution du schéma standard par le schéma court a été 
effectuée. 
Pendant une année, 2800 malades issus de 16 centres de traitement dans 7 pays africains 
endémiques pour la maladie à T.b. gambiense ont été traités avec 10 doses consécutives de 
2.2 mg/kg de poids corporel de mélarsoprol par jour. L’efficacité à court et à long terme du 
schéma de 10 jours fut très bonne. Elle est comparable à celle observée lors d’une étude 
randomisée et contrôlée avec le schéma standard en Angola et à celle observée dans les 
essais cliniques décrits dans la littérature. Néanmoins, le suivi des malades étant un 
problème inhérent au contrôle de la maladie du sommeil, des taux très variables d’examens 
de suivi étaient prévisibles. Dans nos études, ceux-ci ont varié des taux acceptables 
observés dans l’étude contrôlée en Angola jusqu’à des taux plutôt bas observés dans de 
nombreux centres inclus dans l’essai multinational. 
Des taux très variables de résultat ont aussi été observés par rapport à la sûreté du schéma 
de 10 jours, tel que rapporté par les différents centres de traitement inclus dans l’évaluation 
multinationale. Cependant, la sûreté du schéma dans les conditions de terrain s’est révélée 
comparable à celle de l’essai clinique réalisé en Angola, à celle décrite dans la littérature et à 
celle rétrospectivement disponible dans les centres de traitement participant à cette étude. 
Aucun résultat inattendu n’a été observé. 
La tolérabilité et l’efficacité du schéma abrégé chez les enfants ont été évaluées en 
examinant tous les malades au dessous de 15 ans traités lors de l’étude multinationale. Les 
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données montrent que le profil de sûreté et d’efficacité chez l’enfant est identique à celui de 
l’adulte. Le traitement abrégé fut bien toléré chez les enfants; nous avons détecté seulement 
des différences non significatives par rapport aux effets adverses observés chez les adultes. 
Certaines de ces différences pourraient être attribuées aux taux d’infection parasitaire 
supérieurs, observés chez les enfants et au fait que beaucoup d’effets adverses ne soient 
pas facilement séparables des manifestations cliniques de la maladie pédiatrique (par 
exemple les céphalées). Le taux de guérison fut identique dans les deux groupes.  
Nous avons trouvé que le rapport coût efficacité du schéma de 10 jours est meilleur que 
celui du schéma standard ; et de ce fait constitue une option favorable pour le traitement de 
la maladie T.b. gambiense en phase neurologique dans des régions à ressources limitées. 
Le coût du traitement (diagnostic, hospitalisation, et coût du médicament spécifique), en 
termes de coût par DALY épargné, a été évalué dans deux centres de traitement ruraux. Le 
bénéfice net est une réduction de presque de la moitié des coûts, lorsqu’on substitue le 
schéma standard (entre 26 et 30 jours d’hospitalisation) par le schéma de 10 jours, 
représentant ainsi une option valable pour le contrôle de la maladie du sommeil.  
En plus de son efficacité clinique, le schéma court de mélarsoprol représente donc une 
option ayant un rapport coût efficacité fortement favorable. Il présente aussi des avantages 
par rapport aux schémas de thérapeutiques nationaux: il réduit la durée du traitement et 
d’hospitalisation aussi bien que la quantité de médicament utilisé par malade; il est plus 
facile à adopter par des centres de traitement rudimentaires en zone rurale, et de ce fait 
augmente leur capacité opérationnelle. 
En prenant en considération les données de notre étude et l’expérience obtenue par les 
programmes de lutte contre la maladie du sommeil dans chaque pays participant, le 
protocole abrégé a été recommandé en septembre 2003 par le 27ième CISRLT comme le 
nouveau schéma standard pour le traitement de la maladie du sommeil à T.b. gambiense au 
stade neurologique. Jusqu’à ce que la nécessaire évaluation clinique soit effectuée, 
l’utilisation du schéma de 10 jours en cas de T.b. rhodesiense est cependant fortement 
découragée, en fonction des caractéristiques cliniques différentes et de la haute parasitémie 
présenté dans cette forme de la maladie. Étant donné sa plus simple implantation, le schéma 
de 10 jours est aussi très convenable pour utilisation en traitement combinée avec d’autres 
médicaments existants, surtout pour les malades réfractaires au mélarsoprol.   
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INTRODUCTION 
Epidemiology 
Case detection and treatment of the cases is the cornerstone to the control of human African 
trypanosomiasis (HAT) or sleeping sickness, a fatal parasitic disease. Nearly eliminated in 
the 1960s, HAT showed a dramatic comeback of epidemic proportions due to the collapse of 
health systems, other health priorities, war, and population movements over the past two 
decades. 
Today, in 36 sub-Saharan African countries, 60 million people are at risk of infection and less 
than 10% are under surveillance [WHO 1998]. And as only around 40’000 annual cases have 
been reported in the last years, the real prevalence is estimated at around 350’000 cases 
[WHO 2001]. Sleeping sickness affects mainly the poor, rural African population and the 
socio-economic impact is considered very high amongst tropical parasitic diseases. The 
affected population suffers most from economic loss due to reduced workforce and family 
disruption. In terms of disease burden expressed in DALYs (disability-adjusted life years), 
HAT ranks third of all parasitic diseases in sub-Saharan Africa, just behind malaria and 
helminths [WorldBank 1993; WorldHealthReport 2004]. Untreated, the disease leads 
inevitably to death. 
Sleeping sickness is caused by the parasitic protozoa Trypanosoma brucei gambiense (T.b. 
gambiense) and Trypanosoma brucei rhodesiense (T.b. rhodesiense), which are transmitted 
by the bite of the tsetse fly, Glossina sp. The disease is distributed in distinct foci throughout 
the tsetse-infested zone between the latitudes 14°N and 20°S of sub-Saharan Africa and 
considerable variations in the endemicity levels are reported (Figure 1). 
The disease occurs in two distinct forms: the chronic form due to T.b. gambiense that is 
confined to Central and Western Africa and the more acute T.b. rhodesiense form that is 
prevalent in Eastern Africa [WHO 1998]. Currently, most of the cases reported are due the 
gambiense form that has a long course (up to several years) and only a few hundreds of 
cases are being diagnosed with the acute rhodesiense form that exhibits a short disease 
progression (several months).  
T.b. rhodesiense has an important zoonotic component, with only occasional transmission to 
people from both, domestic livestock and game animals [WHO 1998]. Measures within the 
community to reduce morbidity and mortality in individuals include prevention of exposure 
and case management (surveillance of population at risk, treatment and follow-up of cases). 
But more important are control measures that limit the spread and transmission from the 
animal reservoir to the humans, mainly through controlling animal reservoir and vector 
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control (trapping flies, aerial spraying, and destroying breeding sites). The gambiense 
reservoir is almost entirely in the human population. Consequently, the most effective form of 
control of gambiense sleeping sickness is medical surveillance, relying on case detection 
and treatment to reduce the human reservoir of the disease so as to lower its incidence 
[WHO 1998, 2001]. Therefore, appropriate treatment of HAT is a crucial measure for control 
although it is hampered by major obstacles that are discussed in the following sections and 
chapters. 
Figure 1:  Distribution of HAT in sub-Saharan Africa, by endemicity levels of the countries 
affected (© Map: Source: WHO2004) 
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Introduction  3 
Transmission and clinical manifestations 
Symptoms and signs of sleeping sickness are classified according to the clinical progression 
of the disease: the early haemolymphatic stage and the late meningoencephalitic stage and 
may differ substantially between the rhodesiense and gambiense form (Table 1; [Burri and 
Brun 2002]). 
Table 1 Typical symptoms and signs of sleeping sickness 
Early stage  
Chancre (T.b. rhodesiense mainly) 
Unspecific signs: fever, headache, joint pain, general malaise, 
     pruritus, hyperesthesia, (rash) 
Adenopathy (T.b. gambiense) 
Anaemia 
Localized oedema  
Splenomegaly 
Irritability, changes of mood 
Weight loss 
Cardiac abnormalities (tachycardia - pancarditis) 
Late-stage 
Headache 
Abnormal movements 
Sensation problems (hyperesthesia, parestesia, neuralgia) 
Impaired motor functions (walking, speech, dyskinesia) 
Archaic reflexes 
Endocrine disorders (e.g. reduced libido, amenorrhea, bulimia 
     or loss of appetite, facial oedema) 
Psychological problems: changes of behaviour, mental 
     deterioration, psychosis (e.g. mania, paranoia) 
Reduced vigilance and sleep, later reversal of sleep pattern 
Coma 
 
Following an infective bite of the tsetse fly, a swollen chancre may develop at the site (mainly 
with T.b. rhodesiense) with widespread lymph node enlargement. Early in the infection, the 
trypanosomes become established in the lymph and blood where they multiply and signs of 
the disease may be rather unspecific, with episodes of fever, headache, arthralgia and 
generalised weakness. In the blood the trypanosomes survive due to their remarkable 
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degree of antigenic variation that misdirects the immune response and leads to a gradual 
exhaustion of the patient’s immune system. Accompanying the immune stimulation, lymph 
node enlargement is a common sign, especially in T.b. gambiense infection, and often the 
patients present with pruritus, general malaise, localised oedema and cardiac involvement.  
This is followed by the central nervous system (CNS) invasion of the trypanosomes. As the 
disease progresses into the late meningoencephalitic stage, symptoms of the early 
haemolymphatic stage may persist and signs of the nervous system involvement become 
obvious. Clinically, the patients display disturbances of consciousness and reversal of the 
normal sleep-wake cycle in which daytime somnolence alternates with nocturnal insomnia 
(“sleeping sickness”). Characteristic of the disease are mental disturbances that may be 
subtle and include irritability, lassitude, personality changes and overt psychiatric 
presentations such as violence, hallucinations and mania. Motor system and sensory 
involvement are common and may manifest as tremors, speech impairment, abnormal 
movements and hyperaesthesia, respectively [WHO 1998]. The patient, if left untreated, 
progresses to the final stage of the disease, which is characterised by seizures, severe 
somnolence, coma and inevitable death. This progresses much more rapidly in the 
rhodesiense infection, causing the death of the patient within a couple of months. The 
gambiense form of the disease is characterised by low parasitaemia and a gradual onset of 
neurological symptoms and death more than 2 years after initial infection. 
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Diagnosis 
The clinical presentation of the patient is very unspecific and diagnosis is not possible based 
only on the symptoms and signs. Diagnosis usually follows a sequential approach: a card 
agglutination test is used to identify patients with potential T.b. gambiense infections (CATT; 
[Magnus et al., 1978]) while the indirect immuno-fluorescent test is used to detect T.b. 
rhodesiense (IFT; [Geigy et al., 1975]); seropositive cases are confirmed by microscopic 
detection of the parasites in blood, lymph node aspirate and/or cerebrospinal fluid (CSF, 
[Woo 1969; Lumsden et al., 1979; Bailey and Smith 1994]. Parasite detection is mandatory, 
as is the determination of the disease stage, for therapeutic decision and to prevent the 
patient from risks associated with treatment. Accurate staging is crucial because failure to 
treat a patient with CNS infection will inevitably lead to death from the disease, yet 
inappropriate CNS treatment in an early-stage patient carries a high risk of unnecessary drug 
toxicity. Therefore, the CSF is examined for either the presence of trypanosomes by 
concentration techniques (centrifugation, m-AECT, [Louis et al., 2001] and/or an elevation of 
the white blood cell (WBC) count in CSF [WHO 1998]. However, the criteria have been 
challenged by some investigators [Doua et al., 1996; Stanghellini and Josenando 2001; 
Lejon 2002] and thus, different cut-off values are used today in different countries: more than 
5 cells/mm3 in most countries, except for more or equal 10 WBC/mm3 in Equatorial Guinea 
and more or equal 20 WBC/mm3 in Angola and Côte d’Ivoire.  
Recently, a very sensitive marker for CNS involvement –detection of intrathecal IgM 
synthesis- has been demonstrated and translated into a latex agglutination assay that is of 
high value for diagnosis in the field [Lejon et al., 2003]. The CSF IgM quantification assay 
has considerable promise for both, staging sleeping sickness and monitoring relapsing from 
treatment. 
After treatment, a patient is considered cured only when during a 2 year follow-up period no 
trypanosomes can be detected and/or the WBC counts in CSF were reduced to normal 
values and/or no reappearance of the clinical symptoms and signs were observed [WHO 
1998]. 
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Treatment 
Sleeping sickness treatment relies on therapies that are unsatisfactory for several reasons 
[WHO 1998]. Four drugs are currently approved for the treatment of HAT, namely suramin, 
pentamidine, melarsoprol, and eflornithine. And nifurtimox, a drug which is registered for 
Chagas disease, is currently undergoing evaluation in combination therapy with approved 
drugs for HAT (Table 2). Most of these drugs were developed over 50 years ago and bear 
the disadvantages of either unacceptable toxicity, undesirable route of administration, limited 
efficacy, drug resistance, and/or lengthy treatment schedules. Furthermore, the treatment of 
sleeping sickness is complicated by the different disease stages: the selective permeability of 
the blood-brain barrier prevents most drugs from reaching levels in the CSF that can kill the 
parasites. However, a large fraction of infected people only seek treatment when the disease 
has already advanced to the late meningoencephalitic stage. 
Early-stage disease is treated with suramin (Germanin®, Bayer) in rhodesiense infection and 
with pentamidine (Lomidine®, Aventis) in gambiense disease; both drugs are ineffective in 
treating the late-stage. Suramin was introduced in the early 1920s, it is administered by 
intravenous injections and adverse drug reactions include: vomiting, nausea, collapse, 
shock, and delayed reactions as kidney damage, exfoliative dermatitis, jaundice, severe 
diarrhoea, all of which can be fatal. Pentamidine, the drug of choice to treat early T.b. 
gambiense infections, was first introduced in the 1940s and the preferred and most effective 
route of administration is by intramuscular injections. It can cause damage to the liver, 
kidneys, and the pancreas, but generally only minor adverse reactions are observed. Despite 
their use over decades, so far no resistance to the two drugs has emerged [WHO 1998]. 
Melarsoprol (Arsobal®, Aventis) and eflornithine (Ornidyl®, Aventis) are effective for 
treatment of the late meningoencephalitic stage of the disease; however, melarsoprol is the 
only effective drug for both, rhodesiense and gambiense. Eflornithine has become 
increasingly the preferred therapy for gambiense infections, but is largely ineffective for 
rhodesiense infections [Iten et al., 1995] and less effective in children [Milord et al., 1993]. 
Although less toxic than melarsoprol, the drug is far from ideal: it is costly and difficult to 
administer, requiring four daily infusions for 14 days, demanding sophisticated equipment 
and well-trained staff and therefore of limited use in basic, rural treatment centres [Louis et 
al., 2003; Burri and Brun 2003]. An oral formulation of eflornithine would be advantageous 
over the injectable form and greatly facilitate the practical use in resource-poor settings. 
Such development is currently subject of research and under clinical investigation [WHO 
2001].  
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Nifurtimox (Lampit®, Bayer) is the only other potential alternative treatment for late-stage 
disease. It has been registered for the treatment of Chagas disease and is administered 
orally, but well-documented evidence of efficacy and safety for the treatment of HAT is still 
lacking. Its use is more likely to be in the context of combination therapy for melarsoprol 
refractory cases or when eflornithine is not available [Pepin et al., 1989; Jennings 1990; 
Pepin et al., 1992].  
Table 2 Drugs for the treatment of human African trypanosomiasis 
First Stage Introduction Advantage Problem
Suramin 1920 T. b. rhodesiense  and No penetration into CSF
T. b. gambiense
Pentamidine 1940 Few adverse reactions Limited  penetration into CSF
T. b. gambiense  only
Second stage Advantage Problem
Melarsoprol 1949 T. b. rhodesiense and Adverse reactions
T. b. gambiense Empirical schedules
(Treatment duration)
Eflornithine 1981 Few adverse effects Availability 
(DFMO) (Oral application possible) Affordability
Logistics
T.b. gambiense  only
(Nifurtimox) 1972 T. b. rhodesiense and Not registered
T. b. gambiense Alone low efficacy
Adverse reactions
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Melarsoprol  
Melarsoprol is a trivalent organic arsenical that was introduced in 1949 [Friedheim 1949]. 
Today, it is still the most used drug to treat late-stage gambiense disease and the only drug 
for treatment of late-stage rhodesiense sleeping sickness, although it bears severe 
disadvantages. Although a high proportion of the patients are cured with standard regimens, 
there is evidence of an increasing failure rate, up to 30% in northern Uganda, northern 
Angola and southern Sudan [Legros et al., 1999; Stanghellini and Josenando 2001; Moore 
2001]. 
Melarsoprol is insoluble in water and must be given intravenously dissolved in propylene 
glycol, a solvent that is highly irritant to tissues. Adverse drug reactions of melarsoprol may 
be severe and life threatening. The most important is the encephalopathic syndrome that 
occurs in up to 10% of all treated patients, and which is fatal in 50–70% of the cases [Pepin 
and Milord 1994; WHO 1998]. The cause of this reaction has been discussed extensively in 
the past, but still remains a controversial issue and detailed mechanisms remain unknown 
[Haller et al., 1986; Pepin and Milord 1994; WHO 1998]. Generally, an immune reaction is 
thought to underlie the syndrome [Haller et al., 1986; Pepin et al., 1989; Keiser et al., 2000] 
and several additional factors are believed to be associated with the syndrome: concomitant 
infections, other anti-parasitic drugs, presence of trypanosomes in CSF and high white blood 
cell count in CSF, impaired nutritional status, seasonal variations and alcohol intake [Ancelle 
et al., 1994; Pepin et al., 1995; Blum et al., 2001]. Other frequent reactions to melarsoprol 
include exfoliative and maculopapular skin reactions, polyneuropathies, tachycardia, fever, 
abdominal pain, diarrhoea, vomiting, pruritus, chest pain and headache. A local skin reaction 
at the injection site, thrombophlebitis and deep vein fibrosis, may occur due to the propylene 
glycerol solvent [WHO 1998].  
Another major drawback of melarsoprol therapy is the specific treatment regimens that vary 
considerably among different countries and depending on whether the infection is due to T.b. 
rhodesiense or T.b. gambiense. The regimens are based on empiric development, and 
typically a course of 3 to 4 series of 3 to 4 i.v. injections of increasing doses every 24 hours 
spaced by rest periods of 6 to 10 days were given (Figure 2, [WHO 1998]). This empiric 
treatment regimen results in a long hospitalisation period of up to 30 days, which poses 
major social and economic burden to the patients and their accompanying relatives. Recently 
acquired knowledge about the pharmacokinetics of melarsoprol led to the suggestion of a 
concise 10-day treatment schedule [Burri et al., 2000] that is currently being evaluated in a 
multicountry study (IMPAMEL program) and subject of this thesis.  
Introduction  9 
Figure 2: Comparison of melarsoprol treatment schedules for late-stage sleeping sickness  
 
DAY OF DRUG APPLICATION 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
Standard schedule used in Central African Republic, DRC, Equatorial Guinea & Sudan 
(until 2002) 
P P P M3 M3 M3       M3 M3 M3       M3 M3 M3 C      
Standard schedule used in Angola, Côte d’Ivoire & Republic of Congo (until 2002) 
P P P M1 M2 M3 M3        M1 M2 M3 M3        M1 M2 M3 M3 C 
10-day schedule under investigation 
P P P M4 M4 M4 M4 M4 M4 M4 M4 M4 M4 C                 
 
P: anti-parasitic pre-treatment; M1: 1.2 mg/kg melarsoprol; M2: 2.4 mg/kg melarsoprol; M3: 3.6 mg/kg (max 5 ml) 
melarsoprol; M4: 2.2 mg/kg (max 5 ml) melarsoprol; C: treatment control examination 
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Impamel program 
A major disadvantage of melarsoprol treatment is its long duration. 55 years after its market 
introduction [Friedheim 1949], the treatment regimens still vary considerably [WHO 1998] 
and are based on empiricism. To optimise and standardise the treatment with melarsoprol, a 
concise treatment regimen has been elaborated based on rational scientific investigations. 
Table 3 summarises the sequence of scientific investigations done by the Swiss Tropical 
Institute (group of Prof. Brun and Dr. Burri) prior to the clinical evaluation in patients. As a 
result, an abridged 10-day treatment protocol for melarsoprol has been proposed based on 
pharmacological investigations, animal experiments and pilot testing in sleeping sickness 
patients in the former Zaire. The favourable outcome of the pilot trial in 11 sleeping sickness 
patients in Vanga, DRC [Burri et al., 1995] led to a large-scale randomised, controlled clinical 
trial in Angola, which assessed the efficacy and safety of the 10-day schedule in 500 patients 
(IMPAMEL I). 
 
Impamel I: Clinical evaluation in patients in Angola 
In an open, randomized equivalence trial conducted with 500 patients in Kwanza Norte, 
Angola from April 1997 to September 1998, the efficacy and safety of the new 10-day 
treatment schedule for melarsoprol were assessed (IMPAMEL I). The control group followed 
the 26-day standard national Angolan schedule of 3 series of 4 daily injections of melarsoprol 
at doses increasing from 1.2 to 3.6 mg/kg bodyweight within each series, with a 7-day rest 
between series (Figure 2). The new treatment schedule comprised 10 days of one daily 
injection of 2.2 mg/kg bodyweight. The outcome of this trial has recently been published 
[Burri et al., 2000]. It could be shown that the new, concise schedule was equivalent to the 
standard protocol in its short-term efficacy, and that no difference was found for the primary 
safety outcomes (death in temporal relationship to treatment and rate of encephalopathic 
syndromes). A non-significant increase of skin reactions was observed under the 10-day 
schedule, possibly due to hypersensitivity reactions or drug accumulation in the skin. Other 
known adverse reactions (neuropathies, diarrhoea, fever, and headache) occurred at similar 
rates in both groups. During the follow-up, the number of patients who relapsed was 
comparable in both groups, suggesting the new schedule being equivalent to the standard 
protocol in its long-term efficacy as well. The follow-up has just been completed and was 
analysed in detail with regard to risk factors for relapsing (chapter 2).  
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Table 3 Sequence of scientific investigations to the development of the concise 10-day 
schedule for melarsoprol 
Development of analytical methods 
 - Development of bioassay to determine melarsoprol in body fluids 
 - Principle: in vitro killing of trypanosomes by active metabolites of melarsoprol  
 [Burri and Brun 1992] 
Drug metabolism and pharmacokinetics 
 
- Determination of melarsoprol and metabolites concentrations in body fluids by 
HPLC method 
 - Determination of pharmacokinetics in 19 patients of Côte d’Ivoire 
 
- Confirmation of melarsoprol and metabolite concentration in body fluids by 
atomic absorption spectrophotometry  
 - Development of pharmacokinetic model 
 [Burri et al., 1993] 
 [Bronner et al., 1998] 
 [Keiser et al., 2000] 
Computer modelling 
 
- Topfit simulation for alternative treatment protocols based on established 
pharmacokinetics 
 - Proposition of 10-day schedule 
 [Burri et al., 1993] 
Validation in animal model 
 - 6 uninfected vervet monkeys treated with standard or 10-day schedule  
 - Validation of model and confirmation of pharmacokinetics 
 - Establishment of pharmacokinetics in CSF 
 [Burri et al., 1994] 
Pilot testing in humans, DRC 
 
- 11 late-stage T.b. gambiense patients in Vanga, DRC treated with 10-day 
schedule compared to 23 patients previously treated with standard schedule 
 - Equivalent outcome in treatment and adverse events 
 - Elevated fever, diarrhoea and skin reactions in test group 
 - Comparable long-term efficacy at follow-up 
 [Burri 1994] 
 [Burri et al., 1995] 
IMPAMEL I: Clinical evaluation in patients in Angola 
 - Large-scale clinical trial 
 - 500 patients, randomized, controlled 
 - Standard 26-day schedule versus 10-day schedule 
 - Result: proven non-inferiority in efficacy and safety 
 [Burri et al., 2000] 
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Impamel II: Confirmation under field conditions 
The concise 10-day schedule has proved its non-inferiority in terms of safety and efficacy 
(adverse events, fatality, and parasite-free after therapy) in the large-scale clinical trial in 
Angola (IMPAMEL I; [Burri et al., 2000]). Not surprisingly, the shorter course was well 
accepted by the patients and the treating staff through its practical application (no daily dose 
adjustments and no rest periods). Additionally, the short treatment course bears several 
socio-economic advantages, like a reduction of total time spent in hospital per patient, a 
decrease of the total amount of drug per patient, and an increase of the hospital capacity. In 
the view of changing recommendations and harmonising the treatment for late-stage 
gambiense sleeping sickness with melarsoprol among the endemic African countries, the 
promising outcome of the large-scale trial in Angola led to an expansion of the evaluation in 
several African countries under field conditions (IMPAMEL II program).  
 
Aim and objectives of the IMPAMEL II program 
The IMPAMEL II programme aims at the clinical assessment in different populations of the 
new, concise schedule for melarsoprol (Arsobal®) treatment of late-stage sleeping sickness, 
developed under IMPAMEL I, by  
• Monitoring on the basis of a questionnaire the outcome of treatment in selected centres 
in different endemic countries after introduction of the new protocol.  
• Assessing risk factors for an adverse outcome of late-stage sleeping sickness treatment 
with melarsoprol ten days schedule. 
Further, some additional goals of the IMPAMEL II program were defined aiming at the 
assessment of the overall effectiveness of the 10-day treatment schedule, these were:  
• To compare the cost-effectiveness of the new and the standard treatment schedules. 
• To elaborate in collaboration with WHO comprehensive guidelines on the treatment of 
African sleeping sickness, including the management of adverse events and provide 
recommendations for the treatment of non-responders.  
• To establish in collaboration with national Trypanosomiasis Control Programs and WHO, 
in the framework of the Programme Against African Trypanosomiasis (PAAT) and the 
WHO Human African Trypanosomiasis Treatment and Drug Resistance Network, a 
database for clinical data with spatial reference.  
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OBJECTIVES  
The presented Ph.D. thesis was done in the frame of the IMPAMEL II programme. The aim of 
the thesis was to appraise the overall effectiveness of the 10-day treatment schedule for 
melarsoprol under natural conditions, by following the specific objectives: 
 
• To evaluate the long-term efficacy of the 10-day melarsoprol schedule under controlled 
conditions (IMPAMEL I, chapter 1) 
• To assess the safety and efficacy of the10-day melarsoprol schedule under natural field 
conditions (IMPAMEL II, chapter 2) 
• To study the influence of concomitant infections on the disease progression and 
treatment outcome (chapter 3) 
• To assess the safety and efficacy of the 10-day schedule for children below 15 years of 
age (chapter 4) 
• To perform an economic analysis to provide a sound basis for the cost-effectiveness of 
the 10-day treatment schedule (chapter 5) 
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STUDY DESIGN (METHODS) 
General design 
IMPAMEL II was a non-controlled, multinational, multi-centre drug utilisation study to evaluate 
the abridged treatment schedule of melarsoprol in late-stage T.b. gambiense sleeping 
sickness patients under true field conditions. A very simple study design without 
randomisation and sample size calculation was decided due to the limited number of centres 
with good accessibility and security with a sufficiently large number of patients to conduct 
clinical trials and the generally very basic equipment of rural sleeping sickness treatment 
centres. Additionally, the staff in such remote treatment centres are normally not trained for 
clinical trials.  
Based on data of previous years provided by the national sleeping sickness programs and 
NGOs, we could assume more than 2000 patients to be treated in this program (Table 4). 
Centre selection 
The assessment was performed in centres (facilities) that were suggested by the responsible 
national sleeping sickness programs, or NGO’s where applicable, of different countries with 
endemic T.b. gambiense. The national programs of Angola, Central African Republic, Côte 
d’Ivoire, Democratic Republic of Congo, Equatorial Guinea and Republic of Congo and 
NGOs in Republic of Congo and South Sudan agreed to participate with several centres in 
the IMPAMEL II program (Table 4). The national program of Uganda initially agreed to 
participate but at the time of the study start the program has shifted first-line treatment of 
late-stage patients to eflornithine and thus was unable to contribute a centre. 
The criteria for the centre selection were: good accessibility of the centre, provision of 
reliable retrospective data on the standard treatment of melarsoprol for at least one year prior 
to the study period and the exclusive use of the new treatment schedule for melarsoprol for 
all late-stage gambiense sleeping sickness patients. The enrolment period for each centre 
was 12 months to balance seasonal variations [Ancelle et al., 1994].  
Patient inclusion 
The single inclusion criterion for a patient was confirmed late-stage sleeping sickness due to 
T.b. gambiense according to the criteria of the respective national sleeping sickness control 
programs or NGOs. These were: diagnosis of late-stage by microscopic examination of the 
cerebrospinal fluid (CSF) for the presence of trypanosomes and/or an elevated white blood 
cell (WBC) count. Several cut-off criteria for the WBC in CSF for the different countries 
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existed: more than 5 WBC/mm3 in the Central African Republic (CAR), Democratic Republic 
of Congo (DRC), Republic of Congo (RoC) and Sudan, more or equal 10 WBC/mm3 in 
Equatorial Guinea, and more or equal 20 WBC/mm3 in Angola and Côte d’Ivoire [WHO 
1998]. For each patient a case report form was filled, that contained demographic, diagnostic 
and clinical characteristics before and after treatment, and an assessment of adverse events 
during melarsoprol treatment on a graded scale from 0 to 2 (none, moderate, severe 
reaction).  
Table 4 Expected number of patients to be treated in the IMPAMEL II program, estimates 
were provided by the participating countries / organisations and projections are 
based on retrospective data available from the selected centres 
Country 
Authority / Organisation 
Suggested centres Expected number of 
patients (1 year) 
Angola 
Instituto de Combate e de Controlo da 
Tripanossomíase ICCT) 
Viana 
Dondo,  
N’Dalatando  
Caxito 
Uige 
 
500 - 1000 
 
Congo Brazzaville 
Programme National de Lutte Contre la 
Trypanosomiase 
MSF Holland 
Brazzaville  
Mossaka 
Gamboma 
 
> 30 
Côte d’Ivoire 
Programme National de Lutte Contre la 
Trypanosomiase 
 
Daloa 
 
na 
Democratic Republic of Congo 
Programme National de Lutte Contre la 
Trypanosomiase Humaine Africaine 
CDTC Maluku 
CNPP/CUK Kinshasa 
CDTC Kionzo 
 
> 500 
Equatorial Guinea 
Centro de control de Tripanosomiasis 
(Collaboration with Fundació CIDOB) 
Mbini 
Kogo 30 
Central African Republic 
Programme National de Lutte contre la 
Trypanosomiase Humaine Africaine 
 
Batangafo 
 
30 
Sudan (Southern) 
International Medical Corps (IMC) 
MSF Switzerland 
LiRangu 
Tambura 
Ibba 
Kajo Keji 
 
> 900 
 
Uganda 
National Sleeping Sickness Control 
Program 
Moyo 
Adjumani 
 
> 200 
7 countries 19 centres 2200-2700 patients 
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Ethical considerations 
The study was approved by the ethics committee of the two cantons of Basel (EKBB) and the 
relevant ethics committees and authorities in the respective countries. In the selected centres 
the abridged schedule was introduced as the standard treatment and therefore no consent 
was obtained from the patients.  
Treatment 
All patients were treated with 2.2 mg/kg/day melarsoprol for 10 days, as a 3.6% solution in 
propylene glycol, by slow intravenous injection. Before melarsoprol treatment, all patients 
received anti-parasitic medication, multivitamins and paracetamol (acetaminophen) after the 
lumbar puncture. During melarsoprol treatment, prophylactic corticosteroid therapies were 
given according to the national guidelines. 
Adverse events were treated following the national guidelines, and in case of a severe 
adverse drug reaction, the treatment with melarsoprol was suspended and the patient treated 
accordingly and if possible, the melarsoprol treatment was resumed after 1 to 3 days, or 
considered completed if at least 8 doses were given. 
Outcome measures of efficacy 
Efficacy of the treatment was demonstrated by microscopic examination of the blood and/or 
lymph and CSF for the absence of trypanosomes and/or a reduction of the white blood cells. 
Patients were scheduled for clinical examination including lumbar puncture 24 hours after 
treatment and every 6 months during 2 years after treatment to monitor for treatment failures 
and relapses. Treatment failures were defined as cases in which trypanosomes could still be 
found in any body fluid 24 hours after treatment (primary efficacy outcome) and relapses 
(secondary efficacy outcome) as patients presenting at any time during the follow-up with 
trypanosomes in any compartment. Suspected relapses were patients who presented at any 
follow-up examination with an increased WBC count to more than 50 cells/mm3 and have 
doubled compared to previous examination or if the WBC count was 6 to 49 cells/mm3 and 
clear symptoms attributed to relapse (somnolence, long lasting headache, recurrent fever) 
were present. 
Outcome measures of safety 
The safety of the treatment was determined by the frequency of adverse events. The primary 
safety outcomes were death in temporal relation to treatment and the frequency of 
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encephalopathic syndromes. The rate of other severe adverse reactions (skin reactions, 
sensory and motor neuropathies) was defined as secondary outcome. The observation time 
for adverse events that were temporally related to the treatment was defined as from 
treatment start to hospital discharge (irrespective of the duration of hospitalisation). 
Follow-up 
Each patient was scheduled for clinical examination including lumbar puncture every 6 
months during 2 years after treatment to monitor for relapses. In addition to the regular case 
report forms, a follow-up form had to be filled for each patient.  
Conduct, responsibilities and monitoring 
The Swiss Tropical Institute had the overall responsibility of project execution. This included 
the design of the study, administrative aspects (coordination, communication, reporting) and 
the scientific evaluation and documentation of the study. 
On national levels, the program was coordinated with the sleeping sickness programs, or the 
NGO’s responsible for treatment where applicable. Locally, the execution of the project was 
the responsibility of the regular staff of the respective organisations. Apart from the 
introduction of a different treatment schedule and a case report form to fill per patient, a 
minimum of changes of existing structures and organisation was attempted. Each treating 
organisation was responsible for the correct follow-up of the patients according to the rules of 
the respective national authority. 
Ethical clearance in the respective countries for the conduct of the study was the 
responsibility of the national sleeping sickness control authorities. 
A data and safety monitoring board (DSMB) of experts was created to monitor the progress 
of the program on an annual basis and to evaluate cases of severe adverse events. 
Data Management and statistical analysis 
Data Management was done using EpiData 2.1 software [Lauritsen and Bruus 2001] and 
analysis with the statistical software package STATA 7.0 [Stata 2001]. The findings were 
compared to retrospective data of the participating centres, to literature and to the 
randomised clinical trial recently executed in Angola [Burri et al., 2000]. For the calculation of 
the efficacy, all patients treated were used as denominator to allow the comparison to 
previously reported rates. 
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In 2000, we reported that a new short treatment schedule of melarsoprol was not 
worse than the longer and demanding standard treatment for late-stage human African 
trypanosomiasis. This alternative schedule was assessed in an open, randomised 
clinical equivalence trial of 500 patients in Angola. 24 h after treatment, all patients 
were parasite free. Of 442 patients, 12 (3%) had relapsed after one year, of whom 7 
(3%) had had standard treatment and 5 (2%) the alternative treatment. After 2 years, 23 
(5%) relapsing patients were reported, 11 (5%) in the standard treatment group and 12 
(6%) in the new group. The results at the 2 year follow-up support and strengthen our 
previous findings. 
 
Melarsoprol is still the first-line drug for treatment of late-stage human African 
trypanosomiasis. After 50 years of this empirical treatment, an alternative short therapy was 
tested in an open, randomised clinical equivalence trial of 500 patients in two Angolan 
trypanosomiasis treatment centres (Cassoalala, Dondo) [Burri et al., 2000]. The clinical 
efficacy and safety of the alternative schedule was compared with that of the national 
standard treatment. Patients gave informed consent. The study protocol was approved by 
the review board of the Swiss Tropical Institute, the ethics committee of the University 
Hospital, Basel, Switzerland, and the ethics committee of the Ministry of Health, Luanda, 
Angola. The alternative treatment consisted of ten injections (2.2 mg/kg bodyweight) on 
consecutive days. Standard treatment consisted of three series of four consecutive injections 
of melarsoprol at doses increasing from 1.2 to 3.6 mg/kg bodyweight within each series; 
injections were given every 24 h, with a 7-day rest between the series. Parasitological cure 
24 h after treatment was 100% in both groups, and frequency and type of adverse events did 
not differ.  
We have now followed the patients for 2 years, as recommended by WHO [WHO 1998]. 
Patients were examined every 6 months after treatment. At all examinations a lumbar 
puncture was done and blood samples were taken. Blood and cerebrospinal fluid (CSF) were 
examined for trypanosomes and CSF for white blood cell count. Patients who did not attend 
were visited in the village and interviewed about their health status. Those not seen at a 
treatment centre or not interviewed at least once were regarded as lost to follow-up. 
Relapses were defined as patients with trypanosomes in CSF (or blood), or patients with a 
CSF white blood cell count of more than 50 cells per µL, which had at least doubled since the 
previous examination. Generally, the infection rate for sleeping sickness is low, and we did 
not have the technology to identify reinfections. Therefore all treatment failures were 
regarded as relapses.  
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We compared cure rates at 24 h and at 2 years after melarsoprol treatment, expressed as 
percentages of all parasite-negative patients who survived, irrespective the last time point of 
follow-up. Only 46 (9%) of patients treated had a CSF-confirmed infection, and 188 (38%) 
had a CSF white blood cell count of 6 -19 cells per L (standard treatment 102 [41%], 
alternative treatment 86 [34.4%]). This distribution could lead to a general underestimation of 
the relapse rate in this trial. Cure rates were compared by Blackwelder’s [Blackwelder 1982] 
method to test for equivalency, with the one-sided null hypothesis as follows: H0:    
(where  is the difference of the success measures between the standard and the alternative 
treatments, and  the specified difference between the efficacy of the two treatments of no 
more than 5%). Time to relapse was calculated with a modified formula of Blackwelder (SAS 
[Atherton Skaff and Sloan]). 
Of the 500 patients in the original trial, 483 had been discharged as cured (table). Patient 
baseline characteristics were similar for the two treatment regimens in both treatment 
centres. Despite the difficult political situation in Angola, 426 (88%) patients returned for at 
least one lumbar puncture during follow-up. 413 (86%) patients were seen at least once 
during the first year (391 [81.%] lumbar puncture, 22 [5%] interview). 301 (63%) patients 
were seen during the second year of follow-up (295 [61%] lumbar puncture, 6 [1%] 
interview). The compliance of patients with follow-up was acceptable, although it was lowest 
in the alternative treatment group towards the end of the 24 months.  
The cure rates of the two treatment schedules at discharge and at 2 years after treatment 
were much the same (table). During the 2 years of follow-up, 14 (3%) deaths were reported, 
one in each group being due to late complications of trypanosomiasis. Of the survivors, 23 
were deemed to have relapsed. In eight relapsing patients (35%; five [45%] on standard 
treatment; three [25%] on alternative treatment) trypanosomes were identified in CSF or 
blood. All other cases were diagnosed because of substantially raised CSF white blood cell 
counts. 12 (3%) of the relapses were diagnosed in the first year of follow-up and 11 (3%) in 
the second year. The mean time to relapse was 345 days (SD 210) since the end of 
treatment (standard treatment 314 days [SD 192]; alternative treatment 392 days [SD 203]) 
and time to relapse differed between the two treatment schedules (=-78 days; 95% CI - to 
57.5, p=0.128). There was no evidence of increased risk of relapsing in the study population 
(23/442 [5%]) compared with rates reported earlier in this area (2/56 [3.5%] [Ruiz et al., 
2002]), and the rates did not differ between the schedules. 
Irrespective of treatment schedule, several factors present on admission were associated 
with an increased risk of treatment failure: previous treatment for trypanosomiasis; CSF white 
blood cell count greater than 100 cells per L; and trypanosomes in CSF. These findings 
accord with previously described risk factors for treatment failure after melarsoprol [Legros et 
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al., 1999]. Of the enrolled patients, 42 (standard treatment 19, alternative treatment 23) had 
been treated for HAT during the 24 months (median 15 months) before the trial, half with 
melarsoprol. Patients who had been treated previously for trypanosomiasis were at 
increased risk to relapse (risk ratio 5.8 [95% CI 2.5–13.7]; p=0.0003). A CSF white blood cell 
count of more than 100 cells per L on admission was an important determinant of relapse 
(8.2 [2.8–19.7]; p<0.0001). Trypanosomes in CSF were seen in 46 of 500 patients at 
admission, and nine individuals subsequently relapsed (7.6 [2.8–13.8]; p=0.0002). Other 
factors associated with a higher risk of relapse in this study were: patients with a reduced 
level of consciousness at admission (2.6 [1.1–5.8]; p=0.036); body mass index less than 18.5 
(2.8 [1.1–6.4]; p=0.025); and treatment at the Dondo centre (3.8 [1.1–11.9]; p=0.041). In both 
groups, some patients had deviated from the treatment schedules [Burri et al., 2000] 
(standard treatment 89, alternative treatment 44), but this deviation did not have a significant 
effect on the later risk of relapse (1.2 [0.5–2.9]; p=0.853).  
Our results accord with the conclusion from our previous trial and provide evidence for the 
long-term effectiveness of the alternative treatment. The alternative schedule has proved as 
safe and effective as the standard schedule, and even though a lower total dose of 
melarsoprol was given, it did not increase the risk of treatment failure. The new regimen is a 
major advance over conventional regimens: it shortens time in hospital and leads to a 
reduction in melarsoprol dosage and costs. There is evidence that the alternative treatment 
is equal to the standard treatment in terms of safety and efficacy. A large-scale multinational 
trial is underway to corroborate these results. 
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 Table: Treatment outcome and results of follow-up after melarsoprol treatment, by treatment schedule 
Difference* 95% CI† p‡
n N % n N %  (%)
Treatment outcome
Number of patients treated 250 250
Cure rate at discharge§ 239 250 95.6 244 250 97.6 -2.0 -100, 0.7 <0.0001
Follow up (24 months)
Compliance during follow up¶ 224 239 93.7 218 244 89.3 4.4 -100, 8.5 0.403
  Number of patients seen for lumbar puncture 219 239 91.6 207 244 84.8 6.8 -100, 11.6 0.731
  Compliance 12 months¶ 208 239 87.0 205 244 84.0 3.0 -100, 8.3 0.267
  Compliance 13 - 24 months¶ 166 239 69.5 135 244 55.3 14.1 -100, 21.3 0.982
Survival during follow up 216 224 96.4 212 218 97.2 -0.8 -100, 1.9 0.0002
    Survival   12 months 220 224 98.2 214 218 98.2 0.0 -100, 2.1 <0.0001
    Survival 13 - 24 months 220 224 98.2 216 218 99.1 -0.9 -100, 0.9 <0.0001
Non-relapse during follow up 213 224 95.1 206 218 94.5 0.6 -100, 4.1 0.019
    Non-relapse  12 months 217 224 96.9 213 218 97.7 -0.8 -100, 1.7 <0.0001
    Non-relapse 13 - 24 months 220 224 98.2 211 218 96.8 1.4 -100, 3.9 0.008
Cured 24 months after treatment** 205 224 91.5 200 218 91.7 -0.2 -100, 4.1 0.024
Standard schedule (S) Alternative schedule (A)
Patient baseline characteristics and demographics are published in reference 1. n=number of affected individuals. N=Treatment group total. *Percentage difference of the outcome of 
standard and alternative schedules. †According to method of Blackwelder.3 ‡Left-hand sided p-value, a p-value smaller than 0.05 indicates equivalence between the standard and the 
alternative schedule. §Percentage of parasite-negative patients. ¶At least one lumbar puncture or oral interview in the respective period. **Number of patients seen at least once during 
follow up for which no report about a relapse or death was made.
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ABSTRACT  
Background  
Treatment of late-stage human African trypanosomiasis with melarsoprol can be substantially 
improved by abridging the treatment regimen. A previous large-scale controlled clinical trial 
had demonstrated non-inferiority of a new 10-day treatment schedule for melarsoprol. We 
now demonstrated the effectiveness of this abridged treatment in a non-controlled 
multinational drug utilisation study (IMPAMEL II). 
Methods  
2020 late-stage gambiense sleeping sickness patients were treated with the 10-day 
melarsoprol schedule in 16 centres of 7 African countries. The outcome was assessed based 
on the major adverse events and the cure rate after the treatment and a 2 years follow-up 
period. 
Results  
In average, the cure rate 24 hours after treatment was 93.9%. The effectiveness two years 
after treatment was 86%, but many patients did not attend any follow-up examination 
(46.3%). The overall fatality rate was 5.9%. Eight percent of the treated patients suffered 
from an encephalopathic syndrome, with a fatal outcome in 45.5%. The rate of severe 
bullous or maculopapular eruptions was 7.3%. All results showed the expected inter-centre 
variation 
Conclusions 
The treatment outcome of this study is very similar to the previously conducted controlled 
trial, to the retrospective data available from the centres and to literature. The 10-day 
treatment with melarsoprol has several advantages over the standard national treatment 
schedules: It reduces treatment duration, drug amount and hospitalisation costs per patient 
and it increases the treatment centres’ capacity. The abridged protocol was recommended 
by the 27th ISCTRC as the standard schedule for melarsoprol treatment of late-stage 
sleeping sickness due to T.b. gambiense. 
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BACKGROUND 
Human African Trypanosomiasis (HAT or sleeping sickness) ranks 3rd of all parasitic 
diseases in sub-Saharan Africa behind malaria and filariasis [WHO 1998] in terms of disease 
burden expressed in DALYs [2004]. Sixty million people in 36 African countries are at risk of 
becoming infected and the number of cases is estimated at 350’000 [WHO 1998]. Currently, 
only a fraction of the population at risk is under surveillance and therefore the 50’000 cases 
reported and treated per year may be a significant underestimation. Sleeping sickness is 
caused by the protozoan parasite Trypanosoma brucei sp. and is transmitted by the bite of 
the tsetse fly Glossina sp. [Burri and Brun 2002]. 
HAT occurs in two distinct forms: a chronic form due to Trypanosoma brucei gambiense and 
an acute form due to Trypanosoma brucei rhodesiense, whereof T.b. gambiense currently 
represents 99.5 percent of the cases [WHO 1998; Burri and Brun 2002]. In the early haemo-
lymphatic disease stage the trypanosomes multiply in blood and lymph glands, followed by 
central nervous system (CNS) invasion, corresponding to the late or meningo-encephalitic 
disease stage. Without treatment, the disease is invariably fatal. 
Today, two drugs are available for the treatment of the late-stage of HAT, eflornithine and 
melarsoprol. Eflornithine is difficult to administer, requires good logistics, and is expensive to 
manufacture. Therefore, it is of very limited use in rural treatment centres. In addition, it is 
ineffective against the acute form of the disease (T.b. rhodesiense). For those reasons and 
the lack of alternatives, melarsoprol, an organo-arsenic drug which is highly toxic and does 
not have a 100% cure rate [Legros et al., 1999; Stanghellini 2000], still remains the main 
drug for the treatment of late-stage HAT. A major problem of melarsoprol treatment is its long 
duration. 55 years after its market introduction, the treatment regimens vary considerably 
[WHO 1998]. Generally, 3 to 4 series of 3 to 4 injections of increasing doses spaced by rest 
periods of 7 to 10 days were given. To optimise and standardise melarsoprol treatment, an 
abridged 10-day protocol has been elaborated based on pharmacological investigations 
[Burri and Brun 1992; Burri et al., 1993; Burri 1994], animal experiments [Burri et al., 1994] 
and pilot testing in sleeping sickness patients in the former Zaire [Burri et al., 1995]. Its non-
inferiority in terms of safety and efficacy to standard treatment regimen was shown in a large-
scale randomised clinical trial in Angola [Burri et al., 2000; Schmid et al., 2004]. Treatment of 
sleeping sickness is often done in very basic centres in remote areas. To assess the 
effectiveness of the 10-day melarsoprol regimen under such conditions we carried out a 
multinational, multicentre drug utilisation study for the treatment of late-stage T.b. gambiense 
sleeping sickness.  
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METHODS  
Centres and patients 
The study was implemented in 16 sleeping sickness treatment centres suggested by the 
respective national sleeping sickness programs, or NGO’s where applicable, of 7 sub-
Saharan African countries with endemic T.b. gambiense. The minimal conditions for the 
centre selection were: reasonable accessibility, availability of retrospective data on HAT 
treatment for at least 12 months and the exclusive use of the new treatment schedule during 
the enrolment period of 12 months.  
Study design and implementation 
There are only few centres with good accessibility, security, sufficiently large number of 
patients to conduct clinical trials, and the equipment of rural sleeping sickness treatment 
centres is minimal and the staff is not trained for clinical trials. Therefore, a very simple study 
design without randomisation and sample size calculation was chosen. The enrolment period 
for each centre was 12 months to balance seasonal variations. The study was approved by 
the ethics committee of the two cantons of Basel (EKBB) and the relevant ethics committees 
and authorities in the respective countries. In the selected centres the abridged schedule 
was introduced as the standard treatment and therefore no consent was obtained from the 
patients.  
Inclusion criterion was confirmed late-stage gambiense sleeping sickness according to the 
criteria of the respective national sleeping sickness control program. Diagnosis of late-stage 
was done by microscopic examination of the cerebrospinal fluid (CSF) for the presence of 
trypanosomes and/or an elevated white blood cell (WBC) count. Different cut-off criteria for 
the WBC in CSF were used: > 5 WBC/mm3 in the Democratic Republic of Congo, Republic of 
Congo and Sudan;  10 WBC/mm3 in Equatorial Guinea;  20 WBC/mm3 in Angola and Côte 
d’Ivoire. 
Treatment 
Patients were treated with 2.2 mg/kg/day melarsoprol for 10 days, as a 3.6% solution in 
propylene glycol (Arsobal Aventis), by slow intravenous injection. Before melarsoprol 
treatment, all patients received supplementary medication: antimalarials (3 days chloroquine 
or Fansidar or 7 days quinine), mebendazole, multivitamins and paracetamol 
(acetaminophen). During melarsoprol treatment, different prophylactic corticosteroid 
therapies were given: prednisolone at a dose of 1 mg/kg on days 1-7, 0.75 mg/kg on day 8, 
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0.5 mg/kg on day 9 and 0.25 mg/kg on day 10 in Democratic Republic of Congo (Maluku and 
Kionzo), in Equatorial Guinea and in Sudan (Kajo Keji and some patients in LiRangu and 
Tambura); 1 mg/kg on days 1-9, 0.75 mg/kg on day 10, 0.5 mg/kg on day 11 and 0.25 mg/kg 
on day 12 in Angola; 1 mg/kg on days 1-9, 0.75 mg/kg on day 10 and 0.5 mg/kg on day 11 in 
Central African Republic; 0.75 mg/kg on days 1-10 in the Republic of Congo; 1 ml 
bethamethasone in Côte d’Ivoire; no prednisolone but promethazine (antihistamine) on days 
1-10 was given to the patients in one centre of the Democratic Republic of Congo 
(CNPP/CUK Kinshasa). 
In case of a severe adverse event or encephalopathic syndrome, the treatment with 
melarsoprol was suspended and the patient was treated following the national guidelines, 
e.g. with adrenaline (epinephrine), corticosteroids (usually hydrocortisone) and/or diazepam. 
If possible, the melarsoprol treatment was resumed after 1 to 3 days, or considered 
completed if already 8 or more doses were given. 
For each patient a case report form was filled, which contained demographic, diagnostic and 
clinical characteristics before and after treatment, and an assessment of adverse events on a 
graded scale from 0 to 2 (none, moderate, severe reaction). 
Outcome measures 
Efficacy of the treatment was demonstrated by microscopic examination of the blood and/or 
lymph and CSF for the absence of trypanosomes and/or a reduction of the white blood cells. 
Patients were scheduled for clinical examination including lumbar puncture 24 hours after 
treatment and every 6 months during 2 years after treatment to monitor for treatment failures 
and relapses. Treatment failures were defined as cases in which trypanosomes could still be 
found in any body fluid 24 hours after treatment, relapses as patients presenting at any time 
during the follow-up with trypanosomes in any compartment and/or an increase of the WBC 
in CSF to more than 50 cells/mm3 or have a duplication of WBC compared to the previous 
examination with clear symptoms attributed to relapse (somnolence, long lasting headache, 
recurrent fever). The primary efficacy outcome was parasitological cure 24 hours after 
treatment (treatment failures) and the secondary relapsing within the follow-up period.  
The safety of the treatment was determined by the frequency of adverse events. The primary 
safety outcomes were death in temporal relation to treatment and the frequency of 
encephalopathic syndromes. The rate of other severe adverse reactions (skin reactions, 
sensory and motor neuropathies) was defined as secondary outcome.  
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Data Management and statistical analysis 
All data were double entered and verified using EpiData 2.1 [Lauritsen and Bruus 2001] 
software and analysis was done with the statistical software package STATA 7.0 [Stata 
2001]. The findings were compared to historic data from the participating centres, to literature 
(Table 4) and to the randomised clinical trial recently executed in Angola [Burri et al., 2000; 
Schmid et al., 2004]. For calculation of the efficacy the totality of the patients treated were 
used as denominator to allow the comparison to previously reported rates. 
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RESULTS  
Study population and baseline characteristics 
A total of 2800 patients were enrolled between June 1999 and June 2002. 780 patients were 
not eligible for the analysis (Graph 1) due to erroneous classification (early stage patients, 
tuberculosis case), abandon during treatment, other treatment than 10-day melarsoprol 
schedule (eflornithine, nifurtimox or combination therapy), biased inclusion (selected 
enrolment of patients in good health state or restriction to adults only) or centres enrolling for 
less or more than 12 months (in the latter centres the data were truncated to the first 12 
months). The final cohort analysed consisted of 2020 patients correctly diagnosed and 
treated according to protocol with or without treatment interruptions from 10 sleeping 
sickness treatment centres of 5 countries. 
The demographic, diagnostic and clinical characteristics of the patients are shown in Table 1. 
Age, sex and nutritional status distributions at admission were similar in the patients from the 
different centres. The diagnostic findings varied from centre to centre probably influenced by 
different methodology and cut-off criteria. The majority of the patients presented with 
lymphadenopathy, headache, pruritus, general weakness and sleeping disorders but a large 
variation of clinical manifestations between the centres was evident. Concomitant infections 
were frequent, in 70% of all patients at least one other parasitic infection apart from sleeping 
sickness was diagnosed (malaria, schistosomes, filaria, amoeba, giardia, geohelminths or 
hookworms), but not all patients were systematically screened for those diseases, causing a 
high grade of missing data (data not presented). 
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Graph 1: Study profile of IMPAMEL II  
 
 
 
*7 of the relapses died during follow-up and are also included in the deaths during follow-up 
 Total Angola Côte d'Ivoire Dem Rep Congo Equatorial Guinea Sudan
(N = 2020) (N = 337) (N = 27) (N = 532) (N = 13) (N = 1111)
Age (years)
  Median 27 25 15 30 30 26
  Range 1 - 80 1 - 74 2 - 51 1 - 80 11 - 64 1 - 70
Male Sex - no. (%) 988 (49) 177 (53) 13 (48) 261 (49) 9 (69) 528 (48)
Nutritional status
  Body Mass Index (BMI, kg/m2) - mean ± SD 18.5 ± 3.1 18.2 ± 3.4 17 ± 2.7 18.8 ± 3.6 19 ± 2.9 18.4 ± 2.8
  Severe malnutrition (BMI<16.5)* - no. (%) 551 (27) 115 (34) 7 (26) 153 (29) 5 (38) 271 (24)
Previous HAT treatment** - no. (%) 151 (7) 17 (5) 8 (30) 17 (3) 0 (0) 109 (10)
  thereof Arsobal - no. (%) 45 (30) 1 (6) 1 (13) 12 (71) 0 (0) 31 (28)
Diagnostic findings
  Lymphadenopathy - no. (%) 1178 (58) 192 (57) 9 (33) 288 (54) 13 (100) 676 (61)
  Trypanosomes in any compartment - no. (%) 1755 (87) 278 (82) 27 (100) 508 (95) 12 (92) 930 (84)
  Trypanosomes in CSF - no. (%) 816 (40) 227 (67) 25 (93) 229 (43) 6 (46) 329 (30)
  Trypanosomes in blood / lymph - no. (%) 1043 (52) 176 (52) 15 (56) 260 (49) 11 (85) 581 (52)
   White Blood Cell Count in CSF
     5 - 19 cells/ul - no. (%) 536 (26) 2 (1) 0 (0) 151 (28) 0 (0) 383 (34)
     20 - 100 cells/ul - no. (%) 604 (30) 100 (29) 4 (15) 131 (25) 6 (46) 363 (33)
     > 100 cells/ul - no. (%) 880 (44) 235 (70) 23 (85) 250 (47) 7 (54) 365 (33)
     Median 70 170 278 82 118 37
     Mean ± SD 180 ± 240 230 ± 210 320 ± 210 240 ± 310 200 ± 210 130 ± 200
Clinical manifestations
  Drowsy - no. (%) 318 (16) 108 (32) 3 (11) 128 (24) 1 (8) 78 (7)
  Headache - no. (%) 1616 (80) 308 (91) 19 (70) 342 (61) 11 (85) 954 (86)
  Fever (>37.5°C) - no. (%) 326 (16) 41 (12) 13 (48) 25 (5) nd 247 (22)
  Pruritus - no. (%) 1017 (50) 106 (31) 15 (56) 168 (32) 11 (84) 717 (65)
  Weakness - no. (%) 692 (34) 131 (39) 7 (26) 244 (86) 7 (54) 303 (27)
  Walking difficulties - no. (%) 419 (21) 113 (34) 5 (19) 89 (17) 5 (38) 207 (19)
  Abnormal movements - no. (%) 201 (10) 39 (12) 8 (30) 71 (13) 0 (0) 83 (7)
  Speech impairment - no. (%) 266 (13) 77 (23) 6 (22) 79 (15) 2 (15) 102 (9)
  Sleeping disorder - no. (%) 1466 (73) 202 (60) 25 (93) 504 (95) 12 (92) 723 (65)
  Strange behaviour - no. (%) 520 (26) 54 (16) 18 (67) 81 (15) 2 (15) 365 (33)
*age and sex adjusted in case of children; ** within two years before admission to IMPAMEL II; nd: determination not done
Table 1: Pre-treatment characteristics of the patients 
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Treatment compliance 
The average adherence to the treatment regimen was 67.1% (1355/2020; Graph 2). 78.1% 
(1578/2020) finished treatment with an interruption of less than 2 days and overall, 88.8% 
(1793/2020) of the patients received the 10 doses. Non-adherence resulted from treatment 
interruption due to severe adverse reactions but treatment was resumed in most cases after 
2-4 days (median 2; mean 4, standard deviation 4 and range 1–24 days). Most of the 
interruptions occurred on days 8 to 10 of treatment. The treatment centres in South Sudan 
reported a much higher deviation from the treatment schedule and compliance as low as 
54% compared to 67-88% in the other countries. These were also the centres with the 
highest rates of reported moderate adverse events (Table 3). 
Graph 2: Compliance to treatment schedule, by country 
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Effectiveness 
Parasitological cure 24 hours after treatment was 93.9% (1897/2020, centres’ range 85.7–
100%; Graph 1, Table 2). 119 (5.9%) patients died during treatment and in 4 (0.2%) patients 
trypanosomes were detected, they were treated for relapse. Two years after treatment, the 
observed cure rate was 86.2% (1742/2020) with a considerable inter-centre variation (range 
from 70.9 to 100%). Follow-up participation was highly variable (15% to 100%, data not 
shown). Many of the patients cured at discharge did not attend any of the foreseen clinical 
follow-up examination (936/1897, 49.3%) and were considered cured. 50.7% (961/1897) 
underwent at least one of the four prescribed follow-up examinations with lumbar puncture 
(LP) and thereof 144 (7.1%; 144/2020) were diagnosed as relapses. 18 patients (0.9%, 
18/2020) died during the follow-up, 7 after relapsing (0.3%, 7/2020). In 53 (36.8%, 53/144) of 
the relapses, trypanosomes could either be demonstrated in blood (7, 4.9%) or in CSF (46, 
31.9%). All other relapses were diagnosed by an elevated WBC CSF count of more than 50 
cells/mm3 (61, 42.4%) or by a WBC CSF count that had at least doubled since hospital 
discharge and with clear symptoms of the disease (30, 20.8%). Relapses were not further 
analysed due to the high variation of the follow-up coverage of the different centres. 
 
Safety 
The safety results are presented in Table 3, the adverse events are tabulated in numbers 
and proportions of patients affected, detailed by country and the recorded grades. The 
results reflect the expected high variation observed in sleeping sickness treatment.  
During treatment, 119 patients died, in average after 9 days of treatment (range 1–29 days). 
The major causes were encephalopathic syndromes, attributing to 67.2% (80/119) of the 
fatalities. Other causes were: advanced HAT (15, 12.6%), concomitant diseases (10, 8.4%), 
unknown aetiology (9, 7.6%) and bullous skin reactions (5, 4.2%). 
176 (8.7%) patients suffered from an encephalopathic syndrome and they generally received 
i.v. steroids at different doses. The onset of the encephalopathic syndrome was reported 
after an average of 9 days of treatment (median 9, mean 9.2, range 1–28 days). In those 
who survived, treatment was resumed after a suspension of 3 days (median 3, mean 3.2, 
range 1–12 days). No significant seasonal variation was observed in any of the centres (data 
not shown). Headache preceded the onset of the encephalopathic syndrome in 34% (60/176) 
and fever in 54% (95/176) of the cases. In 23% (40/176) of the patients suffering from an 
encephalopathic syndrome, malaria parasites were detected during the syndrome, probably 
causing the fever in 20 (11.4%, 20/176) of them. The effect of prophylactic use of 
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prednisolone could only be evaluated for 2 southern Sudanese centres that provided reliable 
information for each patient. In those centres, 163 of 607 (26.8%) patients received 
prednisolone. The risks of those to develop an encephalopathic syndrome or of a fatal 
outcome were non-significant (RR=1.3, 95% confidence interval 0.8 to 2.2, p=0.286 and 
RR=1.4, 95% confidence interval 0.5 to 3.9, p=0.598, respectively). 
The frequency of skin reactions was high (28.3%, 571/2020) but varied between the centres. 
The majority of recorded skin reactions were moderate (grade 1) pruritus (20.4%, 412/2020). 
Only one third of the patients with skin reactions suffered from severe (grade 2) 
maculopapular eruptions (6.8%, 138/2020), pruritus (3.3%, 66/2020) or bullous eruptions 
(0.84%, 17/2020), which lead to temporary suspension of treatment. Most of the skin 
reactions were consistently not considered a significant problem by the treating staff and 
could be controlled with steroids or promethazine. Patients in south Sudan who received 
prednisolone as prophylactic treatment were at a lower risk of developing a moderate skin 
reaction (RR=0.6, 95% confidence interval 0.4 to 0.8, p=0.0004).  
Motor and sensitivity neuropathies occurred at a frequency of 6.3% (128/2020). Other 
adverse drug reactions often reported included fever and headache. However, these are 
common symptoms and signs of the disease and not easy to discriminate from adverse 
event during treatment. Less frequently reported reactions included diarrhoea, jaundice and 
hypotension. 
 
 Table 2: Short and long-term efficacy of the 10-day melarsoprol treatment schedule (24 hours after treatment and during follow-up), 
compared to IMPAMEL I, centres history and literature 
Impamel II Center History Literature
10-day treatment Standard treatment 10-day treatment Standard treatment Standard treatment
(N = 2020) (N = 2215) (N = 250) (N = 250) (%)*
Fatalities during treatment - no. (%) 119 (5.9) 117 (5.3) 6 (2.4) 6 (2.4) 9.4
Treatment failures at discharge - no. (%) 4 (0.2) 18 (0.8) 0 (0) 0 (0) < 1
Cured at discharge - no. (%) 1897 (93.9) 2080 (93.9) 244 (97.6) 239 (95.6) 90.6
Fatalities during follow up - no. (%) 18 (0.9)** nd 6 (2.8) 8 (3.6) nd
Relapses during follow up - no. (%) 144 (7.7)** 54 (2.6) 12 (5.5) 11 (4.9) < 30
Lost during follow up - no. (%)*** 936 (49.3) 2026 (97.4) 26 (10.7) 15 (6.3) nd
Cured 2 years after treatment - no. (%)*** 1742 (86.2) 2026 (91.5) 226 (90.4) 230 (92) 70-90
Impamel I
*N highly variable, often only percentages were published; **7 of the relapses died and are included in both, the relapses and the deaths;
***Assumption: All patients lost are considered cured, denominator = all patients treated; nd: no data available 
 
 
 
 Total Angola Côte d'Ivoire Dem Rep Congo Equatorial Guinea Sudan
(N = 2020) (N = 337) (N = 27) (N = 532) (N = 13) (N = 1111)
Fatalities - no. (%)* 119 (5.9) 24 (7.1) 2 (7.4) 45 (8.5) 1 (7.7) 47 (4.2)
Encephalopathic syndromes  (ES) 176 (8.7) 18 (5.3) 0 (0) 49 (9.2) 1 (7.7) 108 (9.7)
  Grade 3 (fatal) - no. (%) 80 (4.0) 13 (3.9) 0 (0) 33 (6.2) 1 (7.7) 33 (3)
    Case fatality rate (% fatal ES) 45 72 0 67 100 31
  Grade 2 (coma, convulsion) - no. (%) 72 (3.6) 5 (1.5) 0 (0) 13 (2.4) 0 (0) 54 (4.9)
  Grade 1 (psychotic) - no. (%) 24 (1.2) 0 (0) 0 (0) 3 (0.6) 0 (0) 21 (1.9)
Bulluous eruptions
  Any - no. (%) 30 (1.5) 7 (2.1) 0 (0) 12 (2.3) 1 (7.7) 10 (0.9)
  Severe - no. (%) 17 (0.8) 3 (0.9) 0 (0) 8 (1.5) 0 (0) 6 (0.5)
Maculopapular eruptions
  Any - no. (%) 228 (11.3) 31 (9.2) 9 (33.3) 58 (10.9) 1 (7.7) 129 (11.6)
  Severe - no. (%) 138 (6.8) 25 (7.4) 7 (26.0) 45 (8.5) 0 (0) 61 (5.5)
Pruritus
  Any - no. (%) 478 (23.7) 41 (12.2) 4 (14.8) 44 (8.3) 2 (15.4) 387 (34.8)
  Severe - no. (%) 66 (3.2) 1 (0.3) 0 (0) 26 (4.9) 0 (0) 39 (3.5)
Motor polyneuropathy
  Any - no. (%) 128 (6.3) 13 (3.9) 0 (0) 9 (1.7) 0 (0) 106 (9.5)
  Severe - no. (%) 37 (1.4) 6 (1.8) 0 (0) 8 (1.5) 0 (0) 23 (2.1)
Sensitivity polyneuropathy
  Any - no. (%) 64 (3.2) 1 (0.3) 0 (0) 4 (0.7) 0 (0) 59 (5.3)
  Severe - no. (%) 24 (1.2) 0 (0) 0 (0) 3 (0.6) 0 (0) 21 (1.9)
Febrile reaction
  Any (37.5 - 39°C) 653 (32.3) 39 (11.6) 24 (88.9) 109 (20.5) 2 (15.4) 479 (43.1)
  Severe (>39°C) 233 (11.5) 17 (5.0) 11 (40.7) 53 (10.0) 1 (7.7) 151 (13.6)
Headache
  Any - no. (%) 599 (29.6) 43 (12.8) 4 (14.8) 21 (4) 4 (30.8) 527 (47.6)
  Severe - no. (%) 146 (7.2) 16 (4.8) 0 (0) 11 (2.1) 2 (15.4) 117 (10.5)
Diarrhea
  Any - no. (%) 173 (8.6) 5 (1.5) 0 (0) 11 (2.1) 3 (23.1) 154 (13.9)
  Severe - no. (%) 45 (2.2) 1 (0.3) 0 (0) 3 (0.6) 1 (7.7) 40 (3.6)
Hypotension
  Any - no. (%) 60 (3.0) 5 (0.5) 0 (0) 23 (4.3) 0 (0) 32 (2.9)
  Severe - no. (%) 16 (0.8) 0 (0) 0 (0) 13 (2.4) 0 (0) 3 (0.3)
Jaundice
  Any - no. (%) 9 (0.5) 1 (0.3) 0 (0) 2 (0.4) 0 (0) 6 (0.5)
  Severe - no. (%) 5 (0.2) 0 (0) 0 (0) 2 (0.4) 0 (0) 3 (0.2)
The results are comparable to those obtained in the controlled clinical trial conducted by Burri et al., 2000 in Angola; *All fatalities during treatment, including fatal ES
Table 3: Adverse events by country  
 
 Table 4: Comparison of the occurrence of severe adverse events during the 10-day melarsoprol treatment schedule (IMPAMEL II) with the 
standard treatment (IMPAMEL I), the centres history and the literature 
Impamel II Center History Literature
10 day treatment Standard treatment 10 day treatment Standard treatment Standard treatment
(N = 2020) (N = 2215) (N = 250) (N = 250) mean % (range)*
Fatalities - no. (%) 119 (5.9) 117 (5.3) 6 (2.4) 6 (2.4) 9.4 (2.7 - 34)
Encephalopathic syndromes  (ES)† - no. (%) 152 (7.5) 184 (8.3) 14 (5.6) 14 (5.6) 4.7 (1.5 - 23.5)
  Grade 3 (fatal) - no. (%) 80 (4.0) 87 (3.9) 6 (2.4) 6 (2.4) 4.1 (3.3 - 34)
    Case fatality rate (% fatal ES) 52.6 47.3 42.9 42.9 43.8 (33 - 100)
Skin reactions - no. (%) 166 (8.2) 35 (1.6) 23 (9.2) 13 (5.2) < 3
  Bulluous eruptions - no. (%) 17 (0.8) 4 (0.2) 3 (1.2) 1 (0.4) < 1
  Maculopapular eruptions - no. (%) 138 (6.8) 20 (0.9) 12 (4.8) 6 (2.4) nd
  Pruritus - no. (%) 66 (3.3) 11 (0.5) 8 (3.2) 6 (2.4) 5
Polyneuropathies‡ - no. (%) 54 (2.7) 24 (1.1) 2 (0.8) 1 (0.4) < 10
Febrile reaction - no. (%) 233 (11.5) 72 (3.2) 15 (6.0) 12 (4.8) 12
Headache - no. (%) 146 (7.2) 43 (1.9) nd nd nd
Diarrhea - no. (%) 45 (2.2) 19 (0.9) 6 (2.4) 4 (1.6) < 25
Hypotension - no. (%) 16 (0.8) 19 (0.9) nd nd < 1
Jaundice - no. (%) 5 (0.2) 3 (0.1) nd nd < 3
Impamel I
*N highly variable, often only percentages were published; †Grades 2 (convulsion, coma) and Grades 3 (fatal); ‡motor or sensitivity polyneuropathies; nd: 
not determined or no data available 
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DISCUSSION  
The presented study (IMPAMEL II) was a non-controlled, multinational, multi-centre drug 
utilisation study to evaluate the abridged treatment schedule of melarsoprol in late-stage T.b. 
gambiense sleeping sickness patients under true field conditions. Due to the very basic 
equipment of the treating centres, the often low level of staff qualification and the lack of 
experience in the conduct of clinical trials it was not possible to conduct a randomised study. 
Cluster randomization was also considered impossible because of the inherent differences in 
the outcome of the sleeping sickness treatment in different centres and countries and the 
limited number of centres available for participation. The 12 months enrolment period was 
selected to make apparent a potential seasonal variation of the outcome [Ancelle et al., 
1994]; centres that enrolled patients for less than 12 months were excluded from the formal 
analysis and those reporting for a longer period were truncated after the first 12 months. 
Other patients excluded from the formal analysis were those treated in a centre where a 
patient selection based on self-defined criteria was applied, e.g. adults only or patients 
admitted in a good health state. 
The study population corresponded to the average population of African countries [UNDP 
2003] except for the patients treated in Côte d’Ivoire (n=27), which were much younger 
(median age 15 years) than the overall study population (median age 27 years). The clinical 
conditions and the diagnostic characteristics of the patients at admission were highly variable 
between the centres, reflecting the different levels of surveillance activities in the countries, 
the diverse qualification of staff (nurses versus medical doctors, national control programs 
versus NGOs), and the different possibilities and perceptions of the staff. However, there 
was no difference in the outcome of the treatment between the cohorts diagnosed according 
to the different cut-off criteria in use (data not shown).  
The average short term (93.9%; 1897/2020) and long term (86.2%; 1742/2020) 
effectiveness, based on “all patients treated” as denominator and considering patients not 
seen during the follow-up as cured, were comparable to the standard treatment [Richet et al., 
1959; Dutertre and Labusquiere 1966; Bertrand et al., 1973; Burri et al., 2000; Atouguia and 
Kennedy 2000; Brun et al., 2001; Pepin et al., 2002] and the centre histories, where 
available. This approach is somewhat unsatisfactory since it leads to an overestimation of 
the effectiveness, but allows best the comparison to the literature. The follow-up coverage 
rates in our study were highly variable between the centres (0% - 100%). In average only 
50% of all patients attended at least one follow-up examination, most of them within the first 
year after treatment, and therefore the true failure rates in this study are difficult to estimate.  
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The safety and tolerability of the 10-day melarsoprol treatment schedule were similar to 
those of the standard treatment schedules [Ginoux et al., 1984; Nkanga et al., 1988; Pepin et 
al., 1989; Doua and Yapo 1993; Pepin et al., 1995; Burri et al., 2000; Blum et al., 2001; 
Seixas et al., 2004] with the exception of skin reactions, fever and headache (Table 4). The 
variability of the adverse events between the different study centres was high, but in an 
expected range and comparable results were found in a separate analysis of the patients 
excluded from the formal analysis. Mild symptoms and signs like fever (32.3%), headache 
(29.6%) and pruritus (23.7%), which are also common symptoms and signs of the disease 
were more frequently reported during the study. This may be an observation bias prompted 
by soliciting information which usually is not recorded. The notion that more treatment 
interruptions caused by moderate adverse events were reported in centres run by NGOs 
supports this reflection. 
The frequency of treatment related death was 5.9% (119/2020) and the most severe 
reactions were encephalopathic syndromes (8.7%, 176/2020). These rates are comparable 
to published rates [Kuzoe 1993; Pepin and Milord 1994; Seixas et al., 2004] although at the 
upper end of the range. In line with previous reports [Ginoux et al., 1984; Doua et al., 1985; 
Adams et al., 1986; Pepin and Milord 1994; Ancelle et al., 1994; Soignet et al., 1999; Burri et 
al., 2000; Blum et al., 2001; Seixas et al., 2004] encephalopathic syndromes occurred 
between days 1 and 28 after the initial injection of melarsoprol with a maximum between 
days 9 and 11 (mean 9.2, standard deviation 4 days), supporting the view that the event is 
independent of the treatment schedule and dose applied. Also, the resumption of 
melarsoprol after interruption and improvement of the patient did never result in a recurring 
reaction. In our cohort we could not make a clear distinction of the type of the 
encephalopathic syndrome as described by Blum et al. [Blum et al., 2001] (data not shown). 
The effect of prednisolone prophylaxis could only be evaluated for 2 treatment centres in 
Sudan because all other centres used different dosage regimes or for many patients 
information was not detailed enough. There was no prophylactic effect of prednisolone on the 
development of an encephalopathic syndrome or a difference in the case fatality rate in this 
cohort as was suggested by Pepin et al [Pepin et al., 1989]. However, a clear protection of 
the development of moderate drug related skin reactions could be observed with 
prednisolone [Pepin and Milord 1994].  
This study (IMPAMEL II) corroborates the results of the randomised controlled clinical trial 
previously conducted in Angola [Burri et al., 2000] (IMPAMEL I) that had demonstrated non-
inferiority in terms of efficacy and safety of the 10-day melarsoprol treatment schedule 
compared to the standard treatment schedule: The overall frequency of adverse events was 
high, but again there was no increase compared to the standard treatment schedules, except 
for skin reactions. At hospital discharge, symptoms and signs, like pruritus, fever, headache, 
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tremor, weakness and unusual behaviour had substantially improved (data not shown). Also, 
the long-term effectiveness appeared to be equivalent to the standard treatment [Schmid et 
al., 2004] in our approach where the follow-up activities were purposely not assisted. 
The 10-day schedule has several socio-economic and practical advantages over the very 
lengthy standard schedules: The suggested treatment is comparable in terms of safety and 
effectiveness, and favourable in socio-economic (less drug, shorter hospitalisation, increased 
treatment centre capacity), technical (10 consecutive days, no dosage adjustment), 
pharmacologic (basis of all combinations of melarsoprol in the compassionate treatment of 
refractory cases) and psychological terms (patients’ and doctors’ compliance to adhere to 
treatment). Therefore, the 10-day schedule has already become a useful alternative to the 
lengthy standard treatment (average duration 25 – 30 days). Its use was continued in several 
countries (e.g. Central African Republic, Côte d’Ivoire, Democratic Republic of the Congo, 
Equatorial Guinea and Republic of the Congo). Based on the results of IMPAMEL I and 
IMPAMEL II and the experiences in the countries, the 10-day melarsoprol treatment was 
recommended on request of WHO to the endemic countries as standard schedule for 
treatment of late-stage T.b. gambiense sleeping sickness with melarsoprol at the occasion of 
the 27th ISCTRC congress (International Scientific Counsel for Trypanosomiasis Research 
and Control) in Pretoria in September 2003 [2003]. The 10-day melarsoprol treatment 
schedule is currently being implemented by the national sleeping sickness programs.  
Cleary, the tolerability and safety of melarsoprol are inferior to those of eflornithine [Burri and 
Brun 2003]. However, eflornithine administration as slow infusions every 6 hours over 14 
days is difficult and requires qualified staff and very good logistics. Therefore, eflornithine 
remains restricted to centres with substantial and consistent support by NGOs and the vast 
majority of patients still are treated with melarsoprol.  
Also, melarsoprol is still is the only treatment for T.b. rhodesiense because of inconsistent 
efficacy of eflornithine against this form of the parasite. However, the use of the melarsoprol 
10-day schedule against T.b. rhodesiense is strongly discouraged. The clinical nature of this 
form is very different and high parasitaemia is observed. However the conduct of confirming 
clinical evaluation is still pending. 
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SUMMARY  
In many areas endemic for sleeping sickness, high incidences of malaria, filaria or intestinal 
parasites are common and the overlap in the geographic distribution of these parasites 
implies that co-infections might occur. In the multinational IMPAMEL II study, a high proportion 
of patients was diagnosed with other parasites than trypanosomes. To determine the effect 
of concomitant parasitic infections on the reported adverse events during melarsoprol 
treatment, we analysed the adverse events with special emphasis to their management and 
the associations between the concomitant parasites and the occurrence of the events.  
In average, 41.7% of the patients were diagnosed on admission or during melarsoprol 
treatment with other parasitic infections than trypanosomiasis and the rates differed highly 
between the centres from 0 – 66.3%. Of those, 70.4% suffered from an adverse event during 
treatment with the 10-day schedule of melarsoprol. The general procedures to manage the 
adverse events are summarised and explore the association with concomitant parasitic 
infections, based on the diagnostic findings and the outcome assessment of the study 
obtained through a standardised questionnaire. 
We found elevated risks for adverse events linked to concomitant parasites, which were also 
reflected by the type of medication given during the management of adverse events. It 
remains unclear whether the events were related or aggravated due to the concomitant 
parasitic infections or were real melarsoprol related reactions. Nevertheless, concomitant 
parasitic infections should be considered on hospital admission and throughout the treatment 
course of sleeping sickness patients and therefore be diagnosed and treated accordingly and 
systematically. 
52   
BACKGROUND 
In sub-Saharan Africa, multiple parasitic infections are widespread and pose an enormous 
toll on the socio-economic development [Buck et al., 1978; WorldHealthReport 2004]. 
Amongst all parasitic infections, malaria, filaria and gastro-intestinal parasites are the most 
important, expressed in disease burden (DALY, [WorldHealthReport 2004]). The overlap in 
the geographic distribution implies that co-infections might occur in many sleeping sickness 
endemic areas. In addition, as a result of their disease, sleeping sickness patients are 
believed to be highly immunosuppressed and likely to be more susceptible to concomitant 
infections [Greenwood et al., 1973; Sternberg 1998]. Therefore, concomitant parasitism 
should be a fairly common feature but only few authors have documented concomitant 
parasites in sleeping sickness patients [Sina et al., 1975; Buyst 1975; Balint and Wenninger 
1975; Sina et al., 1977; Buyst 1977; Burri et al., 1995; Aroke et al., 1998]. Even less 
information is available about the influence of concomitant parasitic infections on the clinical 
progression or on the outcome of sleeping sickness treatment with melarsoprol. 
Nevertheless, WHO [WHO 1998], NGOs [Balasegaram et al., 2004] and the national 
sleeping sickness programs recommend a standardised pre-treatment with antimalarial and 
anthelminthic drugs before starting the sleeping sickness therapy. 
The drug most often used to treat late-stage sleeping sickness is melarsoprol, an organo-
arsenic drug which is highly toxic and does not have a 100% cure rate [Legros et al., 1999; 
Stanghellini and Josenando 2001]. For decades, variable treatment regimens [WHO 1998] 
were applied until the introduction of the concise 10-day treatment schedule (IMPAMEL I, 
[Burri et al., 2000]. The effectiveness under normal field conditions of this improved treatment 
schedule was further assessed in a multinational drug utilisation study in late-stage T.b. 
gambiense sleeping sickness patients [Anonymous 2003; Schmid et al., 2004]. Despite the 
advantages of the 10-day treatment regimen (less drug, shorter hospitalisation, 
harmonisation of treatment schedule, increase of treatment centres’ capacity and decrease 
of costs for treatment and hospitalisation), adverse events are still frequent and may be 
severe [WHO 1998].  
The most frequent adverse events are fever, skin reactions and CNS complications like 
encephalopathic syndromes that may arise in up to 10% of the treated patients [Pepin et al., 
1989; Doua and Yapo 1993; WHO 1998]. The measures to reduce the frequency and 
severity of the CNS complications are often erratic and depend much on the available 
resources that are scarce in rural sleeping sickness treatment centres. Interruption of 
melarsoprol and high doses of corticosteroids and anticonvulsive drugs are the 
recommended measures [WHO 1998]. Psychotic reactions are best managed by sedation 
(chlorpromazine or diazepam). In contrast, the concomitant administration of corticosteroids 
Chapter 3  53 
(prednisolone) remains controversial: some authors demonstrated a positive prophylactic 
effect of prednisolone during melarsoprol treatment [Pepin et al., 1989], whereas others warn 
of the administration of immunosuppressants in areas with high prevalence of certain 
infectious diseases for fear of an exacerbation (i.e. HIV, strongyloides, amoeba 
[Balasegaram et al., 2004]). Recommendations for the management of other severe adverse 
events (polyneuropathies, skin reactions) are often more general, advising to interrupt 
treatment (both events) or to perform differential diagnosis to exclude possible concomitant 
infections (skin reactions). Additionally, for those admitted with severe malnutrition, nutritional 
supplementation with multivitamins, specific vitamins and folic acid, in some cases also iron 
is recommended. Routine pre-treatment with broad-spectrum antibiotics is not 
recommended, except if the patient has evidence of a bacterial infection [Balasegaram et al., 
2004].  
To determine the effect of concomitant parasitic diseases on the reported drug related 
adverse events and their management, we analysed the patients treated with melarsoprol in 
the IMPAMEL II study [Schmid et al., 2004].  
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METHODS 
Study design and study population 
Data were collected between June 1999 and June 2002 in the frame of the drug utilisation 
study IMPAMEL II, which evaluated the 10-day melarsoprol treatment protocol under field 
conditions. Detailed characteristics of the study population and study design are presented in 
chapters 2 and 4. Briefly, all patients with confirmed late-stage sleeping sickness due to T.b. 
gambiense were enrolled in 16 selected treatment centres of 7 sub-Saharan African 
countries (Angola, Central African Republic, Côte d’Ivoire, Democratic Republic of Congo, 
Equatorial Guinea, Republic of Congo and Sudan). For each patient a questionnaire was 
completed containing demographic, diagnostic and clinical characteristics at admission, 
tolerability assessment and management of adverse events during treatment, and efficacy 
assessment on discharge (24 hours after treatment) and during the 2 years follow-up.  
The study was approved by the ethics committee of the two cantons of Basel (EKBB) and the 
relevant ethics committees and authorities in the respective countries. In the participating 
centres the abridged schedule was introduced as the sole treatment and therefore no 
consent was obtained from the patients.  
Diagnosis and Treatment  
Diagnosis of late-stage sleeping sickness was done by microscopic examination of the 
cerebrospinal fluid (CSF) for the presence of trypanosomes and/or an elevated white blood 
cell (WBC) count, of which the cut-off differed slightly between the countries (chapter 2). 
Patients were treated with 2.2 mg/kg/day melarsoprol for 10 days, as a 3.6% solution in 
propylene glycol (Arsobal, Aventis), by slow intravenous injection.  
Diagnosis of concomitant parasitic diseases was not mandatory in this study, but prior to 
melarsoprol treatment, all patients were pre-treated with multivitamins, paracetamol and 
antiparasitic drugs for 3 days according the respective national guidelines for sleeping 
sickness therapy: antimalarials - Fansidar for 3 days in Southern Sudan for patients allergic 
or refractory to chloroquine, quinine for 7 days in the CNPP centre in DRC and in some 
patients in Angola, and chloroquine for 3 days (10mg/kg/day) in all other centres; 
anthelminthic – mebendazole for 3 days (4mg/kg/day) in all countries/centres. Prednisolone 
was given at different doses according to the criteria of the respective national sleeping 
sickness control programs or NGOs (detailed in chapter 2). 
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However, in case of an encephalopathic syndrome, examinations of blood-slides for malaria 
parasites were mandatory and any confirmed infection was treated either with Fansidar or 
quinine. 
Assessment of adverse events (AE) and their management 
The safety of the treatment was determined by the frequency of adverse events using a 
graded scale from 0 to 2 (none, moderate, severe) for most reactions. Encephalopathic 
syndromes were scaled from 0 to 3: grade 1 indicating psychotic reactions, grade 2 
occurrence of convulsions and/or loss of consciousness and grade 3 death of the patient. 
Events provoking treatment interruption were defined as severe.  
The management of severe adverse events was done according to the respective national 
guidelines and depended much on the instant resources of the treatment centre. Generally, it 
was recommended to interrupt melarsoprol treatment, manage the adverse event and if 
possible, resume the melarsoprol treatment or consider it completed if at least 8 doses were 
given.  
Data management and analysis 
Data management and analysis were done using EpiData 2.1 [Lauritsen and Bruus 2001] 
and STATA 7.0 [Stata 2001] software. The statistical analysis included those patients who 
were treated exclusively with the 10-day melarsoprol protocol and the proportions were 
compared with the 2 test or the Fisher’s exact test whenever appropriate. Differences in 
proportions, the 95% confidence interval for the difference and the Z test were used in 
variables with a large number of missing data. 
All unstructured data (“observation”, “justification” and “additional drugs” fields) containing 
information on concomitant medications and diseases were coded as follows:  
Drugs used in the management of adverse events were grouped as follows: corticosteroids – 
hydrocortisone, prednisolone, betamethasone and dexamethasone; anti-convulsive – 
diazepam (chlorpromazine); anti-allergic – promethazine and chlorpheniramine; 
analgesic/anti-pyretic – acetaminophen (paracetamol), aspirine, ibuprofen; antibiotics – 
amoxicilline, ampicilline, bactrim, septrim, cloxacilline and penicilline; antimalarial – 
chloroquine, quinine, pyrimethamin/sulfadoxine (Fansidar); anti-protozoal/anthelminthic – 
metronidazole, praziquantel, mebendazole and ivermectin; nutritional supplementation – oral 
rehydration solution (ORS), Ringer solution, vitamins, iron and glucose; topical anti-infective 
– gentian violet, Whitfield’s ointment, benzyl benzoate, zinc oxide and TTC ointment.  
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Concomitant parasitic diseases were grouped as follows: malaria – patients with confirmed 
malaria (parasite positive on blood smears) before and/or during melarsoprol treatment; 
gastro-intestinal parasites – patients with diagnosed amoeba, giardia, hookworm, 
schistosome, or geohelminthic infections; filaria – Loaloa, Mansonella perstans or 
Onchocerca volvulus; skin infections – scabies or fungal skin infections (mainly ringworms). 
Some diseases, symptoms or signs could not be easily grouped or allocated to a specific 
agent or were due to viral or bacterial infections, and thus were not considered in this 
analysis, these included: respiratory infections – upper and lower respiratory tract infections 
as pneumonia, bronchitis, pulmonary infections, cough, flu, common cold; and even more 
general terms like “urinary tract infection, sexually transmitted disease, skin infection, itch, 
pain, general pain, abdominal pain, chest pain, ascites, vomiting, dizziness, nausea, 
conjunctivitis or gastritis”. 
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RESULTS  
Study population and concomitant parasitic infections 
Of the 2800 enrolled patients, 2343 case records of 6 countries were analysed. 457 patients 
could not be considered because they were not eligible for the evaluation for several 
reasons: erroneous classification (other disease than sleeping sickness), abandon during 
treatment (incomplete case records), other treatment than 10-day melarsoprol schedule 
(eflornithine, nifurtimox or a combination therapy of melarsoprol and nifurtimox), or biased 
inclusion (selection of patients in good health state or adults only).  
The study population corresponded to the average rural population and did not differ in 
demographic characteristics (chapter 2, Table 1). The baseline characteristics of the cohort 
analysed here are presented in Table 1. The observed concomitant parasitic infections are 
tabulated versus the demographic and diagnostic characteristics of the patients.  
In 41.7% (977/2343) of the patients, any other parasitic disease apart from trypanosomiasis 
was diagnosed on admission or during melarsoprol treatment. The rates differed highly with 
the geographic regions as well as with the treatment centres: generally more infectious 
diseases were diagnosed in centres run by NGOs or with expatriate doctors, likely due to 
more systematic screening for those diseases, capacity and resources of these centres. The 
most frequently reported concomitant parasite was malaria (24.5%, 574/2343), followed by 
gastro-intestinal parasites (9.8%, 229/2343). In children 14 years of age, more malaria 
parasites (risk rate RR=1.4, 95% confidence interval CI: 1.1-1.7, P value p=0.0035) but less 
filaria (RR=0.4, CI: 0.2–0.9, p=0.0109) were detected than in adults. Fewer concomitant 
parasites were diagnosed in patients with malnutrition on admission (defined as age and sex 
adjusted body mass index) or with a bad general health state (defined by the medical staff), 
in particular malaria parasites (RR=0.8, CI: 0.7–0.9, p=0.0036 and RR=0.8, CI: 0.7–0.9, 
p=0.0006, respectively).  
At hospital admission, fever was associated with malaria parasites (RR=1.3, CI: 1.1–1.6, 
p=0.0025) and pruritus with gastro-intestinal parasites (RR=3.0, CI: 2.3–4.1, p<0.0001), 
filaria (RR= 3.7; CI: 2.3-6.0, p<0.0001) or skin infections (RR=6.1, CI: 3.5-10.4, p<0.0001). 
Most infections of the skin were diagnosed in the first days of the melarsoprol treatment and 
were more common in male patients with pruritus on admission (RR=6.4, CI 3.2-12.7, 
p<0.0001). 
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Table 1: Baseline of the study population: Demographic, diagnostic and clinical 
characteristics are plotted versus the concomitant parasitic infections (in %) 
recorded during the 10-day melarsoprol treatment 
Patients (n) Any Malaria Gastrointestinal Filaria Skin 
parasites infections
Characteristics (N=977) (N=574) (N=229) (N=100) (N=107)
All patients 2343 41.7 24.5 9.8 4.3 4.6
Country
  Angola 547 33.6 32.4 0.2 0.7 0.2
  Central African Republic 30 43.3 0.0 0.0 43.3 0.0
  Côte d'Ivoire 27 51.9 51.9 0.0 0.0 0.0
  Democratic Republic of Congo 561 24.4 21.8 0.0 1.6 0.2
  Equatorial Guinea 23 26.1 4.4 0.0 17.4 0.0
  Sudan 1155 53.9 22.5 19.7 6.1 9.1
Sex
  Female 1199 42.8 25.6 9.3 3.7 3.3
  Male 1144 40.6 23.3 10.3 4.9 *5.9
Age (years)
  14 432 44.0 *28.9 10.2 1.8 3.0
  15-80 1911 41.2 23.5 9.7 *4.8 4.9
Nutritional status
  Normal 1624 42.4 *25.8 9.1 4.2 5.0
  Malnutrition (BMI<17)1 632 38.0 19.1 11.7 4.2 4.1
General health state2
  Good 1461 44.9 27.4 9.7 3.9 4.9
  Bad 852 *37.1 *20.0 10.2 4.9 4.2
Diagnostic and clinical characteristics
  Trypanosomes in CSF 916 38.0 23.4 8.3 4.1 4.4
  WBC 100 cells/mm3 1011 39.4 24.6 7.7 4.8 3.9
  Adenopathy 1356 42.9 23.2 *11.2 5.0 5.8
  Headache 1883 *44.1 25.8 10.8 4.7 4.6
  Fever (>37.5°C) 381 *51.7 *33.3 8.4 4.2 5.8
  Pruritus 1177 *47.9 22.9 *14.7 *6.7 *7.8
  Motor weakness 793 33.1 22.5 6.7 5.8 4.9
  Neurological disorders3 2072 41.1 24.4 9.6 4.6 4.2
*indicates a significant difference (p<0.05); 1age and sex adjusted; 2as defined by medical staff at admission; 
3abnormal movements, speech and sleep disorders, strange behaviour
Concomitant parasitic infections (%)
 
Occurrence and management of adverse events  
During melarsoprol treatment, adverse events were classified by the medical staff according 
to the severity of the event. In 56% (1311/2343) of all treated patients any adverse reaction 
was observed (moderate and severe), 24.7% (578/2343) with a severe reaction. A clear 
association between the intensity and the number of events per patient could be observed in 
our cohort (p<0.0001): patients with moderate reactions normally experienced only 1 or 2 
adverse events (maximum 1, median 2, mean 2.2) and those with severe reactions suffered 
from 3 or more different adverse events (maximum 3, median 3, mean 3.1). The types, 
grades and frequencies of adverse events are detailed in chapter 2 and not all are further 
described here.  
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The most severe complication, the encephalopathic syndrome, occurred in 8.5% (198/2343) 
of all treated patients and they were at a high risk to die (47%); 75% of the patients with an 
encephalopathic syndrome had convulsions, 72% a reduced consciousness level (drowsy or 
comatose) and the syndrome was always associated with other adverse events, mostly with 
fever (51%) and/or headache (32%) within 2 days before onset of the syndrome. Among the 
fatalities during treatment (130, 5.6%), 85 (65.4%) patients died as a consequence of the 
encephalopathic syndrome, 15 (11.5%) of advanced HAT disease, 15 (11.5%) of unknown 
aetiology, 10 (7.7%) of concomitant diseases, and 4 (3.9%) of mucocutaneous reaction. 
In Table 2, the grouped drugs used to manage the different adverse events are presented. 
The frequencies of the drug classes used in patients with adverse events are tabulated 
versus the adverse events and are ranked as follows: x=<30%, xx=30-67% and xxx=>67% of 
the patients with a certain adverse event were treated with the corresponding drug group.  
Most patients suffered from more than one event during the course of treatment; therefore, it 
was difficult to allocate certain groups of drugs solely to a specific type of adverse event. 
However, general approaches and tendencies could still be observed, e.g. encephalopathic 
syndromes were mainly managed by the application of high dose corticosteroids (84.9%) and 
anti-convulsive drugs (64.1%). The additional medication depended on the type of the 
syndrome: psychotic reactions (grade 1 encephalopathic syndrome) were often associated 
with fever (68%), headache (68%), and/or skin reactions (50%) and thus, anti-pyretic and/or 
anti-allergic drugs were given. Encephalopathic patients with convulsions (grade 2 
encephalopathic syndrome) often also suffered from fever (72%), headache (60%), and/or 
polyneuropathies (38%) and received mainly anti-pyretic drugs and nutritional 
supplementation. In patients who died of an encephalopathic syndrome, a high incidence of 
concomitant fever (78%), skin reactions (33%) and/or headache (32%) was reported; 
supplementary medication included mainly anti-pyretic drugs and nutritional 
supplementation.  
Antibiotics and anti–parasitic (antimalarial, anti-protozoal or anthelminthic) drugs were 
administered to patients suffering from all different kinds of conditions during treatment at 
similar frequencies. Antibiotics were more frequently administered to patients suffering from 
diarrhoea and/or motor neuropathy. Anti-protozoal and/or anthelminthic drugs were mainly 
used in association with diarrhoea and/or pruritus and less often with other conditions. 
Antimalarials were mainly received by patients with fever and/or encephalopathic syndrome 
of the convulsion type. Nutritional supplementation was mostly applied to patients with 
polyneuropathies, fever, diarrhoea and/or encephalopathic syndromes and topical anti-
infectives mainly for skin reactions.  
 
 Table 2: Management of severe adverse events of melarsoprol by concomitant medication 
 
Severe adverse event
Cortico-
steroids1
Anti-
convulsive2
Anti-
histaminic3
Analgesic / 
Anti-pyretic4 Anti-biotics5 Anti-malarial6
Anti-protozoal / 
Anti-helminthic7
Nutritional 
supplementation8
Topical anti-
infective9
Encephalopathic syndromes
  grade 3 (death) xxx xxx x xx (x) (x) (x) xx
  grade 2 (convulsion or coma) xxx xx xx xx (x) (xx) (x) xx
  grade 1 (psychotic) xxx xx xxx xx (x) (x) x (x)
Skin reactions
  Maculopapular eruptions xx (x) xx xx (x) (x) (xx) (x)
  Bullous eruptions xx (x) xxx xx (x) (x) x x
  Pruritus x (x) xx xx (x) (x) (x) (x) x
Neuropathy
  motor neuropathy (xx) (x) (x) (xx) (xx) (x) (x) xxx (x)
  sensitivity neuropathy (xxx) (x) (x) (xx) (x) (x) (x) xxx (x)
Fever xx x xx xx x x (x) xx (x)
Headache xx x x xx (x) (x) (x) (xx) (x)
Diarrhea (xx) (x) x (xx) xx (x) xxx xx (x)
xxx: >67% of the cases received this drug group; xx: 30-67%; x: less than 30%; (x) drug was given to control more than one adverse event
Drug groups applied
1hydrocortisone, prednisolone, betamethasone, dexamethasone; 2diazepam; 3promethazine, chlorpheniramine; 4paracetamol, aspirine, ibuprofen; 5amoxicilline, ampicilline, 
bactrim, cloxacilline, penicilline, septrim; 6chloroquine, quinine, Fansidar; 7metronidazole, praziquantel, mebendazole; 8Nutritional supplementation: vitamins, aminoacids, 
ORS (oral rehydration solution), Ringer solution, glucose; 9Gentian violet, Whitfields ointment, Benzyl benzoate, Zinc oxide, TTC
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Concomitant parasitic infections and severe adverse events 
41.7% of the sleeping sickness patients were also diagnosed with another parasitic infection 
(Table 1). 26.9% (630/2343) of them had a single infection, most frequently malaria 
parasites, 9.4% (220/2343) had 2 concomitant infections and 5.2% (127/2343) were 
diagnosed with 3 or more different parasitic infections. The frequencies of concomitant 
parasitic infections in patients with adverse events are displayed in Graph 1. Significantly 
higher rates of malarial infections were observed in patients who suffered from an 
encephalopathic syndrome, or fever, or in patients with a fatal outcome. Gastrointestinal 
parasites were more often diagnosed in patients with severe adverse events, strikingly in 
those with diarrhoea (all p<0.0001, Table 3). No association was found with filaria and any 
adverse event. The effect of prednisolone could only be evaluated for the Sudanese centres 
which were the only ones to provide reliable information for each patient. In patients with 
prednisolone prophylaxis more gastrointestinal parasites were observed (RR= 1.6, CI: 1.2-
2.0, p=0.0007).  
Treatment interruptions increased with the number of adverse events and/or the number of 
concomitant parasitic infections detected. (32.9% with a single concomitant infection up to 
100% with five concomitant parasitic infections interrupted melarsoprol). In average, the 
treatment was interrupted for 2 days (range 1–24 days) in patients with concomitant parasitic 
infections and/or adverse events, in the majority after 7 doses of melarsoprol.  
Treatment efficacy was indirectly associated with the occurrence of severe adverse events 
and concomitant parasitic diseases. Patients suffering from a severe adverse event during 
melarsoprol treatment had a 4-fold higher risk to die (RR=4.0, CI 3.6-4.4, p<0.0001), which 
gradually increased with the number of adverse events. Patients with any concomitant 
parasitic infection were more likely to display an adverse event (RR=1.9, CI 1.7-2.1, 
p<0.0001) and were at an elevated risk to die (RR=1.9, CI 1.6-2.2, p<0.0001).  
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Graph 1: Proportion of patients suffering from an adverse event with concomitant parasitic 
infections, grouped by adverse events 
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Table 3: Significance of malaria and gastro-intestinal parasites in the assessment of 
severe adverse events during melarsoprol treatment 
 
Malaria
Malaria RR 95% CI P value
 (N=574)
Overall prevalence* 35.3
Fatality 47.4 1.4 1.1 to 1.7 0.005
Encephalopathic syndromes 51.4 1.5 1.3 to 1.8 <0.0001
Skin reactions (maculopapular eruptions) 39.3 1.2 1.0 to 1.3 0.043
Motor and sensitivity polyneuropathy 42.5 1.2 1.0 to 1.5 0.050
Fever 42.9 1.4 1.2 to 1.6 <0.0001
Headache 38.8 1.1 1.0 to 1.3 0.063
Diarrhea 32.2 0.9 0.7 to 1.2 0.411
Jaundice 20.0 0.9 0.3 to 2.9 0.920
*denominator=those tested (N=1627)
Gastro-intestinal infections (GI)
GI RR 95% CI P value
 (N=229)
Overall prevalence** 9.8
Fatality 6.2 0.6 0.3 to 1.2 0.153
Encephalopathic syndromes 12.6 1.3 0.9 to 2.0 0.158
Skin reactions (Pruritus) 14.5 1.6 1.3 to 1.9 <0.0001
Neuropathies (sensitivity, motor) 20.8 2.4 1.8 to 3.3 <0.0001
Fever 14.8 1.6 1.4 to 1.9 <0.0001
Headache 20.2 2.3 2.0 to 2.7 <0.0001
Diarrhea 41.1 6.4 5.0 to 8.3 <0.0001
Jaundice 20.0 2.3 0.5 to 10.8 0.225
** denominator=all patients (N=2343)
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DISCUSSION  
Of the parasitic infections, malaria, filaria and intestinal parasites are highly prevalent in 
many areas endemic for sleeping sickness and the overlap in the geographic distribution 
implies that co-infections might occur at substantial rates. However, only few authors have so 
far described the influence or the occurrence of concomitant parasitism in sleeping sickness 
patients [Sina et al., 1975; Buyst 1975; Balint and Wenninger 1975; Sina et al., 1977; Buyst 
1977; Burri et al., 1995; Aroke et al., 1998]. Yet, probably based on extensive field 
experience, comprehensive guidelines of WHO and NGOs exist that recommend anti-
parasitic pre-treatment of sleeping sickness patients before initiating the specific 
trypanosomiasis treatment and to perform differential diagnosis to exclude possible 
concomitant parasitic infections during treatment [WHO 1998; Balasegaram et al., 2004]. The 
influence of concomitant parasitic infections in sleeping sickness patients on the clinical 
progression and the treatment outcome needs to be carefully addressed. 
Here we document the prevalence and types of concomitant parasites of late-stage 
gambiense sleeping sickness patients hospitalised and treated with the 10-day schedule for 
melarsoprol in the multinational study IMPAMEL II (chapter 2). We also describe the 
supplementary medication given to the patients and explored the association of concomitant 
parasitic diseases with the recorded adverse events (that may not necessarily be related to 
melarsoprol). 
The study was not designed to determine concomitant parasitism in sleeping sickness 
patients and consequently, routine screening for concomitant parasites was not mandatory. 
Missing data about concomitant parasitic infections in our study are therefore difficult to 
interpret: either the diagnostic tests were done, but not entered into the questionnaire 
because it was not mandatory (result positive or negative) or concomitant parasitic infections 
were not diagnosed at all for whatever reason (result unclear). Therefore, it remains unclear 
whether the frequencies reported in this study correspond to the true average prevalence in 
the respective areas. 
The study population corresponded to the average rural population of African countries and 
was comparable for all treatment centres (see chapter 2 for detailed description). The clinical 
and diagnostic characteristics of the patients on admission and the frequencies of diagnosed 
concomitant parasitic infections were highly variable between the centres, reflecting the 
differences in endemicity levels of the disease foci, the different diverse qualification and 
origin of staff (nurses versus medical doctors, national control programs versus NGOs), and 
the different capabilities and resources of the treatment centres.  
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It was suspected that concomitant parasitic infections might influence the clinical progression 
of the patients and the adverse events during melarsoprol treatment. For example malaria 
was reported to increase the risk of developing an encephalopathic syndrome [WHO 1998; 
Blum et al., 2001] and gastro-intestinal parasites (strongyloides and amoeba) a steroid-
induced dissemination, respectively [WHO 1998; Balasegaram et al., 2004]. In our study 
population, a quite large proportion of the patients was diagnosed with a concomitant 
parasitic infection which seemed to confound the reported rates of symptoms and signs of 
sleeping sickness or to influence the development of adverse events attributed to 
melarsoprol. On admission, fever was significantly associated with malaria parasites and 
pruritus with parasitic gastro-intestinal infections (Table 1). These parasites are supposed to 
be controlled by the anti-parasitic pre-treatment. Malaria and gastro-intestinal parasites in our 
study population were clearly correlated with a higher frequency of adverse events during 
melarsoprol treatment (Graph 1, Table 3): More often malaria parasites were diagnosed in 
patients who suffered severe adverse events like encephalopathic syndromes, skin reactions 
(maculopapular eruptions) or who died during the treatment. Patients with gastro-intestinal 
parasites were also more likely to suffer from neuropathies (sensitivity and/or motor) and/or 
general symptoms and signs as fever, headache, and pruritus, but were not at higher risk of 
developing an encephalopathic syndrome. Not surprisingly, we found a strong association 
between diagnosed protozoan and/or helminthic intestinal infections and reported diarrhoea 
which has already been shown by Burri et al. (1995). These positive associations were also 
reflected by the types of supplementary drugs given to the patients suffering from adverse 
events: most anti-parasitic drugs were administered in patients with fever, encephalopathic 
syndromes or diarrhoea. Except for an increased frequency of pruritus, filaria or parasitic skin 
infestations showed no significant correlation with other adverse events. 
The management of adverse events in this study depended much on the diverse and instant 
resources the treating organisations had at hand. The questionnaire was not designed for 
detailed evaluation of the management of adverse events during melarsoprol treatment and 
in addition, the centres followed the various national or organisational guidelines. Therefore 
from this study no recommendations for the management of adverse events can be drawn. 
However, it becomes clear that a thorough screening of the patient for concomitant parasites 
would ease the management of adverse events during melarsoprol treatment and reduce the 
risk to develop such.  
This analysis has revealed issues that are important in the view of the structure and strategy 
of the sleeping sickness control. The costs of diagnosis and drugs to treat other conditions 
than sleeping sickness are not the biggest component for a sleeping sickness control 
program and normally the staff are already in place; therefore it could be a feasible issue to 
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systematically screen patients for other diseases, if only these centres had the technical 
resources and the respectively trained staff. The importance of the correct use of drugs to 
treat concomitant diseases has been underlined. In particular malaria treatment should be 
done according the national guidelines. This was often not the case in our study and 
chloroquine was used in most areas with known resistance. The best approach to 
concomitant treatment should be the issue of a specifically designed study. 
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ABSTRACT  
To assess the effectiveness of the 10-day melarsoprol treatment schedule in children with 
late-stage Trypanosoma brucei gambiense trypanosomiasis, we reviewed all children treated 
in the drug utilisation study (IMPAMEL II) executed between June 1999 and June 2002 for 
demographic, diagnostic and clinical features, tolerability and effectiveness of the treatment, 
and for reduction of symptoms and signs after therapy. 18.5% of all patients treated were 
children (n=441) below 15 years of age. There was a non-significant tendency for less 
encephalopathic syndromes in children (6.6% vs. 8.9% in adults) and an equal treatment 
related fatality rate as in adults (5.4% vs. 5.6%). In children, we observed significantly fewer 
polyneuropathies and headache but more maculopapular eruptions and fever, of which the 
latter can probably be partially explained by the higher rate of concomitant malaria in 
children. After treatment, the reduction of the symptoms and signs was comparable between 
children and adults and cure rates were with 94% identical in the subpopulations. There is 
evidence that the safety and efficacy profile of the 10-day schedule is similar in children and 
adults. 
 
Keywords: trypanosomiasis, Trypanosoma brucei gambiense, melarsoprol, treatment 
outcome, adverse events, children 
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INTRODUCTION  
Human African trypanosomiasis (sleeping sickness) in children is clearly underreported in the 
literature given the fact that they may be affected in many ways. First, the proportion of 
children with sleeping sickness below 15 years of age may be as high as 20-30% [Triolo et 
al., 1985; Pepin et al., 2002]; second, quite often children of sleeping sickness patients may 
be at higher risk of infection [Khonde et al., 1997]; and third, an infection in a family reduces 
the workforce and may impair the nutritional status and health of the children. The few 
published reports on children are mainly small-scale studies, retrospective case descriptions 
focussing on clinical symptoms [Debroise et al., 1968; Balint and Wenninger 1975; Le Bras 
et al., 1977; Buyst 1977; Cramet 1982; Triolo et al., 1985; Lingam et al., 1985; Adams et al., 
1986; Buissonniere et al., 1989; Benhamou et al., 1989; Blanchot et al., 1992; Jannin et al., 
1993; Kazumba et al., 1993; Koko et al., 1997; Pepin et al., 2002], describing sleeping 
sickness in children as a fulminant disease, particularly in young children of less than 5 years 
of age [Aroke et al., 1998], but very rarely dealing with the treatment outcome. Children are 
also said to suffer more from sequelae than adults [Cramet 1982; Triolo et al., 1985; 
Kazumba et al., 1993; Koko et al., 1997; Aroke et al., 1998] that may provoke growth 
retardation, delayed sexual maturity and poorer academic performance [Aroke et al., 1998]. 
Considering this and the high proportion of children affected, it remains a mystery why so 
little emphasis has been given to sleeping sickness in children during the past century. 
Sleeping sickness is an inevitably fatal disease if the patients are not treated. The drug 
mainly used to treat second stage Trypanosoma brucei gambiense sleeping sickness is 
melarsoprol, a highly toxic and not 100% effective drug [WHO 1998]. Another drawback are 
the lengthy, empirically developed treatment schedules used since its introduction more than 
50 years ago. Burri et al (2000) developed a new concise treatment schedule and proved its 
non-inferiority of efficacy and safety in a randomised clinical trial in 500 adult patients. 
Thereafter, in a multinational drug utilisation study in sleeping sickness endemic countries 
(IMPAMEL II), the effectiveness under field conditions of the 10-day melarsoprol treatment 
schedule has been demonstrated [Schmid et al., 2004]. Almost one fifth of the patients in this 
study were children below 15 years of age. 
In this report we describe the clinical features of late-stage gambiense sleeping sickness in 
children and the treatment outcome after melarsoprol short course therapy. 
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METHODS  
The study was a non-randomised drug utilisation study (IMPAMEL II, [Schmid et al., 2004]) of 
the 10-day melarsoprol treatment schedule in 16 sleeping sickness treatment centres of 7 
sub-Saharan African countries with endemic T.b. gambiense (Angola, Central African 
Republic, Côte d’Ivoire, Democratic Republic of Congo, Equatorial Guinea, Republic of 
Congo and Sudan). The only inclusion criterion for the patients was confirmed late-stage 
sleeping sickness due to T.b. gambiense according to the criteria of the respective national 
sleeping sickness control programs. Of the 2800 patients enrolled, 415 patients had to be 
excluded from this analysis for several reasons: combination treatment, other drug than 
melarsoprol, other disease than sleeping sickness, run-away during treatment and biased 
inclusion criteria (selection of adults in a better health state only). 2385 were eventually 
treated with the 10-day treatment schedule and among those, 441 (18.5%) were children 
below 15 years of age.  
For each patient, a case report form was filled which contained demographic, diagnostic and 
clinical characteristics before and after treatment, and an assessment of adverse events 
during treatment on a graded scale from 0 to 2 (none, moderate, severe reaction). Diagnosis 
of late-stage was done by microscopic examination of the cerebrospinal fluid (CSF) for the 
presence of trypanosomes and/or an elevated white blood cell (WBC) count. The study was 
approved by the ethics committee of the two cantons of Basel (EKBB) and the relevant 
ethical committees and authorities in the respective countries. The 10-day schedule was 
introduced as the sole treatment in the selected centres and therefore no consent was 
obtained from the patients. 
All patients, adults and children, were treated during 10 days with 2.2 mg/kg/day melarsoprol, 
as a 3.6% solution in propylene glycol (Arsobal Aventis), by slow intravenous injection. 
Before melarsoprol treatment, all patients received supplementary medication: antimalarials 
(3 days chloroquine or Fansidar or 7 days quinine), mebendazole, multivitamins and 
paracetamol. During melarsoprol treatment, different prophylactic corticosteroid therapies 
were given (detailed in [Schmid et al., 2004]). In case of occurrence of a severe (grade 2) 
adverse event, the treatment was interrupted and the patient was treated following the 
national guidelines, e.g. with adrenaline (epinephrine), corticosteroids (hydrocortisone or 
dexamethasone) and/or diazepam.  
The safety and efficacy of the treatment were determined by the frequency of adverse events 
and the parasitological cure after treatment, respectively. Treatment failures were defined as 
cases in which trypanosomes could still be found in any body fluid 24 hours after treatment, 
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relapses as patients presenting at any time during follow-up with trypanosomes in any 
compartment and/or an increase of the white blood cells (WBC) in the cerebro spinal fluid 
(CSF) to more than 50 cells/mm3 and have at least doubled compared to the previous 
examination or with 6 – 49 WBC in CSF and with clear symptoms attributed to relapse 
(somnolence, long lasting headache, recurrent fever). 
Data management and analysis was done using EpiData 2.1 [Lauritsen and Bruus 2001] and 
STATA 7.0 [Stata 2001] software. Proportions were compared with the 2 test or Fisher’s 
exact test whenever appropriate and difference in means was demonstrated with the 
confidence interval for the difference of the means. The findings were compared to the 
literature, the centres’ histories and the randomised clinical trial recently executed in Angola 
[Burri et al., 2000; Schmid et al., 2004]. For the calculation of the efficacy (i.e. cure rate, 
treatment failures and relapses) all patients treated were used as denominator to facilitate 
the comparison to previously reported rates.  
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RESULTS  
Table 1 shows the demographic, diagnostic and clinical characteristics of the study 
population on admission according to age. Similar to adults, children were diagnosed with a 
delay of 5 months after onset of symptoms. The diagnostic findings were comparable to 
adults except for less WBC in the CSF (p<0.05). Malnutrition, defined as age- and sex-
adjusted body mass index (BMI), was more frequent in children (35.1% vs. 19.1%; p<0.05). 
The mean number of symptoms and signs per patient recorded on admission was 4, equal in 
both, children and adults. Yet, pre-treatment clinical characteristics differed substantially 
between the two groups. Children were less frequently admitted with headache, pruritus and 
motor weakness, but more with fever, abnormal movements and strange behaviour (all 
p<0.05). The rate of concomitant malarial infections found was higher in children than in 
adults (29.7% vs. 23.8%, p=0.0023) that probably may have attributed to the higher fever 
rate in children. 
Adherence to the treatment regimen was high in all patients, 69.7% (1663/2385) were 
treated without interruptions. At treatment end there was no difference in the proportion of 
patients that completed the 10 doses of melarsoprol (children 87.5%, adults 89.7%, p=0.18). 
Non-adherence was a result of treatment interruption due to severe (grade 2) adverse 
reactions but treatment was resumed in most cases after 2-4 days. Treatment was 
interrupted more often in children than in adults (35.1% vs. 29.2%; p=0.014).  
Table 2 summarises the adverse events that occurred during the course of treatment 
according to age. A total of 132 (5.5%) patients died: 24/441 (5.4%) among children 
compared with 108/1944 (5.6%) among adults (p=0.93). No difference was reported in the 
cause of death between children and adults: 87 (3.6%) cases died of encephalopathic 
syndrome, 5 (0.3%) of a fatal skin reaction, 15 (0.6%) of advanced disease, 10 (0.4%) of 
concomitant disease and 15 (0.6%) were not classifiable (data not shown). There was a non-
significant tendency in children to develop less encephalopathic syndromes and no 
difference in the types of syndromes compared to adults was observed. In general, children 
experienced more severe reactions (31.7% vs. 22.9%, RR 1.43, CI 1.20 to 1.70, p=0.0001) 
that were resolved with treatment interruption and concomitant medication. They developed 
significantly more fever and maculopapular eruptions, but on the contrary they suffered less 
from polyneuropathies (motor and sensitivity) and severe headache during treatment. Among 
all treated patients, there was no significant difference between children and adults with 
regard to incidence of bullous eruptions, pruritus, hypotension, diarrhoea and jaundice. And 
disregarding the age of the patient, adverse events occurred in average on day 6 of 
treatment and lasted 2 to 4 days (median 6, mean 6.1 and standard deviation 3.4 days).  
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Table 1: Demographic, diagnostic and clinical characteristics of gambiense sleeping 
sickness patients, according to age 
Characteristic n % n % RR (95% CI)a P-value
Total patients (N = 2385) 441 18.5 1944 81.5
Male sex 222 50.3 944 48.6 0.4995
Age categories (years)
  (1)  2 36 8.2
  (2) 3 - 6 65 14.7
  (3) 7 - 10 127 28.8
  (4) 11 - 14 213 48.3
  (5)  15 1944 100.0
Malnutritionb 155 35.1 381 19.6 1.87 (1.58 to 2.22) < 0.0001
Duration of symptoms (months)c -0.7 (-1.4 to 0.1) 0.9645
Previous HAT treatmentd 43 9.8 144 7.4 1.26 (0.96 to 1.67) 0.1086
  thereof Arsobal 12 2.7 55 2.8 0.92 (0.68 to 1.24) 0.5852
Diagnostic findings
  Lymphadenopathy 248 56.2 1135 58.4 0.92 (0.78 to 1.10) 0.3481
  Trypanosomes in any compartment 375 85.0 1653 85.0 1.00 (0.79 to 1.27) 0.9987
  Trypanosomes in CSF 177 40.1 755 38.8 1.04 (0.87 to 1.23) 0.6786
  Trypanosomes in blood / lymph 322 73.0 1421 73.1 1.00 (0.94 to 1.06) 0.9724
   White Blood Cell Count in CSFc -40 (-61 to -19) <0.0001
      19 cells/ul 103 23.4 497 25.6 0.97 (0.80 to 1.67) 0.7248
     20 - 100 cells/ul 167 37.8 565 29.1 1.30 (1.13 to 1.49) 0.0003
     > 100 cells/ul 171 38.8 882 45.4 0.80 (0.67 to 0.95) 0.0097
Clinical manifestations
  Drowsy 67 15.2 278 14.3 1.06 (0.84 to 1.34) 0.6304
  Headache 324 73.5 1580 81.3 0.70 (0.58 to 0.84) 0.0002
  Fever (>37.5°C) 116 26.3 278 14.3 1.80 (1.50 to 2.16) <0.0001
  Pruritus 192 43.5 1015 52.2 0.75 (0.64 to 0.89) 0.0012
  Tremor 73 16.6 393 20.2 0.82 (0.65 to 1.03) 0.0875
  General motor weakness 128 29.0 679 34.9 0.80 (0.66 to 0.96) 0.0188
  Walking difficulties 82 18.6 411 21.1 0.89 (0.71 to 1.11) 0.2927
  Abnormal movements 58 13.2 188 9.7 1.32 (1.03 to 1.68) 0.0295
  Speech impairmente 68 15.4 254 13.1 1.23 (0.96 to 1.55) 0.0842
  Sleeping disorder 343 77.8 1436 73.9 1.20 (0.98 to 1.48) 0.0758
  Appetite problems 111 25.2 426 21.9 1.16 (0.96 to 1.40) 0.1430
  Strange behaviour 135 30.6 461 23.7 1.33 (1.11 to 1.59) 0.0023
  Inactivity 90 20.4 442 22.7 0.89 (0.72 to 1.10) 0.2985
  Aggressivity 39 8.8 132 6.8 1.26 (0.95 to 1.69) 0.1202
Concomitant diseasesf 190 43.1 767 39.5 1.13 (0.95 to 1.34) 0.1604
  Malaria (N=1637) 131 44.0 463 34.6 1.37 (1.12 to 1.69) 0.0023
  Intestinal parasitesg 48 10.9 201 10.3 1.05 (0.80 to 1.37) 0.7355
  Filariah (N=1335) 8 3.5 92 8.3 0.44 (0.22 to 0.87) 0.0087
eonly children 2 years evaluated; flarge number of missing data; gschistosomes, hookworms, geohelminths, amoeba, giardia;
hO. volvulus, Loaloa, M. perstans
Children Adults
N: total number of patients treated; n: number in each sub-population; RR: risk ratio; CI: 95% confidence interval; a P value
smaller than 0.05 is considered significant; CSF: cerebrospinal fluid
aX2 test or 95% CI for the difference of means; bage and sex adjusted malnutrition based on body mass index (adults BMI<17);
cMedian (mean ± standard deviation); dwithin 2 years before admission to IMPAMEL II study
5 (7 ± 7) 5 (7.7 ± 7.8)
76 (178 ± 240)61 (138 ± 192)
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Table 2: Distribution of adverse events during 10-day melarsoprol treatment, according to 
age 
Adverse event n % n % RR (95% CI) P-value
Fatalitiesa 24 5.4 108 5.6 0.98 (0.68 to 1.42) 0.9251
Encephalopathic syndromes 29 6.6 173 8.9 0.76 (0.54 to 1.08) 0.1137
  Grade 3 (fatal) 13 2.9 74 3.8 0.80 (0.48 to 1.33) 0.3852
  Grade 2 (coma, convulsion) 14 3.2 73 3.8 0.87 (0.53 to 1.41) 0.5571
  Grade 1 (psychotic) 2 0.5 26 1.3 0.38 (0.10 to 1.46) 0.1447
Bulluous eruptions
  Any 10 2.3 32 1.6 1.29 (0.75 to 2.24) 0.3703
  Severe 3 0.7 21 1.1 0.67 (0.23 to 1.95) 0.6011
Maculopapular eruptions
  Any 77 17.5 172 8.8 1.81 (1.47 to 2.23) <0.0001
  Severe 44 10.0 105 5.4 1.66 (1.28 to 2.16) 0.0003
Pruritus
  Any 95 21.5 416 21.4 1.00 (0.82 to 1.24) 0.9474
  Severe 16 3.6 53 2.7 1.26 (0.81 to 1.96) 0.3077
Motor polyneuropathy
  Any 16 3.6 135 6.9 0.56 (0.35 to 0.89) 0.0098
  Severe 6 1.4 36 1.9 0.77 (0.36 to 1.62) 0.4788
Sensitivity polyneuropathy
  Any 2 0.5 70 3.6 0.15 (0.04 to 0.58) 0.0001
  Severe 0 0.0 26 1.3
Febrile reaction
  Any (37.5 - 39°C) 177 40.1 532 27.4 1.58 (1.34 to 1.88) <0.0001
  Severe (>39°C) 73 16.6 178 9.2 1.68 (1.36 to 2.09) <0.0001
Headache
  Any 93 21.1 556 28.6 0.71 (0.58 to 0.88) 0.0019
  Severe 33 7.5 125 6.4 1.14 (0.83 to 1.56) 0.4222
Diarrhea
  Any 39 8.8 153 7.9 1.11 (0.83 to 1.49) 0.4977
  Severe 11 2.5 40 2.1 1.07 (0.69 to 1.99) 0.5671
Hypotension
  Any 15 3.4 75 3.9 0.90 (0.56 to 1.43) 0.6496
  Severe 4 0.9 17 0.9 1.03 (0.42 to 2.50) 1.0000
Jaundice
  Any 4 0.9 6 0.3 2.17 (1.01 to 4.66) 0.0954
  Severe 3 0.7 3 0.2 2.71 (1.21 to 6.07) 0.0810
N: total number of patients treated in each sub-population; n: number of events; RR: risk ratio; CI: 95
confidence interval; P-value: a value smaller than 0.05 is considered significant; aAll fatalities during treatment,
including fatal ES
(N = 441) (N = 1944)
Children Adults
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After treatment, the clinical symptoms and signs were substantially reduced in children as 
well as in adults, without significant difference between the groups (Graph 2). 
Graph 2: Percent of reduction of the clinical symptoms and signs in children and adults at 
hospital discharge after 10-day melarsoprol treatment  
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Table 3 shows the treatment efficacy of the 10-day melarsoprol treatment schedule 
according to age. Twenty four hours after treatment, 5 (0.2%) patients were diagnosed 
treatment failures, with trypanosomes in CSF in 4 patients (1 child, 3 adults) and in blood in 1 
patient (1 child). At discharge, the cure rate was 94.3% for all patients (defined as discharged 
alive and no parasites detected) without any disparity for the children. During the 2 years’ 
follow-up period, 24 patients died (1%, 24/2385) and 159 (6.7%, 159/2385) were diagnosed 
as relapses, at comparable rates for children and adults (both not significant). Slightly more 
children (45%) were seen for at least one follow-up examination as compared to adults (40%; 
RR 1.2, CI 1.0 to 1.4, p=0.047).  
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Table 3: Efficacy of the 10-day melarsoprol treatment schedule in children 
 
n % n % RR (95% CI) P value
Treatment
Patients treated (N = 2385) 441 18.5 1944 81.5
Fatalities during treatment 24 5.4 108 5.6 0.98 (0.68 to 1.42) 0.9251
Treatment failures at discharge 2 0.5 3 0.2 2.17 (0.74 to 6.36) 0.2324
Cured at discharge 415 94.1 1833 94.3 0.97 (0.68 to 1.39) 0.7897
Follow up*
Fatalities during follow upa 5 1.1 19 1.0 1.13 (0.51 to 2.47) 0.7910
Relapses during follow upa 33 7.5 126 6.5 1.13 (0.82 to 1.55) 0.4465
Lost during follow up 242 54.9 1163 59.8 0.84 (0.71 to 1.00) 0.0468
Cured 2 years after treatment 378 85.7 1694 87.1 0.91 (0.71 to 1.15) 0.4234
Children Adults
 *Denominator: all patients treated under the assumption that all patients lost were considered cured; a1 child and 6 
adult relapses died and are included in both, the relapses and the fatalities
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DISCUSSION 
Sleeping sickness of the child due to Trypanosoma brucei gambiense is rarely described in 
the literature and in particular, studies on the relationship of age to the effects of melarsoprol 
cannot be found in the paediatric population. Despite of this, some authors and medical 
authorities recommend a reduced dosage regimen for children [Buyst 1975, 1977; Buck et 
al., 1978; Pharmacopeia 2003]. Additionally, medical staff treating sleeping sickness 
inherently believe that melarsoprol harms children more than adults. Therefore, we have 
specifically analysed the outcome of the 10-day melarsoprol treatment schedule in children 
with late-stage gambiense sleeping sickness in the frame of a large multicentre drug 
utilisation study (IMPAMEL II). In this study we could demonstrate that the outcome of 
treatment with the 10-day melarsoprol protocol in children is not worse than in adults. The 
findings in terms of safety and efficacy were highly variable between the treatment centres, 
but in an expected range.  
Some authors raised concern that sleeping sickness was diagnosed in children later after 
infection than in adults [Balint and Wenninger 1975; Kazumba et al., 1993; Koko et al., 1997] 
which was assumed to contribute to a worse outcome of treatment in children and to more 
long-term sequelae from the disease [Cramet 1982; Triolo et al., 1985; Kazumba et al., 1993; 
Koko et al., 1997; Aroke et al., 1998]. This is not the case in our study, where the self-
reported duration of symptoms in the children was in the same range than in adults. The only 
discrepancy we could note was inter-centre differences in the duration of symptoms, which is 
rather reflecting the screening activities and mode of admission of the respective treatment 
centres. The shorter time in hospital allowed by the 10-day treatment schedule may not be 
translated into a quicker overall time to full recovery, which is certainly the reason for the 
poor reduction rate of the neurological symptoms shown in graph 2. However, the limited 
follow-up activities and the design of the study did not allow us to monitor for long-term 
sequelae in children.  
Malnutrition and concomitant diseases in children are known to decrease their resistance for 
infections and possibly decelerate the cure, or even worse, to increase the risk for a fatal 
outcome [Balint and Wenninger 1975; Buyst 1977; Aroke et al., 1998]. In our cohort, no 
effect of malnutrition on the tolerability and effectiveness of the treatment in children could be 
found although a large proportion of children were seriously undernourished on admission. 
Patients at any age with concomitant infectious diseases, mainly malaria, were at higher risk 
to develop an adverse event during treatment (RR 1.9, 95% confidence interval 1.7 to 2.1, 
p<0.0001) and had an elevated risk of a fatal outcome if malaria was diagnosed during the 
treatment course (RR 1.5, 95% confidence interval 1.3 to 1.8, p=0.0002). Hence, in our large 
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cohort we could demonstrate the suspected detrimental effect of concomitant infections, 
especially malaria [Buyst 1975; Balint and Wenninger 1975; Blum et al., 2001] not only for 
the children, but for all patients. Malaria is endemic in the sleeping sickness foci, diagnosis 
rarely done and drugs in use with known high levels of resistance (e.g. chloroquine). In our 
series, 90% of the patients received chloroquine as antimalarial pre-treatment and under the 
assumption that a large proportion of the patients have not been sufficiently cured from 
malaria, reappearance during the course of melarsoprol might have biased and worsened 
the outcome. Therefore, there is evidence that diagnosis and complete treatment of 
concomitant infections with adequate drugs may reduce the risk for the patient. Whereas this 
holds true for malaria, the approach may be less favourable for diseases with a prolonged 
treatment course (e.g. filariasis). 
Children were diagnosed with fewer white blood cells per mm3 in CSF than adults without 
difference in any other diagnostic parameter. Normally, the clinical description is the same as 
in adults [Ngandu-Kabeya 1976; Kazumba et al., 1993]. In our study, the clinical picture of 
sleeping sickness in children varied with that of adults, we found that the incidence of fever, 
altered behaviour and abnormal movements were significantly higher and headache, pruritus 
and motor weakness much lower in children (all p<0.05). Changes in walking ability and 
speech disorder are difficult to compare between the age groups and findings as headache, 
fever, pruritus and polyneuropathies are difficult to relate solely to sleeping sickness or to 
assess in children.  
Overall, the fatality rate in this study was 5.5% (5.4% of children, 5.6% of adults) without any 
difference between the age groups and the distribution of the cause of death. The highest 
treatment related fatality rate was seen in children aged 1-2 years, however the difference 
was not significant (8.3%, p=0.45). 3 of 36 children in this age group died during treatment, 2 
of them from an encephalopathic syndrome and 1 of unknown reason but with malaria 
parasites detected. Treatment related fatality rates in children were reported by other authors 
to be associated with a range of factors on admission [Balint and Wenninger 1975; Kazumba 
et al., 1993; Koko et al., 1997], one of them being the general health state of the child 
(malnutrition, concomitant infections, number of white blood cells in CSF and grade of 
neurological involvement). In our cohort, we could only show this relationship for the adult 
population in which advanced disease (defined as a WBC > 100 cells per mm3 in CSF) was a 
risk factor for a fatal outcome of the treatment (RR 1.3, 95% confidence interval 1.1 to 1.6, 
p=0.0033).  
Children seemed to develop less encephalopathic syndromes (children 6.6%, adults 8.9%) 
and in particular less psychotic reactions (termed grade 1 encephalopathic syndrome; 
children 0.5%, adults 1.3%) but at non-significant levels (p>0.05). The latter are not easy to 
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assess in children and therefore difficult to compare to adults. In addition, there was no 
difference between the age groups in the risk factors present on admission for the 
development of an encephalopathic syndrome during melarsoprol treatment, that were 
identified in previous reports [Ancelle et al., 1994; Pepin et al., 1995; Schmid et al., 2004] like 
elevated white blood cell count in CSF, headache, malaria, general weakness, 
polyneuropathies, drowsiness, or a bad general health state. 
During melarsoprol treatment, children experienced more severe (grade 2) adverse 
reactions, mainly fever and maculopapular eruptions, but also more malaria parasites were 
detected in children than in adults, which may have contributed to the higher fever rate. On 
the contrary, less polyneuropathies and headache were noted in children. The use of the 
questionnaire and the fear of treating children with the new treatment schedule, that was felt 
as more aggressive than the old one, might have introduced an observation bias. 
Additionally, the doctor’s perception may have played an important role in defining the 
tolerability of the treatment in this non-randomised study approach.  
The treatment efficacy of the 10-day melarsoprol schedule was comparable to previous 
studies [Burri et al., 2000; Pepin et al., 2002; Schmid et al., 2004], with cure rates of 94% at 
hospital discharge and 87% 2 years after treatment. Treatment efficacy has rarely been 
described for the children and is therefore difficult to compare to literature. The few reports 
that deal with the melarsoprol long-term efficacy in children [Le Bras et al., 1977; Triolo et al., 
1985; Kazumba et al., 1993] often refer to a high mortality rate in this age group.  
Treatment failures and relapses were difficult to assess in this study, since the follow-up was 
highly variable between centres (0-100%) and only 50% of patients attended at least one 
follow-up examination. Additionally, for many areas the normal failure rate is unknown.  
We showed that the safety and efficacy profile of the 10-day melarsoprol treatment in 
children is similar to the one in adults. Bearing in mind the current drug situation with limited 
drugs available, the difficulties in the regular use of eflornithine and little hope for new drugs 
to come to the market within the next years, melarsoprol remains the most frequently used 
drug to treat late-stage gambiense sleeping sickness. Thus, an abridged treatment schedule 
bears the advantages of a shorter treatment duration and hospitalisation of the patients, less 
drug per patient and reduction of the overall treatment costs.  
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SUMMARY 
The most effective form of control of gambiense sleeping sickness is active case detection 
and treatment of the cases. Until today, the majority of the patients in the advanced stage of 
the disease are treated with melarsoprol. Only recently, the clinical effectiveness of a new 
concise treatment schedule has been demonstrated in a large scale multinational study 
(IMPAMEL II). The focus of this analysis is on the costs of treatment of late-stage sleeping 
sickness with melarsoprol to identify the costs and benefits that are involved in switching 
from the lengthy standard treatment schedules to the shorter 10-day schedule. 
Data were collected during the multinational study IMPAMEL II in 1999-2004 in 7 sub-Saharan 
African countries endemic for T.b. gambiense sleeping sickness. The costs of treatment 
(diagnosis, hospitalisation and sleeping sickness specific treatment) were assessed in two 
rural treatment centres and compared to the benefits of the 10-day treatment and of the 
standard treatments. The effectiveness was measured by the cost of treatment per DALY 
(disability-adjusted life-year) averted.  
We found the 10-day treatment schedule to be more cost-effective than the standard 
treatment. The net benefit from switching from the standard to the 10-day treatment schedule 
did reduce the cost per DALY averted from US$11.5 to US$6.9 in DRC and from US$69.4 to 
US$33.0 in Angola, a saving of US$4.6 (DRC) or US$36.4 (Angola) per DALY. Added to the 
clinical effectiveness, the short course melarsoprol schedule also presents as a highly cost-
effective treatment option. 
 
 
 
Keywords T.b. gambiense, melarsoprol, cost-effectiveness, treatment, late-stage, 
hospitalisation 
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BACKGROUND  
The burden of Human African Trypanosomiasis (HAT) or sleeping sickness ranks third of all 
parasitic diseases in sub-Saharan Africa, just behind malaria and helminths, in terms of 
disease burden expressed in DALYs (disability-adjusted life years, [WorldBank 1993; 
WorldHealthReport 2004]). There are two forms of the disease. The chronic gambiense form, 
which is found in central and western Africa, has a long course, and its reservoir is almost 
entirely in the human population. The rhodesiense or eastern African form is a much more 
acute disease and has an important zoonotic component, with transmission to people from 
both domestic livestock and game [WHO 1998]. 
Untreated, the disease is invariably fatal. The chemotherapy of HAT is unsatisfactory, relying 
on a few drugs which have severe side effects. Melarsoprol, a trivalent organo-arsenical 
derivative developed in 1949 [Friedheim 1949], is used for the treatment of the late-stage of 
the disease. The various treatment schedules were developed empirically and all are of long 
duration. Therefore, a concise treatment regimen has been developed by Burri et al. (2000) 
and shown that it was possible to reduce the duration of treatment from around 30 to 10 days 
[Burri et al., 2000; Schmid et al., 2004; Schmid et al., 2004].  
The most effective form of control of gambiense sleeping sickness is medical surveillance, 
involving case detection and treatment to reduce the human reservoir of the disease, so as 
to lower its incidence [WHO 1998, 2001]. A wide range of options for case detection and 
treatment do exist [Cattand et al., 2001] and evidence-based information on the relative cost-
effectiveness of these is urgently needed both in order to plan resource allocation within the 
field of HAT control and to demonstrate that controlling this disease is a highly cost-effective 
use of scarce health resources. However, the economics of different control strategies and 
their cost-effectiveness have only been studied very sporadically. In their review, [Walker and 
Fox-Rushby 2000] found only 2 out of 107 papers dealing with HAT, and to date there are 
still only a handful of papers [Shaw 1989; Politi et al., 1995; Laveissiere et al., 1998; Shaw 
and Cattand 2001; Ruiz Postigo et al., 2001]. The information that exists is thus often dated, 
very location specific and large gaps remain. The most important gaps with respect to the 
costs are treatment and particularly hospitalisation costs. Estimates indicate that the latter 
may account for 50% or more of the total cost of a control strategy based on active case-
finding and detection once the HAT prevalence exceed 1% [Shaw and Cattand 2001]. 
In the multicountry study IMPAMEL II, we demonstrated the clinical effectiveness of the 10-day 
melarsoprol treatment schedule under field conditions [Schmid et al., 2004], and we claimed 
amongst its major advantages over the lengthy standard treatment schedules were reduced 
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hospitalisation and a lower drug use per patient. To illustrate our assumption we studied the 
costs of treating a late-stage gambiense sleeping sickness patient. The focus of this analysis 
was on the identification of the overall costs of treating late-stage gambiense sleeping 
sickness patients with melarsoprol. This included the costs of diagnostic tests, treatment with 
melarsoprol 10-day schedule, treatment with the standard schedule, hospitalisation of a 
patient in a rural sleeping sickness treatment centre and post-treatment follow-up tests. The 
aim was to calculate net benefit in switching from standard to 10-day melarsoprol treatment 
schedule.  
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METHODS 
Two options of melarsoprol (Arsobal, Aventis) regimens were considered, the standard 
treatment as the baseline and the short, 10-day treatment schedule as the alternative. The 
analysis was done for 2 rural treatment centres in different countries (Maluku in Democratic 
Republic of Congo (DRC) and Ndalatando in Angola) that participated in the multinational 
drug utilisation study (IMPAMEL II). Both centres are operated by the national control 
programs and supported to a high degree by the Belgian Technical Cooperation (CTB). 
Calculations were performed with reference to 494 gambiense sleeping sickness patients 
(201 in Maluku and 293 in Ndalatando) treated during 1 year in the respective centres 
(Maluku in 2001 and Ndalatando in 2003). Current local market prices in each country in US$ 
for March/April 2004 were used throughout. The use of local market prices reflected the 
objective of finding out what the range of financial costs in two contrasting situations will be. 
The resulting analysis is thus, strictly speaking, a financial analysis, but as the value of the 
drugs which are currently supplied free of charge are included as full cost items, it deals with 
most of the parameters normally included in a full economic analysis.  
Treatment schedules under investigation 
Until 2002, the following treatment schedules named “standard” regimens were in use 
[Cattand 2000] (Graph 1). In the Democratic Republic of Congo (DRC), the duration of 
hospitalisation for a patient was normally 25 days, comprising of an anti-parasitic pre-
treatment lasting 3 days, melarsoprol treatment (3 series of 3*3.6 mg/kg bodyweight (max 5 
ml) injections, spaced by 6 days each) and post-treatment examination (1 day). In Angola, 
the duration of hospitalisation under the standard treatment lasted 30 days: anti-parasitic pre-
treatment (3 days), melarsoprol treatment (3 series of 4 injections at increasing doses, 1.2, 
2.4, 3.6, 3.6 mg/kg bodyweight (max 5 ml), spaced by 7 days each) and post-treatment 
examination (1 day). The alternative schedule under investigation consisted of 10*2.2 mg/kg 
bodyweight (max 5ml) without rest periods [Burri et al., 1995; Burri et al., 2000] and complete 
hospitalisation lasted 14 days (consisting of 3 days anti-parasitic pre-treatment, 10 days 
melarsoprol treatment and 1 day post-treatment examination). If treatment was interrupted 
due to the occurrence of severe adverse events, the total hospitalisation increased on 
average by another day.  
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Graph 1:  Comparison of the different schedules for late-stage T.b. gambiense sleeping 
sickness treatment with melarsoprol. 
 
DAY OF DRUG APPLICATION 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
Standard schedule used in DRC until 2002 
P P P M3 M3 M3       M3 M3 M3       M3 M3 M3 C      
Standard schedule used in Angola until 2002 
P P P M1 M2 M3 M3        M1 M2 M3 M3        M1 M2 M3 M3 C 
10-day schedule under investigation 
P P P M4 M4 M4 M4 M4 M4 M4 M4 M4 M4 C                 
 
P: anti-parasitic Pre-treatment; M1: 1.2 mg/kg; M2: 2.4 mg/kg; M3: 3.6 
mg/kg (max 5ml); M4: 2.2 mg/kg  
(max 5ml); C: treatment control 
 
 
Quantifying the costs 
Direct costs linked to the treatment options were measured as the total costs of diagnosis 
(including post-treatment examinations), drug treatment and hospitalisation. Costs involved 
for diagnosis and follow-up examinations are the same irrespective of the treatment schedule 
used. Thus, an average value was calculated based on the types and frequencies of tests 
done during the Impamel II study. The total costs of drug treatment included the cost of 
melarsoprol, drugs used for pre-treatment and concomitant treatment, and drugs to treat side 
effects. Hospitalisation costs were calculated based on the consumption of the Maluku 
treatment centre in DRC in 2001 (at current market prices in US$, March 2004) and the 
number of patients treated. For comparison, similar calculations were done for the 
Ndalatando treatment centre in Angola for the year 2003 (at market prices in US$, April 
2004).  
Quantifying the outcomes 
The non-inferiority of the 10-day treatment schedule for melarsoprol has been demonstrated 
[Burri et al., 2000; Schmid et al., 2004; Schmid et al., 2004], thus, the outcome of both 
treatment schedules was considered the same.  
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Effectiveness was quantified using: the net monetary benefit in US$ for the treatment of a 
late-stage patient with melarsoprol obtained by switching from the lengthy standard treatment 
to the shorter 10-day treatment schedule and the cost per DALY (disability-adjusted life year) 
averted, one DALY being defined as the loss of one year of healthy life to disease. The 
DALY has been calculated based on the method described by Politi et al. (1995) using the 
age-at-death of patients in the IMPAMEL II study and their life expectancies (approximate 
estimation taken from the World Bank Report 1993, Appendix B, Box 1.3) [WorldBank 1993]. 
These ages-at-death were taken as giving the best available estimate within the study for the 
years of life lost (YLL) which late-stage patients who were not treated and cured would have 
encountered. Although, late-stage patients who were not treated and cured would also have 
suffered some years of life with disability (YLD), these could not be estimated here. This 
approach allowed calculation of the cost-effectiveness of the two treatments in this analysis 
to be compared with previous findings [Politi et al., 1995; WHO 1998, 2001] and also with the 
preferred drug for late-stage sleeping sickness, eflornithine.  
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RESULTS 
The cost of diagnosis 
The prices for the diagnostic tests derived from previous calculations (Dr Pere Simarro, Dr 
Veerle Lejon, personal communications and [WHO 1998]) and included only material costs; 
consumables, equipment and salaries of staff were included in the costs of hospitalisation. 
The average cost for diagnosis of a patient was calculated based on the number of tests 
done in the two treatment centres during the IMPAMEL II study. Cost of diagnosis also 
included the examination 24 hours after treatment and the follow-up examinations done 
during the 2 year follow-up period. The same prices were used for both countries and the 
total cost calculated for the diagnosis of a patient at the treatment centre was 3.91 US$, 
comprising the initial serological (CATT) and the subsequent parasitological tests including 
material for blood, lymph and CSF sampling (Table 1).  
Table 1: Cost of diagnosis per patient, based on the frequencies of tests done in DRC and 
Angola during the Impamel II study, in US$. 
Price / test 
US$
Rate of 
population 
tested
Cost per 
test done 
US$
Rate  of 
population 
tested
Cost per 
test done 
US$
Rate  of 
population 
tested
Cost per 
test done 
US$
CATT 0.33 1.00 0.33 0.00 0.00 0.00 0.00
CATT dilution 0.54 0.50 0.27 0.00 0.00 0.00 0.00
Lymph examination 0.16 0.55 0.09 0.17 0.03 0.17 0.03
Blood examination 0.32 0.38 0.12 0.36 0.12 0.10 0.03
CSF examination (LP) 1.25 1.00 1.25 0.93 1.17 0.37 0.46
Double centrifugation of CSF 0.16 0.05 0.01 0.06 0.01 0.00 0.00
Cost per patient 2.07 1.32 0.52
Total diagnostic costs per patient 3.91
Diagnosis Follow up (4 controls)Treatment examination
 
 
The cost of hospitalisation 
The hospitalisation costs included the annual hospital costs and the number of patient days 
spent in the hospital (Table 2). The annual hospital costs were calculated from capital and 
recurrent costs (detailed in Annex I & II), whereas recurrent consisted of running costs, 
salaries and consumables and capital costs of equipment depreciation. The patient days per 
year derived from the number of patients treated during 1 year and were estimated for 
Angola (based on an average stay of 14 days for the 10-day schedule and 30 days for the 
standard schedule) and partially calculated for DRC (calculated for the 10-day schedule 
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based on the IMPAMEL II database and estimated at 25 days for the standard treatment 
schedule). The items included in these hospitalisation costs were broadly the same for both 
countries. Both included a relatively high cost for the use of the hospital and laboratory 
building, a notional rent in DRC and full refurbishment in Angola and in both cases utilities 
(water and electricity) were supplied free. Rather than include a notional cost for the latter, 
we estimated that these were adequately covered by the high building cost. Additionally in 
Angola, some basic food items as sugar, oil and maize were provided to the patients. The 
resulting estimate of the cost of a patient day would then be US$ 10 in DRC and in US$ 66 in 
Angola. The reasons for this wide differential are discussed below. 
Table 2 Hospitalisation costs calculated as cost per patient day, by centres/countries, in 
US$. 
DRC Angola
Maluku Ntalatando
US $ US $
Recurrent costs
Running Costs 9'408 39'664
Salaries 23'280 114'696
Consumables1 280 946
  Total hospital recurrent costs 32'968 155'306
Capital costs
Equipment (itemised depreciation)2 2'771 18'236
  Total hospital capital costs 2'771 18'236
Total annual hospital cost 35'739 173'542
Number of patient days per year3
SS14 612 297
SS25 2'912 2'338
Total patient days 3'524 2'635
Hospitalisation cost per patient day6 10.14 65.86
6excluding sleeping sickness specific medication and tests
3year 2001 for Maluku and 2003 for Ntalatando
1includes syringes, gloves, stationaries
2furniture, miscroscopes etc
4SS1: number of days estimated based on theoretic days of hospitalisation
5SS2: number of days calculated for Maluku from IMPAMEL II study and for Ntalando 
estimated on theoretic days of hospitalisation
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The cost of treatment  
The costs of treatment were calculated based on today’s market prices of the two countries 
(March 2004), the number of patients treated (DRC in 2001, Angola in 2003), and the 
respective drug consumption in the same year. The results are given in Table 3. The prices 
of the drugs were highly variable between the two countries.  
The anti-parasitic pre-treatment was the same in both countries and consisted of anti-
malarial (chloroquine) and anti-helminthic (mebendazole) treatment during 3 days before 
applying melarsoprol, as described more detailed in the overall IMPAMEL II analysis [Schmid 
et al., 2004].  
Melarsoprol was calculated based on a 50 kg patient as follows:  
• 10-day schedule: 10*2.2mg/kg*50 kg = 1100 mg = 6.1 ampoules at the latest price of 8 
US$ = 48.9 US$ and if 20% transport costs added = 58.6 US$ 
• standard schedule in DRC: 3*3*3.6 mg/kg*50 kg = 1620 mg = 9 ampoules at US$ 8 = 72 
US$ and if 20% transport costs added = 86.4 US$ 
• standard schedule in Angola: 3*(1.2+2.4+3.6+3.6) mg/kg*50 kg = 1620 mg = 9 ampoules 
at US$ 8 = 72 US$ and if 20% transport costs added = 86.4 US$ 
Concomitant drugs that were given during melarsoprol treatment varied between the 
centres/countries: in Angola, multivitamins were given to each patient during the whole 
hospitalisation period and in DRC only to those needing re-nutrition. Corticosteroids 
(prednisolone) were given to the patients treated with the 10-day treatment schedule in both, 
Angola and DRC, but at slightly different dosages [Schmid et al., 2004]. However, under the 
standard treatment for melarsoprol, the use of concomitant corticosteroids was very different: 
whereas in DRC no prednisolone was given, the patients in Angola received it. 
Additional drugs used were mainly for the management of adverse effects of melarsoprol 
therapy and the costs calculated for these were based on the number of patients with severe 
adverse events (SAE) and the additional drug consumption in the respective year.  
The costs for treatment varied highly between the countries and the different treatment 
schedules. The large local price differences accounted for the much higher costs in Angola 
(Appendices I & II).  
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Table 3 Cost of treatment calculated as cost per patient day. Drugs for pre-treatment, 
melarsoprol treatment, concomitant medication and management for severe 
adverse events (SAE) are included, in US$. 
+ management 
of SAE
+ management 
of SAE
Democratic Republic of Congo
Pre-treatment 0.66 0.66 0.66 0.66
Melarsoprol 58.60 58.60 86.40 86.40
Concomitant drugs 0.58 0.58 0.06 0.06
Drugs for management of SAE1 0.00 18.30 0.00 18.30
Total drug costs per patient 59.84 78.14 87.12 105.42
Angola
Pre-treatment 2.70 2.70 2.70 2.70
Melarsoprol 58.60 58.60 86.40 86.40
Concomitant drugs 2.13 2.13 1.58 1.58
Drugs for management of SAE1 0.00 80.00 0.00 80.00
Total drug costs per patient 63.43 143.43 90.68 170.68
1estimate based on total extra costs for SAE divided by # patients with SAE
Standard schedule10-day schedule
 
 
Total costs per patient treated 
The total costs per patient treated are summarised in Table 4 and Graph 2. Depending on 
the treatment schedule received, the full costs for treating a late-stage sleeping sickness 
patient varied between 206 and 346 US$ in Maluku, DRC and 990 and 2071 US$ in 
Ndalatando, Angola. This is illustrated in Graph 2, where the various components have been 
broken down into 4 categories. The costs of hospitalisation dominate the total costs; this is 
particularly pronounced in Angola and for the scenarios which illustrate the current financial 
or budgetary cost with melarsoprol being given for free and only transport costs paid for. The 
costs for the melarsoprol treatment itself remain fairly stable at 60 – 90 US$ for the different 
treatment schedules and centres. 
Cost effectiveness of the treatments 
The clinical effectiveness of the two treatment schedules was considered to be the same, 
based on the results of the previous large-scale study IMPAMEL I in Angola [Burri et al., 2000; 
Schmid et al., 2004] and the current multinational evaluation IMPAMEL II [Schmid et al., 2004]. 
As the overall conclusions do not depend on the specific measures of effectiveness (number 
of lives saved, DALYs averted), results are presented in terms of DALYs averted (Table 5). 
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For our study population (IMPAMEL II), 30 DALYs could be saved by treating one patient. For 
both countries we calculated the costs per DALY averted, selecting several alternatives for a 
range of DALYs between 20 to 35 years that correspond to previously described estimates 
[Politi et al., 1995; Moore et al., 1999; Odiit 2003]. In absolute terms, using the 10-day 
schedule meant that the costs for the treatment of a late-stage sleeping sickness patient 
could be reduced to about half of the costs incurred under the standard schedule. 
Graph 2 Total costs for a full treatment of a late-stage sleeping sickness patient in Maluku, 
DRC and Ndalatando, Angola, in US$. 
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Table 4: Total costs for a full treatment of a late-stage sleeping sickness patient in Maluku, 
DRc or Ndalatando, Angola, in US$. 
+ management 
of SAE
+ management 
of SAE
Maluku, DRC
  Days of hospitalisation 14 15 25 26
  Cost per day hopsitalised 10.14 10.14 10.14 10.14
Total hospitalisation cost per patient 141.96 152.10 253.50 263.64
Diagnosis 3.91 3.91 3.91 3.91
Drugs 59.84 78.14 87.12 105.42
Total cost per patient in Maluku 205.71 234.15 344.53 372.97
Ndalatando, Angola
  Days of hospitalisation 14 15 30 30
  Cost per day hopsitalised 65.89 65.89 65.89 65.89
Total hospitalisation cost per patient 922.46 988.35 1976.70 1976.70
Diagnosis 3.91 3.91 3.91 3.91
Drugs 63.43 143.40 90.68 170.68
Total cost per patient in Ndalatando 989.80 1135.66 2071.29 2151.29
10-day schedule Standard  schedule
 
 
Table 5 Cost effectiveness of the two treatment schedules for DRC (A, B) and Angola (C, 
D), per DALY averted 
A: Cost per patient treated (US$), DRC       B: Cost per DALY averted (US$), DRC
Item 10-day 
schedule
Standard DALYs averted1 10-day 
schedule
Standard
Diagnosis & Control 4 4 20 10.3 17.2
Hospitalisation 142 254 25 8.2 13.8
Drugs2 60 87 30 6.9 11.5
Total 206 345 35 5.9 9.8
C: Cost per patient treated (US$), Angola D: Cost per DALY averted (US$), Angola
Item 10-day 
schedule
Standard DALYs averted1 10-day 
schedule
Standard
Diagnosis & Control 4 4 20 49.5 104.1
Hospitalisation 922 1977 25 39.6 83.3
Drugs2 63 91 30 33.0 69.4
Total 990 2071 35 28.3 59.5
1per 2nd stage patient successfully cured; values from literature and IMPAMEL II study
2excluding drugs for management for SAE
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DISCUSSION 
The multinational IMPAMEL II study [Schmid et al., 2004] has demonstrated overall 
effectiveness of the 10-day melarsoprol schedule in the treatment of late-stage sleeping 
sickness due to T.b. gambiense and depicted the numerous advantages over the lengthy 
standard treatment regimens: psychological (patients’ and doctors’ compliance to adhere to 
treatment), technical (10 consecutive days, no dosage adjustment), pharmacologic (due to its 
simple application it forms the basis of all potential combinations of melarsoprol in the 
compassionate treatment of refractory cases) and economic (lower drug requirement, shorter 
hospitalisation leading to increased treatment centre capacity). In this paper we estimated 
the economic advantages of the 10-day schedule by analysing the costs involved for the 
treatment of late-stage sleeping sickness patients with melarsoprol in the two rural treatment 
centres Maluku and Ndalatando that participated in the IMPAMEL II study. The centres were 
chosen based on accessibility to comprehensive data and are believed to represent basic 
(mostly rural) treatment centres operated by the national control programs. 
The treatment effectiveness (i.e. cure rates at discharge and 2 years after treatment) were 
similar for both treatment schedules [Burri et al., 2000; Schmid et al., 2004; Schmid et al., 
2004] and comparable to previous reports [Pepin et al., 1989; Van Nieuwenhove 1992; Politi 
et al., 1995; WHO 1998; Van Nieuwenhove 1999]. Thus, the indicator of effectiveness used 
in this analysis was DALYs gained by treating patients, enabling the comparison to previous 
cost-effectiveness calculations [Politi et al., 1995; WHO 2001]. Although work on this subject 
is ongoing, there is little published information on the burden of the disease in terms of 
DALYs lost due to either form of sleeping sickness. Odiit et al. (2000) have produced 
calculations of DALYs for the rhodesiense sleeping sickness based on the age distribution of 
patients in Uganda and estimated the number of DALYs lost for unreported, therefore 
untreated, patients to be just over 20 years [Odiit 2000]. First estimations for gambiense 
patients were based on the age-at-death distribution for rhodesiense patients in Uganda and 
yielded a DALY of around 25 years [Politi et al., 1995]. Similar results were found in a control 
program in southern Sudan for gambiense patients which estimated just over 30 years 
[Trowbridge et al., 2001]. Currently a study is performed to address the burden of the 
disease in several countries endemic for gambiense sleeping sickness (personal 
communication Dr Anne Moore, CDC Atlanta). We have calculated a similar value for the 
DALY for gambiense sleeping sickness (30 years) based on the age-at-death distribution in 
the IMPAMEL II study which included patients from 7 sub-Saharan African countries. Thus, in 
Table 5, the results are presented for a range of 20 to 35 DALYs averted per person 
successfully treated. 
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The total costs for the treatment of late-stage gambiense sleeping sickness with melarsoprol 
derived from the costs of diagnosis, treatment and hospitalisation. However, some expenses 
could not been taken into account which possibly led to an underestimation of the real costs. 
The screening mode was not considered as in both centres analysed, the patients were 
admitted mostly passively and diagnosis was done at the respective centres. Were patients 
found by active screening, the cost of active surveillance would be very high but the same 
whatever treatment schedule was used; however by detecting second stage patients earlier it 
could mean that more DALYs were gained per patient found. Additionally, the prevalence, 
sensitivity and specificity of the diagnostic tests were not explicitly considered, although this 
could have contributed to slight differences in the overall costs. The figures used represent 
the actual consumption of the test materials and if GCP and GLP rules were followed, some 
expenses in our analysis are then clearly underestimated (consumption of gloves, needles, 
syringes, and disinfectant). Also, the costs borne by patients (including value lost during their 
illness and accompanying relative) were not evaluated; such an analysis is currently being 
performed in DRC [Lutumba et al., 2004]. This is certainly a limitation of our analysis as the 
costs borne by patients due to a long period of illness (months to years) would substantially 
add to the total costs and therefore, the values given here are actually an underestimation of 
the benefit.  
Generally, treatment of late-stage sleeping sickness was six times more expensive in Angola 
than in DRC. Price levels in Angola are amongst the highest in Africa and this is clearly 
reflected in all the cost categories of our analysis. However, differences in staffing levels and 
in the type of equipment used also contributed significantly to the differential in costs. For 
example, the cost of beds accounted for almost $2 of the hospitalisation cost in Angola 
versus $0.04 in DRC.  
Salaries were the largest single component of the cost differential. In addition to the about 
50% higher salaries, the centre in Angola employed more than three times as many people. 
However outcomes and recovery rates between the two centres were similar. But the 
situation in Angola seems to be an exceptional and temporary situation, because the staffs 
from the peripheral units have been concentrated in the safer provincial capital during the 
war. Recalculating the hospitalisation costs (assuming same staffing levels and salaries for 
both countries, taking the average of the two salary levels and a staffing level 50% higher 
than that currently in use in DRC) increased the hospitalisation cost per patient day in DRC 
from US$10 to US$16 and reduced it from US$66 to US$39 in Angola. It is felt that these 
levels probably represent a valid range for this cost in Africa, with the average cost tending to 
be closer to the lower DRC level.  
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The drugs for sleeping sickness are donated free of charge by Aventis until 2006, and only 
the costs of transport and administration are being paid by the national control programs 
today. But nevertheless, from a budgetary viewpoint, the full cost of the drugs was 
considered in this analysis for the case that they have again to be paid for in future. More 
importantly, in an economic analysis this cost must of course be included as it represents a 
use of real resources. In our study, most of the costs are due to the hospitalisation (around 
70% in DRC and approximately 90% in Angola) and melarsoprol contributed 30–34% to the 
total cost in DRC and 5-7% in Angola. 
The costs in DRC for treating a late-stage patient with melarsoprol were US$206 with the 10-
day schedule and US$345 with the standard schedule (including costs for management of 
severe adverse events) and thus, on the basis of 30 DALYs averted per patient successfully 
treated, the costs per DALY averted (US$ 6.9 and US$11.5) was for both treatments below 
the ‘good value for money’ threshold of US$25 [WorldBank 1993]. In Angola, the cost per 
DALY averted approaches this margin only very closely when using the 10-day treatment 
schedule. As discussed above, Angola for a variety of reasons represents a very high cost 
scenario, the type of adjustments to these costs proposed above would bring these costs 
well within the good value for money threshold. 
With the 10-day treatment schedule, the total costs for treatment could almost be halved in 
both countries. The net benefit from switching from the standard to the 10-day treatment 
schedule did reduce the cost per DALY averted from US$11.5 to US$6.9 in DRC and from 
US$69.4 to US$33.0 in Angola, a saving of US$4.6 (DRC) or US$36.4 (Angola) per DALY 
averted. And as already concluded by Politi et al. (1995) “treating late-stage with melarsoprol 
is an extremely good buy in terms of possible alternative uses of scarce health resources…” 
we can only confirm these findings.  
Treatment of early-stage patients is even more cost-effective [WHO 1998], 110US$ or 
US$3.9 per DALY averted and can be even less if these patients are not hospitalised. 
Finding and treating patients in the early stage of the disease would, in terms of disease 
control, be the most effective form in reducing the human reservoir and the disease 
transmission. But one has to clearly bear in mind, that finding patients in the early stage of 
the disease implies periodic and active screening activities that are determined by the local 
prevalence levels and consequently cost more than passive screening. Thus, all cost 
components from screening to treatment, including the costs borne by patients should be 
integrated in the planning of control strategies and funds allocation. 
The preferred treatment for late-stage gambiense sleeping sickness these days is 
eflornithine. Although the drug is being supplied free of charge until 2006, treatment with 
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eflornithine remains expensive; it has to be given as slow infusions every 6 hours over 14 
days, requires expensive administration kits and can only be administered by qualified staff 
in centres with good logistics. The costs of treatment with eflornithine, including the 
administration kits, was calculated by Politi et al. to be at 481US$ in Uganda in 1995 [Politi et 
al., 1995]. However, his finding of US$18.4 per DALY averted seems somewhat an 
underestimation of the real cost today and eflornithine remains restricted to centres with 
substantial and consistent support by NGOs. From the public health perspective however, 
melarsoprol saves a substantial number of lives, at very low costs, despite resulting in deaths 
from its side effects. It can be used as the baseline and decisions about the use of alternative 
treatments (i.e. eflornithine) cannot ignore the effectiveness of melarsoprol.  
Finally, we conclude that the 10-day melarsoprol schedule is a highly cost-effective treatment 
option for late-stage gambiense sleeping sickness in areas with scarce resources by halving 
the total costs in switching from the lengthy standard treatment schedules to the 10-day 
schedule.  
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Annex I - Hospitalisation costs Maluku, DRC 
Hospitalisation costs are calculated from recurrent (made up of running costs, salaries and 
consumables, table 1.1) and capital costs (depreciation of general hospital equipment, table 
1.2). 
Table 1.1 Recurrent costs Maluku, DRC 
Number Amount / month 
(US$)
Frequency Annual cost 
(US$)
Running costs
Building, examination room and hospital (notional rent) 1 500 12 6'000
Laboratory building (notional rent) 1 200 12 2'400
Power, water1 na 0
Transport, fuel 1 64 12 768
Stationery (lab books, records, pens) na 0
Communication (mobile) 1 10 12 120
Communication (phonie) 1 10 12 120
Sub-total building and running costs 9'408
Salaries
  MD 1 541 12 6'492
  Nurses 4 212 12 10'188
  Lab technicians 1 226 12 2'712
  Other (Maintenance) 1 120 12 1'440
  Other (Guardian) 1 204 12 2'448
Sub-total salaries 23'280
Number Price / unit 
(US$)
Frequency Annual cost 
(US$)
Consumables
Syringes, Needles, Lancettes 800 0.11 1 88
Sondes, catheters 20 0.60 1 12
Gloves 200 0.10 1 20
Slides, cover slips 300 0.04 1 12
Alcohol, Giemsa, immersion oil 1 147.75 1 147.75
Sub-total consumables 280
TOTAL RECURRENT COSTS 32'968
1not paid since government institution
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Table 1.2 Capital costs Maluku, DRC 
Number Unit cost 
(US$)
Total cost 
(US$)
Years used Total / year 
(US$)
Beds 20 30 600 10 60
Matresses 20 20 400 5 80
Examinationbed 1 50 50 4 13
Bicycle 1 100 100 4 25
Tables (examination, laboratory and hospital) 3 50 150 2 75
Chairs (examination, laboratory) 8 15 120 2 60
Banks (waiting area patients) 2 25 50 2 25
Cupboards (drugs, files) 3 167 501 2 251
Sideboards 2 28 56 2 28
Curtain 10 30 300 2 150
Paravent 2 20 40 5 8
Microscope (Olympus CH 20) 1 1500 1500 4 375
Centrifuge (benchtop) 1 3394 3394 5 679
Centrifuge (hematocrit) 1 920 920 5 184
Refridgerator 1 830 830 5 166
Freezer 1 450 450 5 90
CATT Rotator 1 150 150 5 30
Weighing balance 1 20 20 3 7
Pipettes 2 300 600 3 200
Counting chambers 2 50 100 1 100
Pots and glasses (staining, storage, waste) 1 200 200 3 67
Thermometers, Stethoscope 2 50 100 3 33
Other lab equipment 1 200 200 3 67
TOTAL CAPITAL COSTS (US$) 2'771
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Annex II - Hospitalisation costs Ndalatando, Angola 
Hospitalisation costs are calculated from recurrent (made up of running costs, salaries and 
consumables, table 2.1) and capital costs (depreciation of general hospital equipment, table 
2.2). 
Table 2.1 Recurrent costs Ndalatando, Angola 
Number Amount / month 
(US$)
Frequency Annual cost 
(US$)
Running costs
Building (examination, laboratory, hospital) - rehabilitation in 2003 1 11000 1 11'000
Power, water1 1 0 12 0
Food (maize, sugar, oil) 1 2186 12 26'232
Transport, fuel 1 40 12 480
Stationery (lab books, records, pens) 1 167 3 500
Communication 1 121 12 1'452
Sub-total building and running costs 39'664
Salaries
  MD 2 1055 12 25'320
  Nurses 18 218 12 47'088
  Lab technicians 12 273 12 39'312
  Other (Maintenance) 2 62 12 1'488
  Other (Administration) 2 62 12 1'488
Sub-total salaries 114'696
Number Price / unit 
(US$)
Frequency Annual cost 
(US$)
Consumables
Syringes, Needles, Lancettes 2500 0.11 1 275
Sondes, catheters 10 0.65 1 7
Gloves 1300 0.15 1 192
Slides, cover slips 700 0.05 1 34
Alcohol, Giemsa, immersion oil 1 438.00 1 438
Sub-total consumables 946
TOTAL RECURRENT COSTS 155'306
1not paid since government institution
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Table 2.2 Capital costs Ndalatando, Angola 
Number Unit cost 
(US$)
Total cost 
(US$)
Years used Total / year 
(US$)
Beds 40 470 18800 5 3'760
Matresses 40 108 4312 3 1'437
Examinationbed 1 400 400 5 80
Bedsheets, blankets, pillows 70 32 2233 2 1'117
Tables (examination, laboratory and hospital) 5 261 1305 3 435
Chairs (examination, laboratory) 16 65 1040 3 347
Cupboard (drugs) 2 480 960 3 320
Cupboard (files, folders) 7 165 1155 3 385
Curtain, Paravent 5 290 1450 1 1'450
Microscope 3 2420 7260 3 2'420
Centrifuge (benchtop) 1 5741 5741 2 2'871
Centrifuge (hematocrit) 1 3840 3840 2 1'920
Refridgerator 1 874 874 3 291
CATT Rotator 1 150 150 3 50
Weighing balance 3 109 326.7 3 109
Pipettes 2 700 1400 2 700
Counting chambers 4 105 420 2 210
Pots and glasses (staining, storage, waste) 1 200 200 1 200
Thermometers, Stethoscope 2 45 90 2 45
Cooking equipment 10 45 450 5 90
TOTAL CAPITAL COSTS (US$) 18'236
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FROM EFFICACY TO EFFECTIVENESS – A DISCUSSION 
The approach for drug development by investing in research of an old and toxic drug as 
melarsoprol, that wouldn’t pass a single drug-safety test today, appears to contrast 
nowadays common agreed policy which aims at the development of safe and effective drugs 
for sleeping sickness treatment. However, in the absence of valid alternatives (detailed in 
introduction), melarsoprol remains the most used drug to treat late-stage sleeping sickness in 
basic rural treatment facilities with scarce resources that are not supported or operated by 
NGOs. The underlying study aimed at an improved approach of the treatment with 
melarsoprol of late-stage gambiense sleeping sickness and provided evidence of its overall 
effectiveness.  
Efficacy and effectiveness, the need for definition 
Efficacy in clinical trials answers the question “does a treatment work under ideal 
conditions?” and is optimally achieved by a well-designed, controlled study, in which the 
intervention is carefully supervised (Table 1). The most common clinical trial which satisfies 
these rules is the double-blind, randomised controlled trial, where neither patient nor the 
person issuing the treatment knows who is receiving the treatment studied. Normally, 
efficacy studies are referred to as Phase I - III clinical trials and the outcome analysed is 
whether a treatment is effective and safe in a restricted (and therefore a very much 
controlled) patient population. However, such trials have limitations and the controlled clinical 
setting used in experiments is a poor model of the complex and dynamic real world. 
Effectiveness in contrast, is more ambiguously described and definitions vary largely, 
generally effectiveness studies do respond to “does the treatment work in the real world?” 
with emphasis on the applicability of the treatment and therefore try to duplicate the 
situations that medical personnel will encounter in the practice. Additional questions about 
outcomes are being answered, patient acceptance, economics of use, long-term safety and 
efficacy, and practice and use patterns. Effectiveness is strongly affected by compliance, 
which is influenced by behavioural factors that are in turn affected by access to the 
intervention, supply, cost, and other factors as differences between population groups and 
settings. Effectiveness may be monitored and a cost-benefit analysis conducted during the 
implementation of an effective intervention, and is normally referred to as post-registration 
study or Phase IV clinical trial. 
For the ease of the reading, in the present work we distinguished between two forms of 
effectiveness, the clinical effectiveness which stands for the clinical outcome and the 
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economic effectiveness that refers to the costs and effects of the treatment from a public 
health perspective (also termed efficiency).  
 
Table 1 Comparison of criteria of efficacy and effectiveness trials  
EFFICACY EFFECTIVENESS
Question
Ideal Condition Real world 
mostly RCT* Trial design
Phase I - III Phase of trial Phase IV
Pre-registration Stage of registration Post-registration, Post-
marketing
Few Eligibility All
Few Inclusion criteria Not restricted
Many Exclusion criteria None
High Degree of control Low
"does a treatment work 
under ideal conditions?"
"does the treatment work in the 
real world?"
*RCT: randomised controlled trial
few RCT*, Historical data design
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Proof of effectiveness 
The efficacy of the 10-day treatment schedule of melarsoprol has been shown in a large-
scale randomised controlled clinical trial executed in a restricted population in Angola 
(IMPAMEL I) [Burri et al., 2000]. The authors clearly demonstrated non-inferiority of the 10-day 
schedule in terms of efficacy and safety compared to the standard treatment schedule used 
at that time in Angola.  
Further, two years after treatment, the follow-up of the patients has been evaluated for its 
long-term efficacy. The follow-up coverage of the patients was very high (>80%) and the 
fatality and relapse rates during the follow-up were equal for both treatment groups (2.9% 
fatalities and 4.8% relapses) and comparable to previous findings in the same area [Ruiz et 
al., 2002]. The results are in agreement with the conclusions anticipated from the IMPAMEL I 
trial and provide evidence for the long-term efficacy of the 10-day treatment schedule 
(chapter 1, [Schmid et al., 2004]). The favourable outcome of the IMPAMEL I trial was received 
with great interest by representatives of national sleeping sickness control programs, WHO 
and NGO’s, however, a conclusive evaluation and systematic introduction of the 10-day 
schedule in the affected countries was demanded. The clinical trial in Angola was conducted 
under controlled conditions in a defined population that may not necessarily reflect the 
normal sleeping sickness patient and situation. The rate of concomitant infectious diseases 
(e.g. filaria, HIV) is rather low in that area and generally the patients’ conditions on admission 
were quite good. In addition, prior to the trial, the infrastructure in the two conducting 
treatment centres was improved, the staff specifically trained, and during the trial, the correct 
conduct assured by expatriate experts. Therefore, a thorough evaluation under various field 
conditions of the 10-day schedule was indispensable which consequently led to the 
multinational evaluation (IMPAMEL II). 
IMPAMEL II was a non-controlled, multinational, multi-centre drug utilisation study to evaluate 
the abridged treatment schedule of melarsoprol in late-stage T.b. gambiense sleeping 
sickness patients under true field conditions. The clinical effectiveness of the 10-day 
treatment schedule was assessed in more than 2000 patients of 16 sleeping sickness 
treatment centres in 7 African countries and was to the best of our knowledge the largest 
clinical study ever conducted in sleeping sickness. The outcome of the IMPAMEL II study 
confirms the results of the IMPAMEL I study and provides strong evidence for the overall 
effectiveness of the 10-day schedule:  
• The compliance of the patients and the medical staff to the treatment schedule was high; 
more than two thirds of the patients received the ten doses without treatment 
interruptions, 89% completed the ten doses, and only 0.3% of the treated patients left the
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hospital before treatment completion for unknown reasons (chapter 2). Normally, the 
compliance of to the lengthy standard treatment schedules of melarsoprol was poor, a 
large proportion of the patients was reported not to stick to the foreseen treatment 
regimen or even escaped from the treatment facility before treatment completion [Weir et 
al., 1985; Burri et al., 2000]. 
• Many patients presented themselves to those treatment facilities where the 10-day 
schedule was offered already during the implementation phase of the study. This 
observation can be interpreted as favouring the 10-day schedule over the old and lengthy 
standard schedule in the respective countries. 
• No unexpected outcome was found in the wider population of this multicentre evaluation. 
Overall, the results were highly variable between the diverse study centres, but this could 
be expected due to the inherent differences of the treatment facilities. Similar large 
differences were already reported by the participating centres for the outcome of 
melarsoprol treatment with the standard schedules prior to the study (chapter 2).  
• Nevertheless, the safety and tolerability of the 10-day schedule were comparable to the 
standard treatment (chapter 2). The average rates of encephalopathic syndromes and 
treatment related fatalities in this study were similar to previously reported rates for the 
standard treatment schedules of melarsoprol (reviewed in [Seixas et al., 2004]. No risk 
factors for an unfavourable outcome could be identified in this study.  
• Also in line with previous reports [Doua et al., 1985; Adams et al., 1986; Blum et al., 
2001] was the timing of the occurrence of the encephalopathic syndromes, strongly 
supporting the view that the event is independent of the treatment schedule and dose 
applied (chapter 2). 
• Elevated rates of skin reactions, fever and headache during treatment with the 10-day 
schedule were already observed in the IMPAMEL I study [Burri et al., 2000] but could be 
managed by adequate concomitant medication and treatment interruption where 
necessary (chapters 2 and 3). 
• Despite the fear of many medical staff of treating children with the 10-day treatment 
schedule, that was felt as more aggressive than the old one, we could confirm a similar 
safety and efficacy profile in children compared to adults (chapter 4). Children seemed to 
experience more severe (grade 2) adverse reactions, these were mainly fever and 
maculopapular eruptions, but the former may have been associated with the higher rate 
of detected malaria parasites in children. However, the most severe adverse events, 
encephalopathic syndromes and treatment related fatalities, occurred at equal rates in 
children as in adults.  
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• Not surprisingly, patients with concomitant parasites detected during the treatment 
course experienced more often adverse events, which put them at a higher risk to die 
and finally led to a reduced clinical effectiveness of the treatment with melarsoprol 
(chapter 3). Earlier reports have already pointed at the possible risk of concomitant 
parasitism during melarsoprol treatment by aggravating the treatment outcome 
regardless of the schedule used [Van Nieuwenhove 1999; Blum et al., 2001]. 
• The short- as well as the long-term clinical effectiveness appeared to be equivalent to the 
standard treatment and without differences between adults and children. 94% of the 
patients were discharged alive without trypanosomes detected in any body fluid. Two 
years after treatment, 86% of all treated patients were termed cured. These rates are 
superior to previously reported outcomes of the standard melarsoprol treatment 
schedules with efficacy as low as 70% [WHO 1998] (chapter 2). 
• The follow-up coverage between the centres was highly variable (15%-100% of the 
treated patients have been followed up in the respective centres), but this discrepancy 
has already been recognised as an inherent problem of the sleeping sickness control 
independent of the treatment [WHO 2001].  
• The follow-up activities were purposely not assisted in this study with the intention not to 
interfere with the “normal situation” in the field. Roughly only half of the treated patients 
have been examined during the follow-up period of two years, and therefore, the average 
relapse rate of 7.1% may be an underestimation (range by centres: 0–26% versus a 
relapse rate between 0–30% in literature). However, the relapse rates reported in this 
study match the rates found in the centre histories of the respective treatment centres 
(chapter 2). 
• Even though a lower total dose of melarsoprol was given, the 10-day schedule did not 
increase the risk of treatment failures (and relapses), which was a highly debated issue 
prior to the implementation of the study. Elevated rates of treatment failures (and 
relapses) were anticipated by introducing a new treatment schedule of melarsoprol 
monotherapy, especially in areas with known melarsoprol resistance. Most of these areas 
did not participate in the study, as they switched to eflornithine treatment as first-line 
treatment for late-stage gambiense sleeping sickness or combination treatment for 
melarsoprol refractory cases. However, in South Sudan, an area with an elevated relapse 
rate (15%), the 10-day schedule was successfully applied without increasing the relapse 
rates. 
• The economic effectiveness was assessed and revealed the 10-day schedule to be a 
highly cost-effective alternative treatment for late-stage gambiense sleeping sickness 
(chapter 5). In switching to the 10-day schedule, the overall treatment and hospitalisation 
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costs could be nearly halved compared to the standard treatment schedules. For 
example, in the Democratic Republic of Congo in 2001, the total costs for treatment and 
hospitalisation of a patient were reduced from US$345 for the standard to US$205 for the 
10-day schedule.  
• With the 10-day schedule, the cost per DALY averted could be reduced from US$11.5 to 
US$6.9 in DRC, which represents an extremely good buy in terms of possible alternative 
uses of scarce health resources for a sleeping sickness control program (chapter 5).  
• The hospitalisation costs were the largest component of the cost differential (US$10 per 
patient day in DRC) which could be substantially reduced when the total hospitalisation 
stay of a patient was reduced by applying the 10-day treatment schedule (from 26 days 
with the standard to 15 days with the 10-day treatment schedule; chapter 5). 
• Even if today the drugs for sleeping sickness treatment are free of charge, donated by 
Aventis until 2006, one should still bear in mind the costs for the drugs in case it has 
again to be paid for in future. Calculating for an average 50 kg bodyweight, the total drug 
amount used per patient could be reduced with the 10-day schedule from 1620 mg (9 
ampoules at US$8 each) by one third to 1100 mg total melarsoprol (6 ampoules). Thus, 
the costs for melarsoprol could be reduced by one third, from US$72 to US$48 for a 
patient with 50 kg bodyweight, which constitutes roughly 20% of the total costs spent for 
the treatment of a patient (chapter 5). 
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Validity of the findings 
Although the present study was the largest clinical study ever performed in sleeping sickness 
with its particular strengths of implementation in multiple populations, settings and under 
absolute real conditions in the field, some limitations became apparent when attempting to 
apply the results of the randomised clinical trial (IMPAMEL I) to the routine practice (IMPAMEL 
II):  
A randomised design was considered not feasible and above all not ethical. Due to the very 
basic equipment of the sleeping sickness treatment facilities, the often low level of staff 
qualification and the lack of experience in the conduct of clinical trials it was not possible to 
conduct a randomised study. Cluster randomisation was also considered impossible because 
of the inherent differences in the outcome of the sleeping sickness treatment in different 
centres and countries and the limited number of centres available for participation. The 
abridged schedule has been demonstrated to be non-inferior, in terms of safety and efficacy, 
and in addition, it depicted numerous advantages over the lengthy standard treatment 
regimens such as psychological (patients’ and doctors’ compliance to adhere to treatment), 
technical (10 consecutive days, no dosage adjustment), pharmacologic (basis of all potential 
combinations of melarsoprol in the compassionate treatment of refractory cases) and 
economic (lower drug requirement, shorter hospitalisation, increased treatment centre 
capacity). Therefore it was considered unethical to deprive a fraction of the patients through 
randomisation from a treatment that was already considered preferable.  
As the present study was non-randomised, the population treated was non-controlled and 
therefore most likely different to the population in the IMPAMEL I trial on which the conclusions 
are based. Additional to the population differences, the disease prevalence and co-
morbidities of the various disease foci did certainly also vary which could have conveyed a 
different outcome than in the randomised controlled clinical trial. In our study, we have 
observed an association of concomitant parasitic diseases on the treatment outcome 
(adverse events, effectiveness) but as the study was not designed to determine concomitant 
parasitism in sleeping sickness patients, routine screening for concomitant parasites was not 
mandatory and therefore, the observed influence could not be anticipated and compared to 
the randomised controlled trial IMPAMEL I. 
Another limitation for analysis of temporal as well as causal associations was the simple 
questionnaire design. It was left as simple as possible in order not to pose too much 
additional work to the local staff in the field and to avoid asking for assessments and 
examinations the staff is not trained for, therefore many items were left out. For example in 
the case of the occurrence of severe adverse events, the investigators were asked to act 
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according to their national or organisational guidelines, which differed between the countries 
and centres. And sometimes even, such guidelines could not be followed due to the lack of 
resources (appropriate staff not in place, no drugs available, inadequate equipment) and the 
deviations from these guidelines were often not documented, which as a result led to 
difficulties in the analysis and interpretation of the management of adverse events.  
Due to the non-randomised approach and low degree of control, potential bias might have 
been introduced. a) The most obvious form, selection bias, was indeed encountered in one 
country of our study: despite the protocol guidance and respective training, the 10-day 
schedule was not solely used and patients were selected according to their health status and 
age due to the fear that the abridged schedule is more harmful to children and the sicker 
adults. All patients from this country treated in the study could not be included in the official 
analysis. b) An observation bias might have been prompted by the solicited information 
which usually is not recorded in the general practice. For example, we have noted elevated 
rates of mild symptoms like fever, headache or pruritus. They are very likely rarely noticed 
and recorded in a sleeping sickness treatment centre, but are also common symptoms and 
signs of the disease and as a consequence, these rates were difficult to compare to 
previously published studies or the centres’ histories. Additionally, the doctor’s perception 
may have played an important role in defining the tolerability of the treatment. The notion that 
more treatment interruptions caused by moderate adverse events were reported in centres 
operated by NGOs or expatriate doctors supports this reflection. 
Additionally, although clearly defined in the study protocol, the definition for the 
encephalopathic syndromes used by the investigators was not consistent and differed 
between the centres/investigators and thus, comparison of the patients with encephalopathic 
syndromes was complicated. Particularly the psychotic reactions were left at a wide range for 
definition. This certainly may have contributed to the large inter-centre differences in the 
analysis of the encephalopathic syndrome and its types. 
However, no similar study exist for melarsoprol, all studies so far documented were of small 
scale or retrospective analysis of treatment centres’ records, with patient cohorts treated with 
various treatment schedules or under different conditions. And despite the limitations of 
which we were fully aware prior to the implementation of the study, a simple study design 
was chosen to duplicate as closely as possible the conditions in the target practice and to 
ensure the applicability to the wider settings in which the results will be applied. Above all, we 
strongly believe that for practical and particularly ethical reasons there was no other option. 
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CONCLUSIONS 
Despite resulting in deaths from its side effects, melarsoprol will remain the most used drug 
for the treatment of late-stage gambiense sleeping sickness. The treatment with melarsoprol 
can be enhanced by abridging its application scheme. The 10-day treatment schedule 
showed to be advantageous in many ways over the lengthy standard schedules hospitalising 
the patients up to 30 days. It is easier to implement even by less qualified staff in resource 
poor treatment facilities in remote areas, as it does not need daily dose adjustments and 
complex coordination of the treatment series and rest periods. Patients and their 
accompanying relatives prefer the shorter course as it renders them an earlier return to their 
home, and most likely increasing their potential productive time at home. The compliance of 
the patients and the medical staff to the treatment schedule is likely to be better than with the 
standard treatment schedules; patients do not run away before treatment completion, which 
may increase their chances of cure. The short and long-term efficacies are equal to the 
standard schedules, the patients can be cured by the abridged schedule and it does not 
cause an increase in the relapse rate. Overall, the safety and efficacy in children are 
comparable to adults. Concomitant parasitic diseases influence the disease progression and 
treatment outcome and therefore should be carefully screened and treated regardless the 
sleeping sickness specific treatment applied. 
A substantial reduction of the overall treatment costs can be achieved by applying the 10-day 
treatment schedule, the total amount of drug used per patient is less (depending on the 
bodyweight, but may be reduced by one third), the hospitalisation time of a patient is reduced 
to almost half of the time and therefore, it is cheaper than the standard schedules. The 
treatment centres’ capacities can be largely improved as the patients free the hospital beds 
earlier and more patients can be treated in the same time as before. 
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PUBLIC HEALTH IMPACT OF THE 10-DAY SCHEDULE AND PERSPECTIVES 
We concluded that the 10-day melarsoprol schedule is a highly cost-effective treatment 
option for late-stage gambiense sleeping sickness in areas with scarce resources by halving 
the total costs in switching from the lengthy standard treatment schedules to the 10-day 
schedule even though the patients are submitted to the risk of a potential terminal outcome 
of the treatment. However, from the public health perspective, melarsoprol saves a 
substantial number of lives, at very low costs, and can be used as the baseline for the 
planning and funds allocation of control strategies and for decisions about the use of 
alternative treatments (i.e. eflornithine).  
Treatment is the cornerstone of human African trypanosomiasis control, the main reservoir of 
T.b. gambiense is in humans and a reduction is achieved by finding and treating those who 
harbour the parasites. It can be assumed that the shorter treatment course of melarsoprol 
may more likely attract the patients much earlier to seek diagnosis and treatment due to its 
various advantages and thus may have an effect in the reduction in the disease reservoir and 
transmission, leading to lower disease prevalence. 
In addition, there is a high gain to the patients and their families. The age distribution of 
trypanosomiasis patients very closely follows that of the active adult population (80% adults 
[Odiit 2003]) and the disease tends to hit the most economically productive group of society 
hardest, affecting family livelihoods and community prosperity very much. Typically, sleeping 
sickness patients have suffered from symptoms for a prolonged time, and the costs borne to 
the patients should not be underestimated, they are presumed to be at around US$25 to 
US$50 [Politi et al., 1995]. These costs include several trips to their rural health centre, or a 
visit to a local healer, being treated for malaria or other diseases before being diagnosed as 
having sleeping sickness, and the time taken by relatives to accompany and care for the 
person [Lutumba et al., 2004]. By treating the patients with the 10-day schedule, the patients 
return to their home much earlier and most probably feeling more comfortable in their own 
environment and thus may have a better and quicker recovery and an earlier return to their 
income generating activities. The accompanying relatives or their families will therefore also 
be able to generate much earlier their household income.  
However, as melarsoprol toxicity is unacceptable new alternatives should arise: There is a 
clear need for new drugs and easier treatments to better address sleeping sickness. The 
ideal trypanocidal drug should be safe and effective, active for both forms, gambiense and 
rhodesiense, cross the blood-brain-barrier to treat the late-stage of the disease, have a 
simple mode of administration to allow its use under basic rural conditions, and above all 
should be affordable.  
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This challenge can only be met by more funding for basic research to find new tools to attack 
the trypanosomes selectively, such as rationally developed agents inhibiting parasite 
metabolic pathways, and to increase funding for clinical trials to investigate the new agents. 
However, the market for sleeping sickness is negligible in comparison with the tremendous 
cost of developing a new drug for human use and within the next years no new drugs are 
likely to appear on the market. Consequently, the currently available drugs will be around for 
at least another decade, and therefore some efforts should be made in improving their use 
and reducing their toxicity. Therefore, future research should also focus on the better use of 
existing drugs that will be around for the next decade for sure. 
Due to the simple application, the 10-day melarsoprol treatment schedule has already been 
adapted for combination therapy with other existing drugs and melarsoprol refractory patients 
are currently treated with those. The combination therapy approach may offer several 
advantages such as: maximum efficacy, minimum toxicity, shortest possible duration, 
simplicity, and minimal costs. Combinations currently under investigation are low-dose 
consecutive melarsoprol combined with short-duration nifurtimox or eflornithine, and 
nifurtimox and eflornithine. Synergism of some of these combinations was suggested, based 
on animal experiments [Jennings 1988] or experience in humans [Simarro and Asumu 1996] 
and has demonstrated superiority to monotherapy with either drug [Mpia and Pepin 2002]. 
Approaches to reduce toxicity of individual drugs without affecting efficacy would include 
reduced treatment schedules, lower doses or changes in the administration route (oral 
application). The latter had been tried in a few instances but never been further followed and 
may be difficult due to its insolubility in water, but a reduced treatment schedule or lower 
doses would be worth considering. Based on our observations, the efficacy of melarsoprol 
was not affected by treatment interruptions that occurred at days 8 or later, thus one would 
like to suggest an even reduced treatment schedule of 7 or 8 consecutive doses only. In the 
presented study, the onset of severe adverse events (events that required treatment 
suspension) was generally reported to happen after 7 or 8 doses of melarsoprol and very 
often the treatment was not resumed in these patients after the management of the events. 
Despite the treatment interruption, these patients were not at higher risk to fail the 
melarsoprol therapy or to relapse during the follow-up period. But of course, even if this is 
probably already done in certain treatment centres, especially in the cases of severe adverse 
events, such a further reduced treatment schedule would need careful investigations. A study 
performed in DRC [Bisser 2001] indicated a decreased efficacy with a reduced melarsoprol 
treatment schedule of 0.6, 1.2 and 8 x 1.8 mg/kg bodyweight (max 2.5ml) on 10 consecutive 
days, a treatment regimen that is already very similar to what we tested. Considering the fact 
that the melarsoprol levels achieved in CSF are only a small fraction (1 – 2%) of those 
measured in serum and that these levels are at the lower limit to kill the trypanosomes and 
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that no accumulation in the CSF of the drug has been observed [Burri et al., 1993], we can 
assume that the 10-day schedule (at 2.2 mg/kg body weight) may already be at the lower 
limit of effective dosage to clear the parasites from all body compartments. Therefore, 
without adequate investigations, it is currently not advisable to further reduce the treatment 
schedule from 10 x 2.2 mg/kg body weight.  
As the melarsoprol treatment in T.b. gambiense patients has been successfully improved by 
developing a concise treatment schedule and harmonising the schedule in use in all 
countries affected by the disease, similar attempts for the use in T.b. rhodesiense patients 
however should be carefully addressed. It is currently not advised to adapt the model to 
treatment of late-stage T.b. rhodesiense infection because of potential dissimilar 
pharmacokinetics, given that this disease form is much more severe than the gambiense 
form (different pathology and higher parasitaemia). The blood-brain barrier may be more 
affected in rhodesiense patients, allowing for higher levels of melarsoprol in the central 
nervous system and possible neurological side effects. A study of the pharmacokinetics of 
melarsoprol in late-stage T.b. rhodesiense infections is therefore necessary and a new 
schedule would need to be very cautiously evaluated.  
The lack of alternative or new drugs for their efficacy against both, disease form and stages, 
indicates that an immense amount of work remains to be done for the discovery of an 
acceptable treatment of sleeping sickness. The situation will become particularly dramatic if 
less and less donors are willed to finance in one or another way the fight against sleeping 
sickness. The Aventis Pharma as an example has committed a substantial support to WHO 
to the control of trypanosomiasis, but this agreement will expire in 2006 and after that, the 
funding nor the production of the existing drugs are secured.  
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Angola 
 
 
Viana treatment centre (Photo Christian Burri, 2001) 
 
 
Viana, patient ward (Photo Christian Burri, 2001) 
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Central African Republic 
 
 
Dr. Nangouma at Nola trypanosomiasis facility (Photo Pierre Lucas, 2001) 
 
 
Batangafo trypanosomiasis facility (Photo Pierre Lucas, 2001) 
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Côte d’Ivoire 
 
 
PRCT Daloa (Photo Christian Burri 1995) 
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Democratic Republic of Congo  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients at Kionzo treatment centre, Bas-Congo (Photo Caecilia Schmid, 2002) 
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Kionzo, Central patient registry (Photo Caecilia Schmid, 2002) 
 
 
Kionzo treatment centre, Bas-Congo (Photo Caecilia Schmid, 2002) 
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Maluku outdoor laboratory (Photo Caecilia Schmid, 2001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CNPP / CUK Kinshasa, sleeping sickness treatment centre (Photo Caecilia Schmid, 2002) 
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Equatorial Guinea 
 
 
Bata, HAT and TB Pavillon (Photo Pere Simarro, 2001) 
 
 
 
Mbini trypanosomiasis centre (Photo Pere Simarro, 2001) 
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Republic of Congo  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gamboma, patients waiting for treatment (Photo Caecilia Schmid, 2001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Brazzaville, young late-stage patient during melarsoprol treatment and weighing of an old 
patient (Photo Caecilia Schmid, 2001) 
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Sudan 
 
 
Kajo Keji sleeping sickness treatment centre (MSF Switzerland, Photo Christian Burri, 2003)
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Dr. Michey Richer (IMC) and her patients in Western Equatoria (Photo Chicago Tribune, 
1999) 
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Grave of Ibba village head, died of melarsoprol adverse event (Photo Chicaco Tribune, 1999) 
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Forms prepared by Dr. C. Burri, STI 
Study Director IMPAMEL II  
CASE REPORT FORM (CRF) IMPAMEL II 
(Fill in the information asked , tick appropriate box , or fill in the grade) 
 
Country Code  Center Code    
Name of responsible 
for treatment  
 
 
Patient No. 
 
Patient full name  
 
Date of admission 
  
 ( d    d       m   m       y    y) 
Date of discharge 
  
 ( d    d       m   m       y    y) 
Present village of 
residence  
Municipality / District  
 
Probable place of 
infection (village)  
Municipality / District  
 
Age 
 (Years) 
Sex          Male   (m)         Female   (f)  
Weight 
 (kg) 
Height 
 (cm) 
How long ago were first signs observed   
 (Months) 
Previous treatment for trypanosomiasis    yes    (y) no     (n) 
 What medication 
 (Check boxes) 
 
Arsobal®    (a) 
Pentamidine    (p) 
Other (å observ.)    (o) 
Not known    (n) 
Where  Private center    (p) 
  Public center       (u) 
Was the treatment  complete yes   (y) 
    no                 (n) 
 How long ago 
 (Best match) 
1 month ago      (m)   6 months ago     (s)  
1 year ago     (y)  2 years or more ago    (y) 
 
PRESENT TREATMENT WITH MELARSOPROL (NIFURTIMOX / DFMO), DAYS OF DRUG APPLICATION  
(Tick box  for each day when melarsoprol was applied, mark box with m for each day when Nifurtimox / DFMO was applied) 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 
26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 
If treatment deviates from normal schedule give justification in observations section (keywords only) 
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LABORATORY EXAMINATIONS AT ADMISSION / DISCHARGE 
 
Before treatment After treatment 
Date of examination 
    
Consciousness Fully conscious  (p) 
Drowsy   (d) 
Comatose   (c) 
Fully conscious   (p) 
Drowsy    (d) 
Comatose    (c) 
Lymphadenopathy 
     (Swollen neck lymph nodes) 
Absent  (a) 
Palpable  (p) 
 
(indicate only if > 1 cm) 
Serology 
     (If other than CATT used specify in field) 
CATT pos    (p) 
neg    (n) 
other    (o) 
n.d.   (b) 
 (If other test specify) 
 
Trypanosomes in lymph nodes Microscopy pos    (p) 
neg    (n) 
n.d.  (b) 
Microscopy pos     (p) 
neg     (n) 
n.d.   (b) 
Trypanosomes in blood 
 
Microscopy 
(Blood smear) 
pos    (p) 
neg    (n) 
n.d.  (b) 
Microscopy 
(Blood smear) 
pos     (p) 
neg     (n) 
n.d.   (b) 
Trypanosomes in CSF 
 
Microscopy pos    (p) 
neg    (n) 
n.d.  (b) 
Microscopy pos     (p) 
neg     (n) 
n.d.   (b) 
Double centrifugation of CSF used 
 
yes    (y) 
no   (n) 
 
yes     (y) 
no   (n) 
White blood cells in CSF (no / mm3) 
(Counting chamber)  
Microscopy 
 
Microscopy 
 
Malaria Microscopy pos    (p) 
neg    (n) 
n.d.  (b) 
 
Filariae (incl. Mansonella perstans) Microscopy pos    (p) 
neg    (n) 
n.d.  (b) 
(Specify species if possible) 
 
CLINICAL EXAMINATIONS AT ADMISSION / DISCHARGE  
 
Before After 
  
Before After 
 
Treatment
 
  
Treatment
 
Nutritional status 
(Circumference  
 of upper arm, cm) . . 
 
Abnormal  
movements 
yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Fever (°C) 
. . 
 Walking disability yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Headache  yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
 General motor 
weakness 
yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Pruritus yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
 Unusual behavior yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Daytime sleep normal  (y) 
not  (n) 
normal  (y) 
not  (n) 
 Inactivity yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Nighttime sleep normal  (y) 
not  (n) 
normal  (y) 
not  (n) 
 Aggressivity yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Tremor yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
 Disturbed appetite 
(bulimia / anorexia) 
yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
Speech 
impairment 
yes   (y) 
no  (n) 
yes   (y) 
no  (n) 
 
Check yes if any deviation from normal pattern 
are observed 
  
 
SAFETY AND TOLERABILITY 
(Complete at day of discharge based on original patient files; indicate maximum degree) 
Adverse effects Grade 0 Grade 1 Grade 2 Maximum 
grade 
Date of onset Duration of 
max [days] 
Motor trouble 
(Polyneuropathy) 
Absent Motor weakness, able to walk Motor weakness, unable to 
walk     
Sensibility trouble 
(Polyneuropathy) 
Absent Parestesia: "stockings and 
gloves distribution" 
Pain, leading to interruption of 
melarsoprol treatment     
Bullous eruptions 
(Exfoliative dermatitis) 
Absent Exfoliative skin eruptions not 
leading to interruption of 
melarsoprol treatment 
Exfoliative skin eruptions 
leading to interruption of 
melarsoprol treatment 
    
Maculopapular eruptions 
(Urticaria) 
Absent Maculopapular or urticarial 
eruptions not leading to 
interruption of melarsoprol 
treatment 
Maculopapular or urticarial 
eruptions leading to 
interruption of melarsoprol 
treatment 
    
Pruritus 
 
Absent Pruritus not leading to 
interruption of melarsoprol 
treatment 
Pruritus leading to interruption 
of melarsoprol treatment     
Febrile reaction Absent 37.5 - 38.9°C  39.0°C 
    
Headache Absent Not leading to interruption of 
melarsoprol treatment 
Leading to interruption of 
melarsoprol treatment     
Diarrhea Absent Watery diarrhea without 
dehydration 
Bloody diarrhea or watery 
diarrhea with dehydration     
Hypotension Absent Systolic blood pressure  
≤ 80 mm/Hg 
Shock 
    
Jaundice Absent Jaundice not leading to 
interruption of melarsoprol 
treatment 
Jaundice leading to interruption 
of melarsoprol treatment     
  Enter “b” for signs / symptoms which can not be assessed for this patient or in this center 
      
Adverse effects Grade 0 Grade 1 Grade 2 Grade 3 Maximum 
grade 
Date occurred Duration 
(if grade 1 / 2) 
Encephalopathy Absent Psychiatric reactions Convulsions and / or 
loss of consciousness 
Death 
    
  If Grade more than zero only: use Table “EXAMINATIONS AND LABORATORY TESTS IN CASE OF ENCEPHALOPATHY” 
  
OBSERVATIONS AND OTHER DIAGNOSIS 
(For additional information and comments only; all entries must be written clearly readable)  
OTHER DRUGS USED 
(Indicate only drugs additional to regular treatment in this center) 
Date Remark Responsible for remark  Additional drugs used 
yes   (y) 
no  (n) 
   
 1. 
   
 2.  
   
 3.  
   
 4.  
   
 5. 
 For remarks use codes where possible (see Investigators manual) 
EXAMINATIONS AND LABORATORY TESTS IN CASE OF ENCEPHALOPATHY 
 
Adverse effects Grade 0 Grade 1 Grade 2 Maximum 
grade 
Date occurred / done Duration of 
max [days] 
Headache 
   (< 24 hours before onset) 
Absent  Sporadic Continuous 
    
Fever 
   (< 24 hours before onset) 
Absent  37.5 - 38.9°C  39.0°C 
    
Aggressivity Absent or  
comatose Verbal attack Physical attack     
Confusion Absent or  
comatose 
Correct response 
on current place Incorrect response     
Convulsions Absent Single Repeated 
    
Consciousness  Fully 
conscious Drowsy Comatose     
Malaria (Thick smear mandatory in all cases of encephalopathy!) pos  (p) 
neg  (n)
 
   
Hemoglobin Method: ____________________ ([g/dl] if not done enter “b”) 
.   n.d.    (b) 
Glucose in blood Method: __________________ ([mg/dl] if not done enter “b”) 
   n.d.    (b) 
HIV -  Test (Only if testing is routinely done at hospital  and if counseling 
to positive patients is regularly provided) 
pos   (p) 
neg  (n) 
n.d.  (b)
 
   
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International Health 
 
FOLLOW UP INFORMATION (IMPAMEL II) 
(Return this form at latest 2 months after examination to the STI) 
Country Code  Center Code    
 
 
Patient No. 
 
Patient full name  
 
Date of follow up 
assessment   
  ( d   d       m   m       y    y) 
Date of discharge 
from hospital   
 ( d    d       m   m       y    y) 
Number of follow up assessment  1(1)       2 (2)      3 (3)      4 (4)      5 (5)      6 (6) 
 
 
 
Patient examined in hospital 
 (h)  
White blood cells in CSF  
 (number / mm3) 
 
  
Trypanosomes in CSF pos (p) neg (n) n.d.  (b) 
Centrifugation of CSF done yes (y) no (n)  
CATT Test pos (p) neg (n) n.d.  (b) 
Trypanosomes in blood  pos (p) neg (n) n.d.  (b) 
Trypanosomes in lymph nodes pos (p) neg (n) n.d.  (b) 
Condition of patient good (g) fair (r) bad  (b) 
 
died (g)   Date       
    ( d   d       m   m       y    y) 
  
 
Patient visited in village    (v) (If visited in village and laboratory examinations 
done: use fields above) 
Information from patient 
  (p)   
Information from relatives / friends 
  (r)   
Condition of patient good (g) fair (r) bad  (b) 
 
died (g)   Date       
   ( d   d       m   m       y    y) 
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